hr-20200930

0000899749-20-000097.txt : 20201104 0000899749-20-000097.hdr.sgml : 20201104 20201104164617 ACCESSION NUMBER: 0000899749-20-000097 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201104 DATE AS OF CHANGE: 20201104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHCARE REALTY TRUST INC CENTRAL INDEX KEY: 0000899749 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 621507028 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11852 FILM NUMBER: 201287317 BUSINESS ADDRESS: STREET 1: 3310 WEST END AVE STREET 2: FOURTH FL SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6152698175 MAIL ADDRESS: STREET 1: 3310 WEST END AVENUE, SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 10-Q 1 hr-20200930.htm 10-Q hr-20200930

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 10-Q


(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended:	September 30, 2020
OR
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to For the transition period to

Commission File Number: 001-11852

HEALTHCARE REALTY TRUST INCORPORATED

(Exact name of Registrant as specified in its charter)


Maryland			62-1507028
(State or other jurisdiction of Incorporation or organization)			(I.R.S. Employer Identification No.)

3310 West End Avenue, Suite 700

Nashville, Tennessee 37203

(Address of principal executive offices)

(615) 269-8175

(Registrant's telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common stock, $0.01 par value per share

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer ☒ Accelerated filer ☐

Non-accelerated filer ☐ Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 30, 2020, the Registrant had 136,054,024 shares of Common Stock outstanding.

HEALTHCARE REALTY TRUST INCORPORATED

FORM 10-Q

September 30, 2020

Table of Contents


PART I - FINANCIAL INFORMATION
Item 1	Financial Statements	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Income	2
	Condensed Consolidated Statements of Comprehensive Income (Loss)	3
	Condensed Consolidated Statements of Equity	4
	Condensed Consolidated Statements of Cash Flows	6
	Notes to the Condensed Consolidated Financial Statements	7
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3	Quantitative and Qualitative Disclosures about Market Risk	33
Item 4	Controls and Procedures	33

PART II - OTHER INFORMATION
Item 1	Legal Proceedings	35
Item 1A	Risk Factors	35
Item 2	Unregistered Sales of Equity and Use of Proceeds	38
Item 6	Exhibits	39

SIGNATURE		40

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Healthcare Realty Trust Incorporated

Condensed Consolidated Balance Sheets

Amounts in thousands, except per share data


ASSETS
	Unaudited SEPTEMBER 30, 2020		DECEMBER 31, 2019
Real estate properties
Land	$	330,840	$	289,751
Buildings, improvements and lease intangibles	4,014,740		3,986,326
Personal property	10,962		10,538
Construction in progress	—		48,731
Land held for development	24,647		24,647
Total real estate properties	4,381,189		4,359,993
Less accumulated depreciation and amortization	(1,198,444)		(1,121,102)
Total real estate properties, net	3,182,745		3,238,891
Cash and cash equivalents	121,992		657
Restricted cash	60,644		—

Assets held for sale, net	20,051		37
Operating lease right-of-use assets	123,807		126,177
Financing lease right-of-use assets	19,776		12,667

Other assets, net	182,436		185,426
Total assets	$	3,711,451	$	3,563,855

LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities
Notes and bonds payable	$	1,554,395	$	1,414,069
Accounts payable and accrued liabilities	79,528		78,517
Liabilities of assets held for sale	548		145
Operating lease liabilities	91,466		91,574
Financing lease liabilities	18,697		18,037
Other liabilities	66,442		61,504
Total liabilities	1,811,076		1,663,846
Commitments and contingencies
Stockholders' equity
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding	—		—
Common stock, $.01 par value per share; 300,000 shares authorized; 136,054 and 134,706 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	1,361		1,347
Additional paid-in capital	3,532,130		3,485,003
Accumulated other comprehensive loss	(19,267)		(6,175)
Cumulative net income attributable to common stockholders	1,215,362		1,127,304
Cumulative dividends	(2,829,211)		(2,707,470)
Total stockholders' equity	1,900,375		1,900,009


Total liabilities and stockholders' equity	$	3,711,451	$	3,563,855

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, are an integral part of these financial statements.

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Income

For the Three and Nine Months Ended September 30, 2020 and 2019

Amounts in thousands, except per share data

Unaudited


	THREE MONTHS ENDED September 30,				NINE MONTHS ENDED September 30,
	2020		2019		2020		2019
Revenues
Rental income	$	123,384	$	117,740	$	368,385	$	342,787

Other operating	1,868		2,059		5,364		5,987
	125,252		119,799		373,749		348,774
Expenses
Property operating	50,171		46,777		146,305		133,790
General and administrative	7,299		10,802		23,498		27,157
Acquisition and pursuit costs	440		501		1,621		1,227
Depreciation and amortization	47,143		45,137		142,331		131,725


	105,053		103,217		313,755		293,899
Other Income (Expense)
Gain on sales of real estate assets	2,177		200		70,395		5,065
Interest expense	(14,154)		(14,181)		(42,556)		(41,619)


Impairment of real estate assets	—		—		—		(5,610)

Interest and other income (expense), net	8		—		225		(736)
	(11,969)		(13,981)		28,064		(42,900)






Net Income	$	8,230	$	2,601	$	88,058	$	11,975





Basic earnings per common share	$	0.06	$	0.02	$	0.65	$	0.08


Diluted earnings per common share	$	0.06	$	0.02	$	0.65	$	0.08

Weighted average common shares outstanding - basic	134,309		128,090		133,662		126,571
Weighted average common shares outstanding - diluted	134,357		128,169		133,736		126,657
Dividends declared, per common share, during the period	$	0.30	$	0.30	$	0.90	$	0.90

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Comprehensive Income (Loss)

For the Three and Nine Months Ended September 30, 2020 and 2019

Amounts in thousands

Unaudited


	THREE MONTHS ENDED September 30,				NINE MONTHS ENDED September 30,
	2020		2019		2020		2019
Net income	$	8,230	$	2,601	$	88,058	$	11,975
Other comprehensive income (loss)


Interest rate swaps
Reclassification adjustments for losses included in net income (interest expense)	1,101		60		2,367		74
Losses arising during the period on interest rate swaps	(74)		(2,341)		(11,192)		(7,642)
Losses on settlement of treasury rate locks arising during the period	—		—		(4,267)		—
	1,027		(2,281)		(13,092)		(7,568)

Comprehensive income	$	9,257	$	320	$	74,966	$	4,407

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Equity

For the Three Months Ended September 30, 2020 and 2019

Amounts in thousands, except per share data

Unaudited


	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Cumulative Net Income		Cumulative Dividends		Total Stockholders’ Equity
Balance at June 30, 2020	$	1,360	$	3,529,559	$	(20,294)	$	1,207,132	$	(2,788,396)	$	1,929,361
Issuance of common stock, net of issuance costs	1		126		—		—		—		127

Share-based compensation	—		2,445		—		—		—		2,445
Net income	—		—		—		8,230		—		8,230
Reclassification adjustments for losses included in net income (interest expense)	—		—		1,101		—		—		1,101
Losses arising during the period on interest rate swaps and treasury rate locks	—		—		(74)		—		—		(74)
Dividends to common stockholders ($0.30 per share)	—		—		—		—		(40,815)		(40,815)
Balance at September 30, 2020	$	1,361	$	3,532,130	$	(19,267)	$	1,215,362	$	(2,829,211)	$	1,900,375

	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Cumulative Net Income		Cumulative Dividends		Total Stockholders’ Equity
Balance at June 30, 2019	$	1,292	$	3,305,344	$	(6,189)	$	1,097,493	$	(2,628,497)	$	1,769,443
Issuance of common stock, net of issuance costs	22		71,792		—		—		—		71,814
Common stock redemptions	—		(2,695)		—		—		—		(2,695)
Share-based compensation	—		5,131		—		—		—		5,131
Net income	—		—		—		2,601		—		2,601
Reclassification adjustments for losses included in net income (interest expense)	—		—		60		—		—		60
Losses arising during the period on interest rate swaps	—		—		(2,341)		—		—		(2,341)
Dividends to common stockholders ($0.30 per share)	—		—		—		—		(38,852)		(38,852)
Balance at September 30, 2019	$	1,314	$	3,379,572	$	(8,470)	$	1,100,094	$	(2,667,349)	$	1,805,161

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Equity

For the Nine Months Ended September 30, 2020 and 2019

Amounts in thousands, except per share data

Unaudited


	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Cumulative Net Income		Cumulative Dividends		Total Stockholders’ Equity
Balance at December 31, 2019	$	1,347	$	3,485,003	$	(6,175)	$	1,127,304	$	(2,707,470)	$	1,900,009
Issuance of common stock, net of issuance costs	13		40,477		—		—		—		40,490
Common stock redemptions	—		(798)		—		—		—		(798)
Share-based compensation	1		7,448		—		—		—		7,449
Net income	—		—		—		88,058		—		88,058
Reclassification adjustments for losses included in net income (interest expense)	—		—		2,367		—		—		2,367
Losses arising during the period on interest rate swaps	—		—		(15,459)		—		—		(15,459)
Dividends to common stockholders ($0.90 per share)	—		—		—		—		(121,741)		(121,741)
Balance at September 30, 2020	$	1,361	$	3,532,130	$	(19,267)	$	1,215,362	$	(2,829,211)	$	1,900,375

	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Cumulative Net Income		Cumulative Dividends		Total Stockholders’ Equity
Balance at December 31, 2018	$	1,253	$	3,180,284	$	(902)	$	1,088,119	$	(2,552,112)	$	1,716,642
Issuance of common stock, net of issuance costs	61		192,414		—		—		—		192,475
Common stock redemptions	(1)		(3,266)		—		—		—		(3,267)
Share-based compensation	1		10,140		—		—		—		10,141
Net income	—		—		—		11,975		—		11,975
Reclassification adjustments for losses included in net income (interest expense)	—		—		74		—		—		74
Losses arising during the period on interest rate swaps	—		—		(7,642)		—		—		(7,642)
Dividends to common stockholders ($0.90 per share)	—		—		—		—		(115,237)		(115,237)
Balance at September 30, 2019	$	1,314	$	3,379,572	$	(8,470)	$	1,100,094	$	(2,667,349)	$	1,805,161

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2020 and 2019

Amounts in thousands

Unaudited


OPERATING ACTIVITIES
	NINE MONTHS ENDED September 30,
	2020		2019
Net income	$	88,058	$	11,975
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	142,331		131,725
Other amortization	3,409		2,279
Share-based compensation	7,449		10,141
Amortization of straight-line rent receivable (lessor)	(2,722)		(1,833)
Amortization of straight-line rent on operating leases (lessee)	1,122		1,159
Gain on sales of real estate assets	(70,395)		(5,065)

Impairment of real estate assets	—		5,610
Loss from unconsolidated joint ventures	194		16
Distributions from unconsolidated joint ventures	193		277
Proceeds from disposition of sales-type lease properties	244,454		—
Changes in operating assets and liabilities:

Other assets, including right-of-use-assets	(965)		(6,740)
Accounts payable and accrued liabilities	5,098		3,220
Other liabilities	(6,662)		5,709
Net cash provided by operating activities	411,564		158,473

INVESTING ACTIVITIES
Acquisitions of real estate	(199,162)		(271,575)
Development of real estate	(2,941)		(19,152)
Additional long-lived assets	(62,707)		(45,902)
Proceeds from sales of real estate assets	4,905		14,151

Net cash used in investing activities	(259,905)		(322,478)

FINANCING ACTIVITIES
Net (repayments) borrowings on unsecured credit facility	(293,000)		60,000
Borrowings on term loan	150,000		50,000

Borrowings of notes and bonds payable	298,995		—
Repayments of notes and bonds payable	(32,704)		(12,663)


Dividends paid	(121,741)		(115,237)
Net proceeds from issuance of common stock	40,296		192,514
Common stock redemptions	(892)		(2,343)


Settlement of treasury rate locks	(4,267)		—
Debt issuance and assumption costs	(3,057)		(4,589)
Payments made on finance leases	(3,310)		(249)
Net cash provided by financing activities	30,320		167,433

Increase in cash, cash equivalents and restricted cash	181,979		3,428
Cash and cash equivalents at beginning of period	657		8,381
Cash, cash equivalents and restricted cash at end of period	$	182,636	$	11,809

Supplemental Cash Flow Information
Interest paid	$	39,165	$	37,946
Invoices accrued for construction, tenant improvements and other capitalized costs	$	12,709	$	10,702
Mortgage notes payable assumed upon acquisition (adjusted to fair value)	$	19,269	$	—
Capitalized interest	$	913	$	999

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Summary of Significant Accounting Policies

Business Overview

Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2020, the Company had gross investments of approximately $4.3 billion in 211 real estate properties located in 24 states totaling approximately 15.5 million square feet. The Company provided leasing and property management services to approximately 11.9 million square feet nationwide. Square footage and property count disclosures in these Notes to the Company's Condensed Consolidated Financial Statements are unaudited.

Basis of Presentation

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2019. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2020 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties, such as the impact of the COVID-19 pandemic.

Use of Estimates in the Condensed Consolidated Financial Statements

Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.

The Company considered the impact of COVID-19 on these assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position at September 30, 2020. There can be no assurance that COVID-19 will not have a future material adverse impact on the financial results and business operations of the Company.

COVID-19 Update

Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.

In response to the COVID-19 pandemic, all of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants temporarily closed their offices or clinical space or operated on a reduced basis in response to government requirements or recommendations. Many of these restrictions have been lifted, but could be reimposed. In response to these disruptions, the Company provided some of its tenants with deferred rent arrangements. Such arrangements were made primarily in the second quarter of 2020, and less than $0.1 million of deferred rent arrangements originated in the third quarter. Through November 2, 2020, the Company has collected more than 99% of second and third quarter 2020 aggregate tenant billings. The Company has collected 96% of total scheduled deferral payments due in the third quarter of 2020. In addition, the Company has remaining various forms of rent deferrals outstanding representing

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

approximately $1.2 million, or less than 1% of second and third quarter 2020 aggregate tenant billings. The tenant deferral agreements generally require the deferred amounts to be repaid by the fourth quarter of 2020.

For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease. However, in light of the COVID-19 pandemic in which many leases are being modified, the Financial Accounting Standards Board (the "FASB") and U.S. Securities and Exchange Commission (the "SEC") have provided relief that will allow companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. The Company has elected to use this relief where applicable and therefore will have no change in the current classification of its leases in connection with many of the leases impacted by negotiations with its tenants. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. If the cash flows are substantially the same or less, there are two methods to potentially account for such rent deferrals under the relief. The first would be as if no changes to the lease contract were made. Under that accounting, a lessor would increase its lease receivable and a lessee would increase its accounts payable as receivables/payments accrue. In its income statement, a lessor would continue to recognize revenue during the deferral period. The second method would be to treat the deferred payments as variable lease payments (i.e., revenue recognized when cash received). The Company has elected the first method described above, which results in the revenue being recognized on an accrual basis.

If tenants are unable to timely repay deferred rent, or repay at all, request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads, the impact on the Company’s results of operations and financial condition could be material. In the second quarter of 2020, the Company recognized approximately $0.7 million general reserve against the deferred rent balance. Following positive collection trends in the third quarter of 2020, the Company released approximately $0.3 million of the general reserve. As of September 30, 2020, the Company had a remaining general reserve of $0.4 million against an approximate $1.7 million deferred rent balance.

Given the daily evolution of the COVID-19 pandemic and the global response to curb its spread, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for the fiscal year 2020. The Company continues to evaluate the impact of various forms of governmental assistance that may be or become available to the Company or its tenants.

Revenue from Contracts with Customers (Topic 606)

The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:


	THREE MONTHS ENDED September 30,				NINE MONTHS ENDED September 30,
in thousands	2020		2019		2020		2019
Type of Revenue
Parking income	$	1,764	$	1,935	$	5,042	$	5,538
Rental lease guaranty	—		—		—		128
Management fee income	62		69		209		201
Miscellaneous	42		55		113		120
	$	1,868	$	2,059	$	5,364	$	5,987

The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents includes short-term investments with original maturities of three months or less when purchased. Restricted cash includes cash held in escrow from the sale of a property in Oklahoma. These proceeds have been or will be disbursed as the Company acquires real estate investments in like-kind exchanges under Section 1031 of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”). The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Condensed Consolidated Balance Sheets to the combined amounts shown on the Company's Condensed Consolidated Statements of Cash Flows:


In thousands	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	121,992	$	657
Restricted cash	60,644		—
Total cash, cash equivalents and restricted cash	$	182,636	$	657

New Accounting Pronouncements

Accounting Standards Update No. 2016-13

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. Operating lease receivables, representing the majority of the Company's receivables, are not within the scope of the new standard. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Accounting Standards Update No. 2017-04

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Accounting Standards Update No. 2020-04

On March 12, 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Note 2. Real Estate Investments

2020 Acquisitions

The following table details the Company's acquisitions for the nine months ended September 30, 2020:


Dollars in millions	TYPE 1	DATE ACQUIRED	PURCHASE PRICE		MORTGAGE NOTES PAYABLE		CASH CONSIDERATION 2		REAL ESTATE		OTHER 3		SQUARE FOOTAGE
Los Angeles, CA	MOB	1/3/20	$	42.0	$	(19.3)	$	22.8	$	42.4	$	(0.3)	86,986
Atlanta, GA	MOB	2/13/20	12.0		—		11.8		12.1		(0.3)		64,624
Raleigh, NC	MOB	2/25/20	6.3		—		6.5		6.5		—		15,964
Colorado Springs, CO	MOB	3/9/20	8.2		—		8.3		8.6		(0.3)		34,210
Denver, CO 4	MOB	3/13/20	33.5		—		33.2		34.0		(0.8)		136,994
San Diego, CA	MOB	7/1/20	16.7		—		16.7		16.9		(0.2)		46,083
Los Angeles, CA	MOB	7/17/20	35.0		—		37.7		37.7		—		49,785
Seattle, WA	MOB	7/23/20	11.0		—		10.9		11.3		(0.4)		21,309
Atlanta, GA	MOB	7/31/20	20.5		—		21.6		21.3		0.3		48,145
Houston, TX	MOB	9/24/20	11.0		—		10.9		11.0		(0.1)		40,235
Los Angeles, CA	MOB	9/28/20	14.0		—		14.0		13.9		0.1		24,252

Total real estate acquisitions			$	210.2	$	(19.3)	$	194.4	$	215.7	$	(2.0)	568,587
Land acquisition 5			1.6		—		1.7		1.7		—		—
Land acquisition 6			1.0		—		1.1		1.1		—		—
			$	212.8	$	(19.3)	$	197.2	$	218.5	$	(2.0)	568,587

1MOB = medical office building.

2Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.

3Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.

4Includes three properties.

5The Company acquired land parcels under four existing buildings (previously ground leased).

6The Company acquired a land parcel under an existing building (previously ground leased). The building and land were sold on September 30, 2020.

Subsequent Acquisition

On October 7, 2020 the Company acquired a 36,720 square foot medical office building in Colorado Springs, CO for a purchase price of $8.9 million.

2020 Real Estate Asset Dispositions

The following table details the Company's dispositions for the nine months ended September 30, 2020:


Dollars in millions	TYPE 1	Date Disposed	Sale Price		Closing Adjustments		Net Proceeds		Net Real Estate Investment		Other (including receivables)2		Gain/(Impairment)		Square Footage (Unaudited)
Springfield, MO 3	SF	7/30/20	$	138.0	$	—	$	138.0	$	92.4	$	3.9	$	41.7	186,000
Oklahoma City, OK 3	MOB	7/30/20	106.5		—		106.5		76.8		3.1		26.6		200,000
Miami, FL	MOB	9/30/20	5.0		(0.2)		4.8		2.6		0.1		2.1		26,000

Total dispositions			$	249.5	$	(0.2)	$	249.3	$	171.8	$	7.1	$	70.4	412,000

1.MOB = medical office building; SF = surgical facility

2.Includes straight-line rent receivables, leasing commissions and lease inducements.

3.In the second quarter of 2020, the Company entered into agreements to sell two single-tenant net leased properties, resulting in a lease modification and classification change from operating to sales-type.

Assets Held for Sale

In September 2020, the Company reclassified four medical office buildings and a land parcel to assets held for sale upon acceptance of an offer from a third party to purchase the properties under a single sales agreement. The contractual sales price of $23.0 million is greater than the current net investment of approximately $18.1 million. As

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

of September 30, 2020 and December 31, 2019, the Company had four and zero properties, respectively, classified as assets held for sale.

The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2020 and December 31, 2019:


(Dollars in thousands)	September 30, 2020		December 31, 2019
Balance Sheet data:
Land	$	1,664	$	—
Building, improvements and lease intangibles	26,871		—
Personal property	39		—
	28,574		—
Accumulated depreciation	(10,443)		—
Real estate assets held for sale, net	18,131		—
Other assets, net	1,920		37
Assets held for sale, net	$	20,051	$	37

Accounts payable and accrued liabilities	$	437	$	37
Other liabilities	111		108
Liabilities of assets held for sale	$	548	$	145

Note 3. Leases

Lessor Accounting

The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2035. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s single-tenant net leases generally require the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.

The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three and nine months ended September 30, 2020 was $123.4 million and $368.4 million, respectively.

In May 2020, the Company and Mercy Health negotiated the sale of two single-tenant net leased properties, a medical office building in Oklahoma and an orthopedic specialty hospital in Missouri, for $244.5 million. The sale was structured through amendments to the leases to allow for the early exercise of existing purchase options. The amendments resulted in the application of lease modification accounting under ASC Topic 842, which resulted in lease classification changes from operating to sales-type. During the second quarter, the Company derecognized the real estate assets on the Condensed Consolidated Balance Sheets and recognized the net investment in sales-type leases, resulting in a gain of $68.3 million. The Company disposed of these properties on July 30, 2020.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Tabular Disclosure of the Components of Sales-Type Leases

The table below presents the components of sale-type leases for the three and nine months ended September 30, 2020:


	SALES-TYPE LEASES
In thousands	three months ended September 30, 2020		nine months ended September 30, 2020
Profit recognized at commencement date	$	—	$	68,267	Gain on sales of real estate assets
Interest income	1,454		3,007		Rental income

Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2020 were as follows:


In thousands	Operating
2020	$	93,722
2021	352,341
2022	307,166
2023	261,187
2024	200,578
2025 and thereafter	555,264
	$	1,770,258

Lessee Accounting

As of September 30, 2020, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of September 30, 2020, the Company had 103 properties totaling 8.7 million square feet that were held under ground leases. Some of the ground leases' renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2119. Any rental increases related to the Company’s ground leases are generally either stated or based on the CPI. The Company had 42 prepaid ground leases as of September 30, 2020. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately $0.2 million of the Company’s rental expense for the three months ended September 30, 2020 and 2019, respectively and $0.5 million and $0.4 million for the nine months ended September 30, 2020 and 2019, respectively.

The Company’s future lease payments (primarily for its 61 non-prepaid ground leases) as of September 30, 2020 were as follows:


In thousands	OPERATING		FINANCING
2020	$	1,008	$	143
2021	4,844		930
2022	4,875		783
2023	4,913		793
2024	4,969		815
2025 and thereafter	307,665		88,808
Total undiscounted lease payments	328,274		92,272
Discount	(236,808)		(73,575)
Lease liabilities	$	91,466	$	18,697

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2020 and 2019:


	THREE MONTHS ENDED September 30,						NINE MONTHS ENDED September 30,
In thousands	2020			2019			2020		2019
Operating lease cost
Operating lease expense	$	1,180		$	1,169		$	3,534	$	3,448
Variable lease expense	1,066			845			2,664		2,380

Finance lease cost
Amortization of right-of-use assets	88			51			236		101
Interest on lease liabilities	245			196			722		392
Total lease expense	$	2,579		$	2,261		$	7,156	$	6,321

Other information
Operating cash flows outflows related to operating leases	$	1,440		$	1,313		$	5,412	$	5,461
Financing cash flows outflows related to financing leases	$	143		$	107		$	3,310	$	249
Right-of-use assets obtained in exchange for new finance lease liabilities	$	—		$	—		$	7,212	$	14,294

Weighted-average remaining lease term (excluding renewal options) - operating leases	48.9			49.7
Weighted-average remaining lease term (excluding renewal options) -finance leases	64.7			70.1
Weighted-average discount rate - operating leases	5.7		%	5.7		%
Weighted-average discount rate - finance leases	5.4		%	5.5		%

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Note 4. Notes and Bonds Payable

The table below details the Company’s notes and bonds payable.


	MATURITY DATES	BALANCE AS OF				EFFECTIVE INTEREST RATE as of 9/30/2020
Dollars in thousands		9/30/2020		12/31/2019
$700 million Unsecured Credit Facility	5/23	$	—	$	293,000	N/A
$200 million Unsecured Term Loan Facility, net of issuance costs 1	5/24	199,180		199,013		1.99	%
$150 million Unsecured Term Loan due 2026 2	6/26	149,455		—		3.14	%
Senior Notes due 2023, net of discount and issuance costs	4/23	248,863		248,540		3.95	%
Senior Notes due 2025, net of discount and issuance costs 3	5/25	248,711		248,522		4.08	%
Senior Notes due 2028, net of discount and issuance costs	1/28	296,003		295,651		3.84	%
Senior Notes due 2030, net of discount and issuance costs 4	3/30	296,384		—		2.71	%
Mortgage notes payable, net of discounts and issuance costs and including premiums	1/21-4/27	115,799		129,343		4.38	%
		$	1,554,395	$	1,414,069

1The effective interest rate includes the impact of interest rate swaps on $75.0 million at a weighted average rate of 2.37% (plus the applicable margin rate, currently 100 basis points).

2The effective interest rate includes the impact of interest rate swaps on $100.0 million at a weighted average rate of 2.23% (plus the applicable margin rate, currently 160 basis points).

3The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.

4The effective interest rate includes the impact of the $4.3 million settlement of forward interest rate hedges that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.

Changes in Debt Structure

On February 3, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.10% per annum with an outstanding principal of $5.9 million. The mortgage note encumbered a 68,860 square foot property in Oklahoma.

On March 4, 2020, the Company issued $300.0 million of unsecured senior notes due 2030 (the "Senior Notes due 2030") in a registered public offering. The Senior Notes due 2030 bear interest at 2.40%, payable semi-annually on March 15 and September 15, beginning September 15, 2020, and are due on March 15, 2030, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $1.0 million and the Company incurred approximately $2.8 million in debt issuance costs. Concurrent with this transaction, the Company settled two treasury rate locks for $4.3 million. Inclusive of the discount, debt issuance costs and settlement of the treasury rate locks, the effective interest rate was 2.71%. The Senior Notes due 2030 have various financial covenants that are required to be met on a quarterly and annual basis.

On May 4, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.74% per annum with an outstanding principal of $0.3 million. The mortgage note encumbered an 83,318 square foot property in Iowa.

On May 29, 2020, the Company borrowed $150.0 million pursuant to its unsecured term loan due 2026.

On June 2, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.44% per annum with an outstanding principal of $12.6 million. The mortgage note encumbered a 67,510 square foot property in Washington.

On June 25, 2020, the Company repaid in full three mortgage notes bearing interest at rates of 5.63%, 6.63% and 6.88% per annum with outstanding principal of $0.5 million, $2.8 million, and $7.0 million, respectively. The mortgage notes encumbered a 60,476 square foot property in Minnesota.

Subsequent Changes in Debt Structure

On October 1, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.47% per annum with an outstanding principal of $4.2 million. The mortgage note encumbered a 40,171 square foot property in Georgia.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

On October 19, 2020, the Company redeemed its unsecured senior notes due 2023 (the "Senior Notes due 2023"). The aggregate redemption price of $270.5 million consisted of outstanding principal of $250.0 million, accrued interest of $0.1 million, and a "make-whole" amount of approximately $20.4 million for the early extinguishment of debt. The unaccreted discount and unamortized costs on these notes of $1.1 million was written off upon redemption. In October 2020, the Company recognized a loss on early extinguishment of debt of approximately $21.5 million related to this redemption.

Note 5. Derivative Financial Instruments

Risk Management Objective of Using Derivatives

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.

On February 24 and 25, 2020, the Company entered into two treasury rate locks totaling $75.0 million and $40.0 million, respectively. The treasury rate locks were settled for an aggregate amount of $4.3 million on March 4, 2020 concurrent with the Company's issuance of its Senior Notes due 2030. The settlement will be amortized over the 10-year term of the notes.

As of September 30, 2020, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:


DERIVATIVE INSTRUMENT	NUMBER OF INSTRUMENTS	NOTIONAL AMOUNT in millions
Interest rate swaps	8	$175.0

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet

The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2020.


	BALANCE AT SEPTEMBER 30, 2020
In thousands	BALANCE SHEET LOCATION	FAIR VALUE
Derivatives designated as hedging instruments
Interest rate swaps	Other liabilities	$	14,460
Total derivatives designated as hedging instruments		$	14,460

Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)

The table below presents the effect of cash flow hedge accounting on AOCI during the three and nine months ended September 30, 2020 and 2019 related to the Company's outstanding interest rate swaps.


	LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended September 30,					(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended September 30,
In thousands	2020		2019			2020		2019
Interest rate swaps	$	74	$	2,341	Interest expense	$	952	$	18
Settled treasury hedges	—		—		Interest expense	107		—
Settled interest rate swaps	—		—		Interest expense	42		42
	$	74	$	2,341	Total interest expense	$	1,101	$	60


	LOSS RECOGNIZED IN AOCI ON DERIVATIVE nine months ended September 30,					(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME nine months ended September 30,
In thousands	2020		2019			2020		2019
Interest rate swaps	$	11,192	$	7,642	Interest expense	$	2,012	$	(52)
Settled treasury hedges	4,267		—		Interest expense	229		—
Settled interest rate swaps	—		—		Interest expense	126		126
	$	15,459	$	7,642	Total interest expense	$	2,367	$	74

The Company estimates that $4.4 million will be reclassified from AOCI to interest expense over the next 12 months.

Credit-risk-related Contingent Features

The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

As of September 30, 2020, the fair value of derivatives in a net liability position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was $15.1 million. As of September 30, 2020, the Company has not posted any collateral related to these agreements and was not in breach of any agreement.

Note 6. Commitments and Contingencies

Legal Proceedings

The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Redevelopment Activity

The Company initiated the redevelopment of a 110,883 square foot medical office building in Memphis, Tennessee ("Memphis Redevelopment") in December 2019. As of September 30, 2020, the Company funded approximately $5.7 million in project costs, excluding the purchase price of $8.7 million for the land and building. The building will continue to operate with in-place leases during construction. The core and shell portion of the Memphis Redevelopment is expected to be completed in the first quarter of 2021, with construction of tenant spaces to be completed throughout the remainder of 2021.

Table of Contents

Development Activity

In the first quarter of 2020, the Company completed the construction of the core and shell of a 151,031 square foot medical office building in Seattle, Washington. As of September 30, 2020, the Company had funded approximately $59.1 million towards the development and additional tenant improvements. The Company expects to fund an additional amount of approximately $5.0 million for additional tenant improvements associated with this project. The first tenant commenced rent payment in the first quarter of 2020.

Note 7. Stockholders' Equity

Common Stock

The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2020 and the year ended December 31, 2019:


	SEPTEMBER 30, 2020	DECEMBER 31, 2019
Balance, beginning of period	134,706,154	125,279,455
Issuance of common stock	1,292,324	9,251,440
Nonvested share-based awards, net of withheld shares	55,462	175,259
Balance, end of period	136,053,940	134,706,154

At-The-Market Equity Offering Program

On February 14, 2020, the Company entered into sales agreements with six investment banks to allow sales under its at-the-market equity offering program of up to an aggregate of $500.0 million of common stock. The Company sold 1,268,237 shares under the Company's at-the market equity offering program during the nine months ended September 30, 2020. The sales generated $39.9 million in net proceeds at prices to the public ranging from $30.50 to $36.15 per share (weighted average of $31.86 per share). The sales occurred during the following time periods:

•During the first quarter of 2020, the Company sold 196,250 shares generating approximately $7.0 million in net proceeds at prices to the public ranging from $33.00 to $36.15 per share (weighted average of $36.09 per share).

•During the second quarter of 2020, the Company sold 1,071,987 shares generating approximately $32.9 million in net proceeds at prices to the public ranging from $30.50 to $31.29 per share (weighted average of $31.08 per share).

In addition, the Company has entered into three forward equity agreements totaling 3.6 million shares at a weighted average price of $31.30 per share:

•In the second quarter of 2020, the Company entered into a forward equity agreement for a total of 1,579,371 shares at a weighted average price of $31.66 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in June 2021.

•In the third quarter of 2020, the Company entered into a forward equity agreement for a total of 764,472 shares at a weighted average price of $31.84 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in July 2021.

•In the fourth quarter of 2020, the Company entered into a forward equity agreement for a total of 1,235,129 shares at a weighted average price of $30.52 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in October 2021.

After taking into account the forward equity contracts discussed above, the Company has approximately $347.6 million remaining available to be sold under the current sales agreements at the date of this filing.

Common Stock Dividends

During the nine months ended September 30, 2020, the Company declared and paid common stock dividends totaling $0.90 per share. On November 3, 2020, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on December 1, 2020 to stockholders of record on November 16, 2020.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Earnings Per Common Share

The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method.

During the nine months ended September 30, 2020, the Company entered into forward sale agreements to sell approximately 2.3 million shares of common stock through the Company's at-the-market equity offering program. The Company considered the accounting guidance governing financial instruments and derivatives to account for these agreements and concluded that it was not a liability as it did not embody obligations to repurchase our shares of common stock nor did it embody obligations to issue a variable number of shares for which the monetary value was predominately fixed, varying with something other than the fair value of the shares, or varying inversely in relation to the shares. In addition, the Company evaluated whether the agreements met the derivative and hedging guidance scope exception to be accounted for as an equity instrument and concluded that the agreements can be classified as equity.

The Company used the treasury method to determine the dilution from the forward equity agreements during the period of time prior to settlement. The number of weighted-average shares outstanding used in the computation of earnings per common share for the three and nine months ended September 30, 2020 included the effect from the assumed issuance of 2.3 million shares of common stock pursuant to the settlement of the forward equity agreements at the contractual price, less the assumed repurchase of the common stock at the average market price using the proceeds of approximately $72.7 million, adjusted for costs to borrow. For the three and nine months ended September 30, 2020, 137,757 and 51,133 weighted-average incremental shares of common stock were excluded from the computation of weighted-average common shares outstanding - diluted, as the impact was anti-dilutive.

The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2020 and 2019.


	THREE MONTHS ENDED SEPTEMBER 30,				NINE MONTHS ENDED SEPTEMBER 30,
Dollars in thousands, except per share data	2020		2019		2020		2019
Weighted average common shares outstanding
Weighted average common shares outstanding	136,048,781		129,865,985		135,393,798		128,348,638
Non-vested shares	(1,739,364)		(1,775,911)		(1,731,658)		(1,777,743)
Weighted average common shares outstanding - basic	134,309,417		128,090,074		133,662,140		126,570,895

Weighted average common shares outstanding - basic	134,309,417		128,090,074		133,662,140		126,570,895
Dilutive effect of forward equity shares	—		—		—		—
Dilutive effect of employee stock purchase plan	47,810		78,610		74,029		85,690
Weighted average common shares outstanding - diluted	134,357,227		128,168,684		133,736,169		126,656,585

Net Income	$	8,230	$	2,601	$	88,058	$	11,975
Dividends paid on nonvested share-based awards	(522)		(534)		(1,561)		(1,603)
Net income applicable to common stockholders	$	7,708	$	2,067	$	86,497	$	10,372





Basic earnings per common share - net income	$	0.06	$	0.02	$	0.65	$	0.08


Diluted earnings per common share - net income	$	0.06	$	0.02	$	0.65	$	0.08

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Incentive Plans

A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2020 and 2019 is included in the table below.


	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,
	2020	2019	2020	2019
Share-based awards, beginning of period	1,739,258	1,778,134	1,754,066	1,769,863
Granted	188	—	79,025	89,767
Vested 1	—	(204,548)	(93,645)	(286,044)

Share-based awards, end of period	1,739,446	1,573,586	1,739,446	1,573,586

1The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of 204,548 outstanding nonvested share-based awards.

During the nine months ended September 30, 2020 and 2019, the Company withheld 23,563 and 100,036 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2020 and 2019 is included in the table below.


	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,
	2020	2019	2020	2019
Outstanding and exercisable, beginning of period	361,719	363,218	332,659	328,533
Granted	—	—	212,716	235,572
Exercised	(3,504)	(9,927)	(17,871)	(28,943)
Forfeited	(6,659)	(11,762)	(36,154)	(51,559)
Expired	—	—	(139,794)	(142,074)
Outstanding and exercisable, end of period	351,556	341,529	351,556	341,529

Note 8. Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

•Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.

•Borrowings under the Unsecured Credit Facility and the Term Loans Due 2024 and 2026 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.

•Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.

•Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.

The table below details the fair values and carrying values for notes and bonds payable at September 30, 2020 and December 31, 2019.


	September 30, 2020				December 31, 2019
Dollars in millions	CARRYING VALUE		FAIR VALUE		CARRYING VALUE		FAIR VALUE
Notes and bonds payable 1	$	1,554.4	$	1,621.7	$	1,414.1	$	1,425.8

1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Disclosure Regarding Forward-Looking Statements

This report and other materials the Company has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, disclosures that are “forward-looking statements.” Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “target,” “intend,” “plan,” “estimate,” “project,” “continue,” “should,” “could," "budget" and other comparable terms. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of risks and uncertainties, including the duration and scope of the COVID-19 pandemic; the impact of the COVID-19 pandemic on occupancy rates for the Company's properties, actions governments take in response to the COVID-19 pandemic, including the introduction of public health measures and other regulations affecting the Company’s properties and the operations of the Company and its tenants; the effects of health and safety measures adopted by the Company and its tenants related to the COVID-19 pandemic; the impact of the COVID-19 pandemic on the operations, business and financial condition of the Company and its tenants; general economic uncertainty in key markets as a result of the COVID-19 pandemic and a worsening of global economic conditions or low levels of economic growth; the status of capital markets, including availability and cost of capital; and the risks described in this report and the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, that could significantly affect the Company’s current plans and expectations and future financial condition and results.

The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Stockholders and investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in the Company’s filings and reports, including, without limitation, estimates and projections regarding the performance of development projects the Company is pursuing.

For a detailed discussion of the Company’s risk factors, please refer to the Company’s filings with the Securities and Exchange Commission, including this report, its Annual Report on Form 10-K for the year ended December 31, 2019, and the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020.

COVID-19 Update

In response to the COVID-19 pandemic, all of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants temporarily closed their offices or clinical space or operated on a reduced basis in response to government requirements or recommendations. Many of these restrictions have been lifted, but could be reimposed. In response to these disruptions, the Company provided some of its tenants with deferred rent arrangements. Through November 2, 2020, the Company has collected more than 99% of second and third quarter 2020 aggregate tenant billings. The Company has collected 96% of total scheduled deferral payments in the third quarter of 2020. In addition, the Company has remaining various forms of rent deferrals outstanding representing approximately $1.2 million, or less than 1% of second and third quarter 2020 aggregate tenant billings. The tenant deferral agreements generally require the deferred amounts to be repaid by the fourth quarter of 2020.

If tenants are unable to timely repay, or repay at all, deferred rent, if they request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads (See “Expiring Leases” below), the impact on the Company’s results of operations and financial condition could be material. In the second quarter of 2020, the Company recognized an approximately $0.7 million general reserve against the deferred rent balance. Following positive collection trends in the third quarter of 2020, the Company released approximately $0.3 million of the general reserve. As of September 30, 2020, the Company had a remaining general reserve of $0.4 million against an approximate $1.7 million deferred rent balance.

Table of Contents

At September 30, 2020, the Company had available $882.6 million in liquidity (See “Sources and Uses of Cash” and “Financing Activities” below) and no significant debt maturities prior to 2023. In addition, the Company has entered into forward equity agreements that have expected proceeds of up to approximately $112.0 million, before the costs of borrowing, that can be settled at the Company's election anytime through October 2021. The COVID-19 pandemic has affected the availability and cost of capital and may continue to do so for some time. Management believes that the Company currently has adequate liquidity to operate its business without significant disruption. However, if the pandemic continues to have an impact on the availability and cost of capital, the Company’s business could be materially affected.

Liquidity and Capital Resources

Sources and Uses of Cash

The Company’s primary sources of cash include rent receipts from its real estate portfolio based on contractual arrangements with its tenants, borrowings under the Company's Unsecured Credit Facility and Term Loan, proceeds from the sales of real estate properties and proceeds from public or private debt or equity offerings. As of September 30, 2020, the Company had $700.0 million available to be drawn on its Unsecured Credit Facility and $182.6 million in cash and restricted cash. In addition, the Company has entered into forward equity agreements that have expected proceeds of up to approximately $112.0 million, before the costs of borrowing, that can be settled at the Company's election anytime through October 2021.

The Company expects to continue to meet its liquidity needs, including funding additional investments, paying dividends, and funding debt service, through cash flows from operations and the cash flow sources described above. The Company had unencumbered real estate assets with a gross book value of approximately $4.1 billion at September 30, 2020, of which a portion could serve as collateral for secured mortgage financing. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Investing Activities

Cash flows used in investing activities for the nine months ended September 30, 2020 were approximately $259.9 million. Below is a summary of significant investing activities.

2020 Acquisitions

The following table details the Company's acquisitions for the nine months ended September 30, 2020:


Dollars in millions	HEALTH SYSTEM AFFILIATION	DATE ACQUIRED	PURCHASE PRICE		SQUARE FOOTAGE	CAP RATE		MILES TO CAMPUS
Los Angeles, CA	MemorialCare Health	1/3/20	$	42.0	86,986	5.3	%	0.14
Atlanta, GA	Wellstar Health System	2/13/20	12.0		64,624	5.6	%	0.10
Raleigh, NC	WakeMed Health	2/25/20	6.3		15,964	6.7	%	0.04
Colorado Springs, CO	None	3/9/20	8.2		34,210	6.5	%	1.60
Denver, CO 1	UCHealth	3/13/20	33.5		136,994	6.1	%	0.24
San Diego, CA	Palomar Health	7/1/20	16.7		46,083	5.9	%	0.04
Los Angeles, CA	Cedars-Sinai/Huntington	7/17/20	35.0		49,785	5.4	%	0.11
Seattle, WA	MultiCare Health System	7/23/20	11.0		21,309	5.6	%	0.06
Atlanta, GA	Wellstar Health System	7/31/20	20.5		48,145	6.2	%	0.13
Houston, TX	Memorial Hermann Health	9/24/20	11.0		40,235	5.6	%	0.03
Los Angeles, CA	Providence St. Joseph Health	9/28/20	14.0		24,252	5.6	%	0.03

Total real estate acquisitions			$	210.2	568,587	5.7	%
Land acquisition 2			1.6		—
Land acquisition 3			1.0		—
			$	212.8	568,587

1Includes three properties.

2The Company acquired land parcels under four existing buildings (previously ground leased with the hospital system).

3The Company acquired a land parcel under an existing building (previously ground leased). The building and land were disposed September 30, 2020.

Table of Contents

Subsequent Acquisition

On October 7, 2020 the Company acquired a 36,720 square foot medical office building in Colorado Springs, CO for a purchase price of $8.9 million.

2020 Dispositions

The Company disposed of three properties during the nine months ended September 30, 2020 for a total sales price of $249.5 million, including cash proceeds of $249.3 million and $0.2 million of closing costs and related adjustments. The following table details these dispositions for the nine months ended September 30, 2020:


Dollars in millions	Date Disposed	Sales Price		Square Footage	3Q 2020 NOI		Disposition Cap Rate		Property Type
Springfield, MO	7/30/20	$	138.0	186,000	$	0.8	7.5	%	SF
Oklahoma City, OK	7/30/20	106.5		200,000	0.6		7.5	%	MOB
Miami, FL	9/30/20	5.0		26,000	—		3.9	%	MOB
Total dispositions		$	249.5	412,000	$	1.4	7.4	%

1MOB = Medical office building; SF = Surgical facility

Capital Funding

During the nine months ended September 30, 2020, the Company funded the following:

•$17.3 million toward development and redevelopment of properties;

•$14.2 million toward first generation tenant improvements and planned capital expenditures for acquisitions;

•$17.4 million toward second generation tenant improvements; and

•$12.8 million toward capital expenditures.

Financing Activities

Cash flows provided by financing activities for the nine months ended September 30, 2020 were approximately $30.3 million. Inflows from equity related to the Company's common stock issuances and net borrowings totaled $160.5 million, net of issuance costs incurred. Aggregate cash outflows totaled approximately $130.2 million primarily associated with dividends paid to common stockholders. See Notes 4 and 7 to the Condensed Consolidated Financial Statements for more information about capital markets and financing activities.

Common Stock Issuances

In addition, the Company has entered into three forward equity agreements totaling 3.6 million shares at a weighted average price of $31.30 per share:

Table of Contents

Debt Activity

On March 4, 2020, the Company issued $300.0 million of Senior Notes due 2030 in a registered public offering. The Senior Notes due 2030 bear interest at 2.40%, payable semi-annually on March 15 and September 15, beginning September 15, 2020, and are due on March 15, 2030, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $1.0 million and the Company incurred approximately $2.8 million in debt issuance costs. Concurrent with this transaction, the Company settled two treasury rate locks for $4.3 million. Inclusive of the discount, debt issuance costs and settlement of the treasury rate locks, the effective interest rate was 2.71%. The Senior Notes due 2030 have various financial covenants that are required to be met on a quarterly and annual basis.

On May 29, 2020, the Company borrowed $150.0 million from its unsecured term loan due 2026.

The Company has outstanding interest rate derivatives totaling $175.0 million to hedge one-month LIBOR. The following details the amount and rate of each swap (dollars in thousands):


EFFECTIVE DATE	AMOUNT		WEIGHTED AVERAGE RATE		EXPIRATION DATE
December 18, 2017	$	25,000	2.18	%	December 16, 2022
February 1, 2018	50,000		2.46	%	December 16, 2022
May 1, 2019	50,000		2.33	%	May 1, 2026
June 3, 2019	50,000		2.13	%	May 1, 2026
	$	175,000	2.29	%

Subsequent Debt Activity

Table of Contents

On October 2, 2020, the Company issued $300.0 million of Senior Notes due 2031 in a registered public offering. The Senior Notes due 2031 bear interest at 2.05%, payable semi-annually on March 15 and September 15, beginning March 15, 2021, and are due on March 15, 2031, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $2.4 million and the Company incurred approximately $2.8 million in debt issuance costs. Inclusive of the discount and debt issuance costs, the effective interest rate was 2.24%. The Senior Notes due 2031 have various financial covenants that are required to be met on a quarterly and annual basis.

On October 19, 2020, the Company redeemed its Senior Notes due 2023. The aggregate redemption price of $270.5 million consisted of outstanding principal of $250.0 million, accrued interest of $0.1 million, and a "make-whole" amount of approximately $20.4 million for the early extinguishment of debt. The unaccreted discount and unamortized costs on these notes of $1.1 million was written off upon redemption. In October 2020, the Company recognized a loss on early extinguishment of debt of approximately $21.5 million related to this redemption.

Operating Activities

Cash flows provided by operating activities increased from $158.5 million for the nine months ended September 30, 2019 to $411.6 million for the nine months ended September 30, 2020. Items impacting cash flows from operations include, but are not limited to, cash generated from property operations, interest payments and the timing related to the payment of invoices and other expenses. Also included in operating cash flows was approximately $244.4 million of proceeds from the dispositions of sale-type lease properties.

The Company may, from time to time, sell properties and redeploy cash from property sales into new investments. To the extent revenues related to the properties being sold exceed income from these new investments, the Company's results of operations and cash flows could be adversely affected.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

New Accounting Pronouncements

See Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report for information on new accounting standards.

Trends and Matters Impacting Operating Results

Management monitors factors and trends important to the Company and the REIT industry to gauge the potential impact on the operations of the Company. In addition to the matters discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, below are some of the factors and trends that management believes may impact future operations of the Company.

COVID-19 Pandemic

For information on the ways that the COVID-19 pandemic is impacting the Company and its tenants, see "COVID-19 Update" above.

Expiring Leases

The Company expects that approximately 15% to 20% of the leases in its multi-tenanted portfolio will expire each year in the ordinary course of business. There are 211 leases totaling 0.8 million square feet in the Company's multi-tenant portfolio that will expire during the remainder of 2020. Approximately 85% of the leases expiring in 2020 are in buildings located on or adjacent to hospital campuses, are distributed throughout the portfolio, and are not concentrated with any one tenant, health system or market area. The Company typically expects to retain 75% to 90% of multi-tenant property tenants upon expiration, and the retention ratio for the first nine months of the year has been within this range.

Previously included in the 2020 lease expirations was a 111,000 square foot fitness center leased by Baylor Scott & White Health. The fitness center is located in a 217,000 square foot on-campus medical office building. A new operator, Cowboys Fit, executed an approximately 14-year lease for a reconfigured 52,000 square foot fitness center.

Table of Contents

Baylor has executed a temporary lease at a reduced rental rate to continue to operate the existing fitness center until the construction of the new center is complete. Once the Baylor lease expires, the remaining 59,000 square feet is expected to be redeveloped into clinical space. In addition, the Company plans to upgrade the common areas, bathrooms, and the exterior of the building.

Previously included in the 2020 lease expirations was the July 31 expiration of a 62,000 square foot office lease. A telecommunication company occupied three floors of a 145,000 square foot office building and vacated upon expiration of the lease. The Company recognized revenue of approximately $0.1 million related to this lease in the third quarter of 2020. The Company intends to reposition the property, converting the vacated space from full floor to multi-tenant configurations. The Company has begun marketing the space and has executed a 10,000 square foot lease.

The Company had an 83,000 square foot, single-tenant net leased, on-campus medical office building with a lease term that expired in the second quarter of 2020. The Company has been in discussions about a long-term lease renewal, but given the COVID-19 pandemic, executed a 6-month extension through December 31, 2020 to allow more time to finalize a long-term lease agreement.

Operating Expenses

The Company has historically experienced increases in property taxes throughout its portfolio as a result of increasing assessments and tax rates levied across the country. The Company continues its efforts to appeal property tax increases and manage the impact of the increases. In addition, the Company has historically incurred variability in portfolio utilities expense based on seasonality, with the first and third quarters usually reflecting greater amounts. The effects of these operating expense increases are mitigated in leases that have provisions for operating expense reimbursement. As of September 30, 2020, leases for 89% of the Company's multi-tenant leased square footage allow for some recovery of operating expenses, with 31% having modified gross lease structures and 58% having net lease structures.

Purchase Options

Information about the Company's unexercised purchase options and the amount and basis for determination of the purchase price is detailed in the table below (dollars in thousands):


	NUMBER OF PROPERTIES		GROSS REAL ESTATE INVESTMENT AS OF SEPTEMBER 30, 2020
YEAR EXERCISABLE	MOB	INPATIENT	FAIR MARKET VALUE METHOD 1		NON FAIR MARKET VALUE METHOD 2		TOTAL
Current 3	3	1	$	96,865	$	—	$	96,865
2021	1	—	—		14,984		14,984
2022	—	—	—		—		—
2023	—	—	—		—		—
2024	—	—	—		—		—
2025	4	—	48,165		19,459		67,624
2026	—	—	—		—		—
2027	—	—	—		—		—
2028	1	—	43,961		—		43,961
2029	1	—	26,494		—		26,494
2030 and thereafter	4	—	101,118		—		101,118
Total	14	1	$	316,603	$	34,443	$	351,046

1The purchase option price includes a fair market value component that is determined by an appraisal process.

2Includes properties with stated purchase prices or prices based on fixed capitalization rates.

3These purchase options have been exercisable for an average of 12.1 years.

Table of Contents

Non-GAAP Financial Measures and Key Performance Indicators

Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of these measures to the most directly comparable GAAP financial measures.

The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.

Funds from Operations ("FFO"), Normalized FFO and Funds Available for Distribution ("FAD")

FFO and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to “net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus depreciation and amortization, impairment, and after adjustments for unconsolidated partnerships and joint ventures.”

In addition to FFO, the Company presents Normalized FFO and FAD. Normalized FFO is presented by adding to FFO acquisition-related costs, acceleration of debt issuance costs, debt extinguishment costs and other Company-defined normalizing items to evaluate operating performance. FAD is presented by adding to Normalized FFO non-real estate depreciation and amortization, deferred financing fees amortization, stock-based compensation expense and provision for bad debts, net; and subtracting maintenance capital expenditures, including second generation tenant improvements and leasing commissions paid and straight-line rent income, net of expense. The Company's definition of these terms may not be comparable to that of other real estate companies as they may have different methodologies for computing these amounts. Normalized FFO and FAD should not be considered as an alternative to net income as an indicator of the Company's financial performance or to cash flow from operating activities as an indicator of the Company's liquidity. Normalized FFO and FAD should be reviewed in connection with GAAP financial measures.

Management believes FFO, Normalized FFO, FFO per share, Normalized FFO per share and FAD ("Non-GAAP Measures") provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, Non-GAAP Measures can facilitate comparisons of operating performance between periods. The Company reports Non-GAAP Measures because these measures are observed by management to also be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these Non-GAAP Measures. However, none of these measures represent cash generated from operating activities determined in accordance with GAAP and are not necessarily indicative of cash available to fund cash needs. Further, these measures should not be considered as an alternative to net income as an indicator of the Company’s operating performance or as an alternative to cash flow from operating activities as a measure of liquidity. The table below reconciles net income to FFO, Normalized FFO and FAD for the three and nine months ended September 30, 2020 and 2019.

Table of Contents


	THREE MONTHS ENDED SEPTEMBER 30,				NINE MONTHS ENDED SEPTEMBER 30,
Amounts in thousands, except per share data	2020		2019		2020		2019
Net income	$	8,230	$	2,601	$	88,058	$	11,975
(Gain) on sales of real estate assets	(2,177)		(200)		(70,395)		(5,065)
Impairment of real estate assets	—		—		—		5,610
Real estate depreciation and amortization	48,295		45,926		145,564		133,993
FFO attributable to common stockholders	$	54,348	$	48,327	$	163,227	$	146,513
Acquisition and pursuit costs 1	440		501		1,621		1,227
Lease intangible amortization	(35)		5		694		143
Accelerated Stock Awards	—		2,854		—		2,854
Debt financing costs	—		—		—		760
Normalized FFO attributable to common stockholders	$	54,753	$	51,687	$	165,542	$	151,497
Non-real estate depreciation and amortization	785		838		2,430		2,430
Non-cash interest expense amortization 2	934		727		2,715		2,136
Provision for bad debt, net	(144)		(32)		718		43
Straight-line rent, net	(535)		(379)		(1,577)		(650)
Stock-based compensation 3	2,445		2,375		7,449		7,386
Normalized FFO adjusted for non-cash items	$	58,238	$	55,216	$	177,277	$	162,842
2nd generation TI	(5,323)		(6,114)		(17,368)		(16,564)
Leasing commissions paid	(1,999)		(2,697)		(7,081)		(6,359)
Capital additions	(4,580)		(3,543)		(12,827)		(11,998)
FAD	$	46,336	$	42,862	$	140,001	$	127,921
FFO per common share - diluted	$	0.40	$	0.37	$	1.21	$	1.15
Normalized FFO per common share - diluted	$	0.41	$	0.40	$	1.23	$	1.19
FFO weighted average common shares outstanding - diluted 4	135,159		129,015		134,537		127,424

1Acquisition and pursuit costs include third party and travel costs related to the pursuit of acquisitions and developments.

2Includes the amortization of deferred financing costs, discounts and premiums.

3The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in a $2.9 million charge for the acceleration of his outstanding nonvested share-based awards and associated taxes.

4The Company utilizes the treasury stock method which includes the dilutive effect of nonvested share-based awards outstanding of 801,382 and 800,370, respectively for the three and nine months ended September 30, 2020.

Cash NOI and Same Store Cash NOI

Cash NOI and Same Store Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level operating results. The Company defines Cash NOI as rental income and property lease guaranty income less property operating expenses. Cash NOI excludes non-cash items such as above and below market lease intangibles, straight-line rent, lease inducements, tenant improvement amortization and leasing commission amortization. The Company also excludes cash lease termination fees. Cash NOI is historical and not necessarily indicative of future results.

Same Store Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented and include redevelopment projects. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, reposition properties and newly developed properties. The Company utilizes the reposition classification for properties experiencing a shift in strategic direction. Such a shift can occur for a variety of reasons, including a substantial change in the use of the asset, a change in strategy or closure of a neighboring hospital, or significant property damage. Such properties may require enhanced management, leasing, capital needs or a disposition strategy that differs from the rest of the portfolio. To identify properties exhibiting these reposition characteristics, the Company applies the following Company-defined criteria:

•Properties having less than 60% occupancy that is expected to last at least two quarters;

•Properties that experience a loss of occupancy over 30% in a single quarter; or

Table of Contents

•Properties with negative net operating income that is expected to last at least two quarters.

Any recently acquired property will be included in the same store pool once the Company has owned the property for eight full quarters. Newly developed properties will be included in the same store pool eight full quarters after substantial completion. Any additional square footage created by redevelopment projects at a same store property is included in the same store pool immediately upon completion. Any property included in the reposition property group will be included in the same store analysis once occupancy has increased to 60% or greater with positive net operating income and has remained at that level for eight full quarters.

During the third quarter of 2020, the Company's reposition pool increased by one property to a total of 11 properties. Two properties were reclassified from reposition to held for sale, two properties were reclassified into reposition pursuant to the Company-defined criteria outlined above and one property that is undergoing a shift in strategic direction as a significant portion of the building is being repurposed from fitness space to clinical space was reclassified from same store to reposition . This 217,000 square foot on-campus medical office building included a 111,000 square foot fitness center previously leased by Baylor Scott & White Health. A new operator, Cowboys Fit, executed an approximately 14-year lease for a reconfigured 52,000 square foot fitness center. Baylor has executed a temporary lease for the remaining 59,000 square feet at a reduced rental rate to continue to operate the existing fitness center until the construction of the new center is complete. Once the Baylor lease expires, the remaining 59,000 square feet is expected to be redeveloped into clinical space. In addition, the Company plans to upgrade the common areas, bathrooms, and the exterior of the building.

The following table reflects the Company's same store cash NOI for the three months ended September 30, 2020 and 2019.


	NUMBER OF PROPERTIES	GROSS INVESTMENT at September 30, 2020		SAME STORE CASH NOI for the three months ended September 30,
Dollars in thousands	NUMBER OF PROPERTIES	GROSS INVESTMENT at September 30, 2020		2020		2019
Multi-tenant properties	156	$	3,237,143	$	57,663	$	56,317
Single-tenant net lease properties	12	257,229		6,033		5,870
Total	168	$	3,494,372	$	63,696	$	62,187

The following tables reconcile net income to same store NOI and the same store property metrics to the total owned real estate portfolio for the three months ended September 30, 2020 and 2019:

Reconciliation of Same Store Cash NOI


	THREE MONTHS ENDED SEPTEMBER 30,
Dollars in thousands	2020		2019
Net income	$	8,230	$	2,601


Other income (expense)	11,969		13,981
General and administrative expense	7,299		10,802
Depreciation and amortization expense	47,143		45,137
Other expenses 1	2,737		2,462
Straight-line rent revenue	(915)		(770)
Other revenue 2	(3,062)		(1,726)
Cash NOI	73,401		72,487
Cash NOI not included in same store	(9,705)		(10,300)
Same store cash NOI	63,696		62,187
Reposition NOI	1,358		1,660
Same store and reposition cash NOI	$	65,054	$	63,847

1Includes acquisition and pursuit costs, bad debt, above and below market ground lease intangible amortization, leasing commission amortization and ground lease straight-line rent expense.

2Includes management fee income, interest, above and below market lease intangible amortization, lease inducement amortization, lease terminations and tenant improvement overage amortization.

Table of Contents

Reconciliation of Same Store Properties


	AS OF SEPTEMBER 30, 2020
	PROPERTY COUNT	GROSS INVESTMENT		SQUARE FEET	OCCUPANCY
Same store properties	168	$	3,494,372	12,795,403	88.4	%
Acquisitions	31	647,974		1,667,990	91.4	%
Development completions	1	51,889		151,031	60.5	%
Reposition	11	142,381		859,004	62.1	%
Total owned real estate properties	211	$	4,336,616	15,473,428	87.0	%

Results of Operations

Three Months Ended September 30, 2020 Compared to Three Months Ended September 30, 2019

The Company’s results of operations for the three months ended September 30, 2020 compared to the same period in 2019 were impacted by acquisitions, developments, dispositions, gains on sale, and capital markets transactions.

Revenues

Total revenues increased $5.5 million, or 4.6%, to approximately $125.3 million for the three months ended September 30, 2020 compared to $119.8 million in the prior year period. This increase is comprised of the following:


	THREE MONTHS ENDED SEPTEMBER 30,				CHANGE
Dollars in thousands	2020		2019		$		%
Property operating	$	114,921	$	105,805	$	9,116	8.6	%
Single-tenant net lease	7,548		11,165		(3,617)		(32.4)	%
Straight-line rent	915		770		145		18.8	%
Rental income	123,384		117,740		5,644		4.8	%
Other operating	1,868		2,059		(191)		(9.3)	%
Total revenues	$	125,252	$	119,799	$	5,453	4.6	%

Property operating revenue increased $9.1 million, or 8.6%, from the prior year period primarily as a result of the following activity:

•Acquisitions in 2019 and 2020 contributed $7.4 million.

•A development completed in 2020 contributed $0.8 million.

•Leasing activity, including contractual rent increases, contributed $1.4 million.

•Dispositions in 2019 and 2020 resulted in a decrease of $0.5 million.

Single-tenant net lease revenue decreased $3.6 million, or 32.4%, from the prior year period primarily as a result of the following activity:

•Dispositions in 2019 and 2020 resulted in a decrease of $3.8 million.

•An acquisition in 2020 contributed $0.1 million.

•Leasing activity contributed $0.1 million.

Table of Contents

Straight-line rent revenue increased $0.1 million or 18.8% from the prior year period primarily as a result of the following activity:

•Acquisitions in 2019 and 2020 contributed $0.4 million.

•A development completed in 2020 contributed $0.1 million.

•Leasing, including contractual rent increases, resulted in a decrease of $0.3 million.

•Dispositions in 2019 and 2020 resulted in a decrease of $0.1 million.

Other operating income decreased $0.2 million or 9.3% from the prior year period primarily due to a reduction in variable parking revenue.

Expenses

Property operating expenses increased $3.4 million, or 7.3%, for the three months ended September 30, 2020 compared to the prior year period primarily as a result of the following activity:

•Acquisitions in 2019 and 2020 resulted in an increase of $3.1 million.

•A development completed in 2020 resulted in an increase of $0.2 million.

•Increases in portfolio operating expenses as follows:

•Portfolio property tax expense of $0.6 million;

•Janitorial expenses of $0.2 million; and

•Portfolio insurance expense of $0.1 million.

•Maintenance and repair expense decreased $0.3 million.

•Utilities expense decreased $0.1 million.

•Dispositions in 2019 and 2020 resulted in a decrease of $0.4 million.

General and administrative expenses decreased approximately $3.5 million, or 32.4%, for the three months ended September 30, 2020 compared to the prior year period primarily as a result of the following activity:

•The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in a $2.9 million charge for the three months ended September 30, 2019 because of the acceleration of his outstanding nonvested share-based awards and associated taxes.

•Decrease in performance-based awards of approximately $0.2 million.

•Decrease in travel expense of $0.4 million.

Depreciation and amortization expense increased $2.0 million, or 4.4%, for the three months ended September 30, 2020 compared to the prior year period primarily as a result of the following activity:

•Acquisitions in 2019 and 2020 and a development in 2020 resulted in an increase of $4.2 million.

•Various building and tenant improvement expenditures resulted in an increase of $2.8 million.

•Dispositions in 2019 and 2020 resulted in a decrease of $1.6 million.

•Assets that became fully depreciated resulted in a decrease of $3.4 million.

Other income (Expense)

Gains on sale of real estate properties

In the third quarter of 2020, the Company recognized a gain of approximately $2.2 million on the sale of one property.

In the third quarter of 2019, the Company recognized gains of approximately $0.2 million on the sale of two properties.

Interest expense

Table of Contents

Interest expense did not change significantly for the three months ended September 30, 2020 compared to the prior year period. The components of interest expense are as follows:


	THREE MONTHS ENDED SEPTEMBER 30,				CHANGE
Dollars in thousands	2020		2019		$		%
Contractual interest	$	13,182	$	13,605	$	(423)	(3.1)	%
Net discount/premium accretion	102		72		30		41.7	%
Deferred financing costs amortization	683		613		70		11.4	%
Interest rate swap amortization	42		42		—		—	%
Treasury hedge amortization	107		—		107		—	%
Interest cost capitalization	(207)		(347)		140		(40.3)	%
Right-of-use assets financing amortization	245		196		49		25.0	%
Total interest expense	$	14,154	$	14,181	$	(27)	(0.2)	%

Contractual interest expense decreased $0.4 million, or 3.1%, primarily due to the following activity:

•The Senior Notes due 2030 accounted for an increase of $1.8 million.

•The Term Loan due 2024 and the initial funding of the Term Loan due 2026, net of swaps, accounted for an increase of approximately $0.4 million.

•The Unsecured Credit Facility principal and rate decreases accounted for a decrease of approximately $2.3 million.

•Mortgage note assumptions and repayments accounted for a net decrease of $0.3 million.

Nine Months Ended September 30, 2020 Compared to Nine Months Ended September 30, 2019

The Company’s results of operations for the nine months ended September 30, 2020 compared to the same period in 2019 were impacted by acquisitions, developments, dispositions, gains on sale, and capital markets transactions.

Revenues

Total revenues increased $25.0 million, or 7.2%, to approximately $373.7 million for the nine months ended September 30, 2020 compared to $348.8 million in the prior year period. This increase is comprised of the following:


	NINE MONTHS ENDED SEPTEMBER 30,				CHANGE
Dollars in thousands	2020		2019		$		%
Property operating	$	337,144	$	307,606	$	29,538	9.6	%
Single-tenant net lease	28,519		33,348		(4,829)		(14.5)	%
Straight-line rent	2,722		1,833		889		48.5	%
Rental income	368,385		342,787		25,598		7.5	%
Other operating	5,364		5,987		(623)		(10.4)	%
Total revenues	$	373,749	$	348,774	$	24,975	7.2	%

Property operating revenue increased $29.5 million, or 9.6%, from the prior year period primarily as a result of the following activity:

•Acquisitions in 2019 and 2020 contributed $24.5 million.

•A development completed in 2020 contributed $1.6 million.

•Leasing activity, including contractual rent increases, contributed $5.6 million.

•Dispositions in 2019 and 2020 resulted in a decrease of $2.2 million.

Single-tenant net lease revenue decreased $4.8 million, or 14.5%, from the prior year period primarily as a result of the following activity:

•Dispositions in 2019 and 2020 resulted in a decrease of $5.2 million.

•Leasing activity, including contractual increases, contributed $0.4 million.

Table of Contents

Straight-line rent revenue increased $0.9 million or 48.5% from the prior year period primarily due to acquisitions in 2019 and 2020 and a development in 2020 totaling $1.2 million, partially offset by 2019 and 2020 dispositions totaling $0.3 million.

Other operating income decreased $0.6 million or 10.4% from the prior year period primarily due to a reduction in variable parking revenue.

Expenses

Property operating expenses increased $12.5 million, or 9.4%, for the nine months ended September 30, 2020 compared to the prior year period primarily as a result of the following activity:

•Acquisitions in 2019 and 2020 resulted in an increase of $10.8 million.

•A development completed in 2020 resulted in an increase of $0.4 million.

•Increases in portfolio operating expenses as follows:

•Portfolio property tax expense of $1.9 million;

•Compensation related expenses of $0.3 million;

•Administration and legal fees of $0.3 million;

•Portfolio insurance expense of $0.5 million;

•Portfolio security expense of $0.3 million; and

•Portfolio janitorial expense of $0.2 million.

•Utilities expense resulted in a decrease of $0.6 million.

•Maintenance and repair expense resulted in a decrease of $0.6 million.

•Increase in intangible amortization expense totaling $0.7 million.

•Dispositions in 2019 and 2020 resulted in a decrease of $1.7 million.

General and administrative expenses decreased approximately $3.7 million, or 13.5%, for the nine months ended September 30, 2020 compared to the prior year period primarily due to travel expense.

•The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in a $2.9 million charge for the nine months ended September 30, 2019 because of the acceleration of his outstanding nonvested share-based awards and associated taxes.

•Decrease in incentive-based awards of approximately $0.6 million.

•Decrease in travel expense of $0.6 million.

•Increase in compensation expense of approximately $0.4 million.

Depreciation and amortization expense increased $10.6 million, or 8.1%, for the nine months ended September 30, 2020 compared to the prior year period primarily as a result of the following activity:

•Acquisitions in 2019 and 2020 and a development in 2020 resulted in an increase of $15.3 million.

•Various building and tenant improvement expenditures resulted in an increase of $7.8 million.

•Dispositions in 2019 and 2020 resulted in a decrease of $3.7 million.

•Assets that became fully depreciated resulted in a decrease of $8.8 million.

Other income (expense)

Gains on sale of real estate properties

Gains on sale of real estate properties totaling approximately $70.4 million and $5.1 million are associated with the three and six real estate properties during 2020 and 2019, respectively.

Interest expense

Table of Contents

Interest expense increased $0.9 million, or 2.3%, for the nine months ended September 30, 2020 compared to the prior year period. The components of interest expense are as follows:


	NINE MONTHS ENDED SEPTEMBER 30,				CHANGE
Dollars in thousands	2020		2019		$		%
Contractual interest	$	40,031	$	40,091	$	(60)	(0.1)	%
Net discount/premium accretion	358		174		184		105.7	%
Deferred financing costs amortization	2,003		1,835		168		9.2	%
Interest rate swap amortization	126		126		—		—	%
Treasury hedge amortization	229		—		229		—	%
Interest cost capitalization	(913)		(999)		86		(8.6)	%
Right-of-use assets financing amortization	722		392		330		84.2	%
Total interest expense	$	42,556	$	41,619	$	937	2.3	%

Contractual interest expense decreased $0.1 million, or 0.1%, primarily due to the following activity:

•Senior Notes due 2030 accounted for an increase of approximately $3.9 million.

•The Term Loan due 2024 and the initial funding of the Term Loan due 2026, net of swaps, accounted for an increase of approximately $1.2 million.

•The Unsecured Credit Facility principal and rate decrease accounted for a decrease of approximately $4.7 million.

•Mortgage note assumptions and repayments accounted for a net decrease of $0.5 million.

Impairment of real estate assets

Impairment of real estate assets totaling approximately $5.6 million is associated with the sales of two real estate properties during 2019.

Interest and other income (expense)

In 2019, the Company expensed approximately $0.8 million of debt issuance costs as a result of the Term Loan modification.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed to market risk in the form of changing interest rates on its debt and mortgage notes. Management uses regular monitoring of market conditions and analysis techniques to manage this risk. During the nine months ended September 30, 2020, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports it files or submits under the Exchange Act.

Table of Contents

Changes in Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Item 1A. Risk Factors

In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and the Company's quarterly reports on the Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020 which could materially affect the Company’s business, financial condition or future results. The risks, as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and the Company's quarterly reports on the Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020 are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company’s business, financial condition, operating results or cash flows.

The ongoing COVID-19 pandemic and measures intended to prevent its spread could have a material adverse effect on the Company's business, results of operations, cash flows and financial condition.

The COVID-19 pandemic has had, and another pandemic in the future could have, repercussions across regional and global economies and financial markets. The outbreak of COVID-19 in many countries has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. The global impact of the outbreak has been rapidly evolving and many countries, including the United States, have reacted by instituting quarantines, mandating business and school closures and restricting travel.

All of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants temporarily closed their offices or clinical space or operated on a reduced basis in response to government requirements or recommendations. Many of these restrictions were lifted during the second quarter of 2020, but could be reimposed.

Through November 2, 2020, the Company has collected more than 99% of second and third quarter 2020 aggregate tenant billings. The Company has collected 96% of total scheduled deferral payments in the third quarter of 2020. In addition, the Company has remaining various forms of rent deferrals outstanding representing approximately $1.2 million, or less than 1% of second and third quarter 2020 aggregate tenant billings.

The COVID-19 pandemic has also caused, and is likely to continue to cause, severe economic, market and other disruptions worldwide. There can be no assurance that conditions in the bank lending, capital and other financial markets will not continue to deteriorate as a result of the pandemic, or that the Company's access to capital and other sources of funding will not become constrained, which could adversely affect the availability and terms of future borrowings, renewals or refinancings. In addition, the deterioration of economic conditions as a result of the pandemic may ultimately decrease occupancy levels and average rent per square foot across the Company's portfolio as tenants reduce or defer their spending.

The extent of the COVID-19 pandemic’s effect on the Company's operational and financial performance will depend on future developments, including the duration, spread and intensity of the outbreak, all of which are uncertain and difficult to predict. Due to the speed with which the situation is developing, the Company is not able at this time to estimate the effect of these factors on its business, but the adverse impact on the business, results of operations,

Table of Contents

financial condition and cash flows could be material. Moreover, many risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019 should be interpreted as heightened risks as a result of the impact of the COVID-19 pandemic.

Settlement provisions contained in a forward equity agreement could result in substantial dilution to the Company's earnings per share and return on equity or result in substantial cash payment obligations.

The Company has outstanding forward equity agreements and may enter into additional forward equity agreements in the future. Forward equity agreements typically provide that the relevant forward purchaser will have the right to accelerate that particular forward equity agreement (with respect to all or any portion of the transaction under that particular forward equity agreement that the relevant forward purchaser determines is affected by such event) and require us to settle on a date specified by the relevant forward purchaser if:

•the relevant forward purchaser is unable to establish, maintain or unwind its hedge position with respect to that particular forward equity agreement;

•a termination event occurs as a result of us declaring a dividend or distribution on our common stock with a cash value in excess of a specified amount per calendar quarter, or with an ex-dividend date prior to the anticipated ex-dividend date for such cash dividend;

•an extraordinary event (as such term is defined in that particular forward equity agreement and which includes certain mergers and tender offers and the delisting of our common stock) occurs or our board of directors votes to approve or there is a public announcement of, in either case, any action that, if consummated, would constitute such an extraordinary event; or

•certain other events of default, termination events, or other specified events occur, including, among other things, any material misrepresentation made by us in connection with entering into that particular forward equity agreement, or a nationalization, a bankruptcy termination event or a change in law (as such terms are defined in that particular forward equity agreement).

A forward purchaser’s decision to exercise its right to accelerate the settlement of a particular forward equity agreement will be made irrespective of the Company's need for capital. In such cases, we could be required to issue and deliver shares of common stock under the physical settlement provisions of that particular forward equity agreement or, if we so elect and the forward purchaser so permits our election, net share settlement provisions of that particular forward equity agreement irrespective of our capital needs, which would result in dilution to our earnings per share and return on equity.

We expect that settlement of any forward equity agreement will generally occur no later than the date specified in the particular forward equity agreement, which will generally be no later than twelve months following the trade date of that forward equity agreement. However, any forward equity agreement may be settled earlier than that specified date in whole or in part at our option. We expect that each forward equity agreement will be physically settled by delivery of shares of common stock unless we elect to cash settle or net share settle a particular forward equity agreement. Upon physical settlement or, if we so elect, net share settlement of a particular forward equity agreement, delivery of shares of common stock in connection with such physical settlement or net share settlement will result in dilution to our earnings per share and return on equity. If we elect cash settlement or net share settlement with respect to all or a portion of the shares of common stock underlying a particular forward equity agreement, we expect that the relevant forward purchaser (or an affiliate thereof) will purchase a number of shares of common stock necessary to satisfy its or its affiliate’s obligation to return the shares of common stock borrowed from third parties in connection with sales of shares of common stock under that forward equity agreement, adjusted in the case of net share settlement by any shares deliverable by or to us under the forward equity agreement. In addition, the purchase of shares of common stock in connection with the relevant forward purchaser or its affiliate unwinding its hedge positions could cause the price of shares of common stock to increase over such time (or prevent a decrease over such time), thereby increasing the amount of cash we would owe to the relevant forward purchaser (or decreasing the amount of cash that the relevant forward purchaser would owe us) upon a cash settlement of the relevant forward equity agreement or, in the event of net share settlement, increasing the number of shares of common stock we would deliver to the relevant forward purchaser (or decreasing the number of shares of common stock that the relevant forward purchaser would deliver to us).

Table of Contents

The forward equity price that we expect to receive upon physical settlement of a particular forward equity agreement will be subject to adjustment on a daily basis based on a floating interest rate factor equal to a specified daily rate less a spread and will be decreased based on amounts related to expected dividends on shares of common stock during the term of the particular forward equity agreement. If the specified daily rate is less than the spread on any day, the interest factor will result in a daily reduction of the applicable forward equity price. If the market value of shares of common stock, determined in accordance with the terms of the relevant forward equity agreement, during the relevant valuation period under the particular forward equity agreement is above the applicable forward equity price, in the case of cash settlement, we would pay the relevant forward purchaser under that particular forward equity agreement an amount in cash equal to the difference or, in the case of net share settlement, we would deliver to the relevant forward purchaser a number of shares of common stock having a value, determined in accordance with the terms of the relevant forward equity agreement, equal to the difference. Thus, we could be responsible for a potentially substantial cash payment in the case of cash settlement of a particular forward equity agreement. If the market value of the Company’s common stock, determined in accordance with the terms of the relevant forward equity agreement, during the relevant valuation period under that particular forward equity agreement is below the applicable forward equity price, in the case of cash settlement, we would be paid the difference in cash by the relevant forward purchaser under that particular forward equity agreement or, in the case of net share settlement, we would receive from the relevant forward purchaser a number of shares of common stock having a value equal to the difference.

The U.S. federal income tax treatment of the cash that we might receive from cash settlement of a forward equity agreement is unclear and could jeopardize the Company's ability to meet the REIT qualification requirements.

In the event that we elect to settle any forward equity agreement for cash and the settlement price is below the applicable forward equity price, we would be entitled to receive a cash payment from the relevant forward purchaser. Under Section 1032 of the Internal Revenue Code of 1986, as amended (the "Code"), generally, no gains and losses are recognized by a corporation in dealing in its own shares, including pursuant to a "securities futures contract" (as defined in the Code, by reference to the Securities Exchange Act of 1934, as amended). Although we believe that any amount received by us in exchange for our stock would qualify for the exemption under Section 1032 of the Code, because it is not entirely clear whether a forward equity agreement qualifies as a "securities futures contract," the U.S. federal income tax treatment of any cash settlement payment we receive is uncertain. In the event that we recognize a significant gain from the cash settlement of a forward equity agreement, we might be unable to satisfy the gross income requirements applicable to REITs under the Code. In that case, we may be able to rely upon the relief provisions under the Code in order to avoid the loss of our REIT status. Even if the relief provisions apply, we will be subject to a 100% tax on the greater of (i) the excess of 75% of our gross income (excluding gross income from prohibited transactions) over the amount of such income attributable to sources that qualify under the 75% test or (ii) the excess of 95% of our gross income (excluding gross income from prohibited transactions) over the amount of such gross income attributable to sources that qualify under the 95% test, multiplied in either case by a fraction intended to reflect our profitability. In the event that these relief provisions were not available, we could lose our REIT status under the Code.

In case of our bankruptcy or insolvency, any forward equity agreements will automatically terminate, and we would not receive the expected proceeds from any forward sale of shares of the Company’s common stock.

If we file for or consent to a proceeding seeking a judgment in bankruptcy or insolvency or any other relief under any bankruptcy or insolvency law or other similar law affecting creditors’ rights, or we or a regulatory authority with jurisdiction over us presents a petition for our winding-up or liquidation, and we consent to such a petition, any forward equity agreements that are then in effect will automatically terminate. If any such forward equity agreement so terminates under these circumstances, we would not be obligated to deliver to the relevant forward purchaser any shares of common stock not previously delivered, and the relevant forward purchaser would be discharged from its obligation to pay the applicable forward equity price per share in respect of any shares of common stock not previously settled under the applicable forward equity agreement. Therefore, to the extent that there are any shares of common stock with respect to which any forward equity agreement has not been settled at the time of the commencement of any such bankruptcy or insolvency proceedings, we would not receive the relevant forward equity price per share in respect of those shares of common stock.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Authorized Repurchases of Equity Securities by the Issuer

On May 5, 2020, the Company’s Board of Directors authorized the repurchase of up to $50 million of outstanding shares of the Company’s common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints, and other customary conditions. The Company is not obligated under this authorization to repurchase any specific number of shares. This authorization supersedes all previous stock repurchase authorizations. As of the date of this report, the Company has not repurchased any shares of its common stock under this authorization.

Table of Contents

Item 6. Exhibits


EXHIBIT			DESCRIPTION
Exhibit 3.1			Second Articles of Amendment and Restatement of the Company, as amended 1
Exhibit 3.2			Amended and Restated Bylaws of the Company, as amended 1
Exhibit 4.1			Specimen Stock Certificate 2
Exhibit 4.2			Indenture, dated as of May 15, 2001, by and between the Company and Truist Bank, formally known as Branch Banking and Trust Company , as trustee (as successor to the trustee named therein) 3
Exhibit 4.3			Fifth Supplemental Indenture, dated March 26, 2013, by and between the Company and Truist Bank, formally known as Branch Banking and Trust Company , as Trustee (as successor to the trustee named therein)4
Exhibit 4.4			Form of 3.75% Senior Notes due 2023 (set forth in Exhibit B to the Fifth Supplemental Indenture filed as Exhibit 4.3 thereto) 4
Exhibit 4.5			Sixth Supplemental Indenture, dated April 24, 2015, by and between the Company and Truist Bank, formally known as Branch Banking and Trust Company , as Trustee (as successor to the trustee named therein) 5
Exhibit 4.6			Form of 3.875% Senior Notes due 2025 (set forth in Exhibit B to the Sixth Supplemental Indenture filed as Exhibit 4.5 thereto) 5
Exhibit 4.7			Seventh Supplemental Indenture, dated December 11, 2017, by and between the Company and Truist Bank, formally known as Branch Banking and Trust Company , as Trustee. 6
Exhibit 4.8			Form of 3.625% Senior Note due 2028 (set forth in Exhibit B to the Seventh Supplemental Indenture filed as Exhibit 4.7 hereto). 6
Exhibit 4.9			Eighth Supplemental Indenture, dated March 18, 2020, by and between the Company and Truist Bank, formally known as Branch Banking and Trust Company , as Trustee.7
Exhibit 4.10			Form of 2.400% Senior Note due 2030 (set forth in Exhibit B to the Eighth Supplemental Indenture filed as Exhibit 4.9 hereto). 7
Exhibit 4.11			Ninth Supplemental Indenture, dated October 2 , 2020, by and between the Company and Truist Bank, formally known as Branch Banking and Trust Company , as Trustee. 8
Exhibit 4.12			Form of 2.050% Senior Note due 2031 (set forth in Exhibit B to the Ninth Supplemental Indenture filed as Exhibit 4.11 hereto). 8
Exhibit 31.1			Certification of the Chief Executive Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
Exhibit 31.2			Certification of the Chief Financial Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
Exhibit 32			Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
Exhibit 101.INS			The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
Exhibit 101.SCH			XBRL Taxonomy Extension Schema Document (furnished electronically herewith)
Exhibit 101.CAL			XBRL Taxonomy Extension Calculation Linkbase Document (furnished electronically herewith)
Exhibit 101.LAB			XBRL Taxonomy Extension Labels Linkbase Document (furnished electronically herewith)
Exhibit 101.DEF			XBRL Taxonomy Extension Definition Linkbase Document (furnished electronically herewith)
Exhibit 101.PRE			XBRL Taxonomy Extension Presentation Linkbase Document (furnished electronically herewith)

1Filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2018 filed February 13, 2019 and hereby incorporated by reference.

2Filed as an exhibit to the Company’s Registration Statement on Form S-11 (Registration No. 33-60506) filed April 2, 1993 and hereby incorporated by reference.

3Filed as an exhibit to the Company's Current Report on Form 8-K filed May 17, 2001 and hereby incorporated by reference.

4Filed as an exhibit to the Company's Current Report on Form 8-K filed March 26, 2013 and hereby incorporated by reference.

5Filed as an exhibit to the Company's Current Report on Form 8-K filed April 24, 2015 and hereby incorporated by reference.

6Filed as an exhibit to the Company’s Current Report on Form 8-K filed December 11, 2017 and hereby incorporated by reference.

7Filed as an exhibit to the Company's Current Report on Form 8-K filed March 18, 2020 and hereby incorporated by reference.

8Filed as an exhibit to the Company's Current Report on Form 8-K filed October 2, 2020 and hereby incorporated by reference.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			HEALTHCARE REALTY TRUST INCORPORATED

			By:			/s/ J. CHRISTOPHER DOUGLAS
						J. Christopher Douglas
						Executive Vice President and Chief Financial Officer
						November 4, 2020

EX-31.1 2 hr-2020930xex311.htm EX-31.1 Document

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302

Exhibit 31.1

Healthcare Realty Trust Incorporated

Quarterly Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Todd J. Meredith, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date:	November 4, 2020
		/s/ TODD J. MEREDITH
		Todd J. Meredith
		President and Chief Executive Officer

EX-31.2 3 hr-2020930xex312.htm EX-31.2 Document

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302

Exhibit 31.2

Healthcare Realty Trust Incorporated

Quarterly Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, J. Christopher Douglas, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date:	November 4, 2020
		/s/ J. CHRISTOPHER DOUGLAS
		J. Christopher Douglas
		Executive Vice President and Chief Financial Officer

EX-32 4 hr-2020930xex32.htm EX-32 Document

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350 SECTION 906

Exhibit 32

Healthcare Realty Trust Incorporated

Certification Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Healthcare Realty Trust Incorporated (the “Company”) on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Todd J. Meredith, President and Chief Executive Officer of the Company, and I, J. Christopher Douglas, Executive Vice President and Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:	November 4, 2020
		/s/ TODD J. MEREDITH
		Todd J. Meredith
		President and Chief Executive Officer

		/s/ J. CHRISTOPHER DOUGLAS
		J. Christopher Douglas
		Executive Vice President and Chief Financial Officer

EX-101.SCH 5 hr-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Statement link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2107102 - Disclosure - Real Estate Investments link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - Real Estate Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Real Estate Investments - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Real Estate Investments - Dispositions (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2112103 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Leases - Lease Income (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Leases - Lessor Accounting (Details) link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - Leases - Ground Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2417410 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2417410 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2418411 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2119104 - Disclosure - Notes and Bonds Payable link:presentationLink link:calculationLink link:definitionLink 2320304 - Disclosure - Notes and Bonds Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2421412 - Disclosure - Notes and Bonds Payable (Details) link:presentationLink link:calculationLink link:definitionLink 2122105 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2323305 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2425414 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2426415 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 2127106 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - Commitments and Contingencies - Construction Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2129107 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2330306 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2431417 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2432418 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2433419 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) link:presentationLink link:calculationLink link:definitionLink 2434420 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) link:presentationLink link:calculationLink link:definitionLink 2435421 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2136108 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2337307 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2438422 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hr-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 hr-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 hr-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Square footage of owned real estate properties Area of real estate property Approximate square feet Area of Real Estate Property Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Acquisitions of real estate Payments to Acquire Real Estate Interest and other income (expense), net Other Nonoperating Income (Expense) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Number of properties acquired Number of Properties Acquired Number of Properties Acquired Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities San Diego, CA San Diego, California [Member] San Diego, California [Member] Number of investment banks included in the program Number of Investment Banks Number of Investment Banks $200 million unsecured term loan facility, net of issuance costs Term Loan due 2024 [Member] Term Loan due 2024 [Member] Number of prepaid ground leases Number of Ground Leases Prepaid Number of Ground Leases Prepaid Dilutive effect of employee stock purchase plan (in shares) Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan Incremental common shares attributable to dilutive effect of employee stock purchase plan. Medical office building expansion Medical Office Building Expansion [Member] Medical Office Building Expansion [Member] Denver, CO Denver, CO [Member] Denver, CO [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Line of credit Line of Credit [Member] Other information Leases, Operating [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Derivative financial instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Deferred rent reserve recognized in the period Contract with Customer, Liability, Reserve Recognized in Period Contract with Customer, Liability, Reserve Recognized in Period Senior Notes due 2023, net of discount and issuance costs Senior Notes due 2023 [Member] Senior Notes due 2023 [Member] Estimated amount to complete project Construction Activity, Estimated Remaining Fundings Construction Activity, Estimated Remaining Fundings Debt issuance and assumption costs Payments of Debt Issuance Costs Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Real Estate Investment Real Estate Investment Net Disposed of During Period Real estate investment net disposed of during the Period. Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and contingencies Commitments and Contingencies Total undiscounted lease payments Finance Lease, Liability, Payment, Due Common stock redemptions Payments for Repurchase of Common Stock ASSETS Assets [Abstract] Finance lease cost Lessee, Finance Lease, Description [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Cash, cash equivalents and restricted cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cover [Abstract] Cover [Abstract] Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Operating cash flows outflows related to operating leases Operating Lease, Payments Document Type Document Type Components of Sales-type Leases Sales-type Lease, Lease Income [Table Text Block] Other Commitments [Table] Other Commitments [Table] 2020 Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Senior Notes due 2028, net of discount and issuance costs Senior Notes due 2028 [Member] Senior Notes due 2028 [Member] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Losses arising during the period on interest rate swaps Losses arising during the period on interest rate swaps and treasury rate locks Impact of settlement of forward-starting interest rate swap Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Loss on early extinguishment of debt Gain (Loss) on Extinguishment of Debt Debt discount Debt Instrument, Unamortized Discount $700 million Unsecured Credit Facility Unsecured Credit Facility [Member] Unsecured Credit Facility [Member] Land held for development Land Available for Development 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Outstanding and exercisable, beginning of period (in shares) Outstanding and exercisable, end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2021 Finance Lease, Liability, to be Paid, Year One Stockholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Land Acquisition, Subsequently Disposed Land Acquisition, Subsequently Disposed [Member] Land Acquisition, Subsequently Disposed Long Lived Assets Held-for-sale [Line Items] Long Lived Assets Held-for-sale [Line Items] Profit recognized at commencement date Gains (Losses) on Sales of Investment Real Estate, Sales-Type Leases Gains (Losses) on Sales of Investment Real Estate, Sales-Type Leases Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Hedging Designation [Domain] Hedging Designation [Domain] Total lease expense Lease, Cost Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Quarterly Report Document Quarterly Report Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Payments made on finance leases Financing cash flows outflows related to financing leases Finance Lease, Principal Payments Cumulative net income attributable to common stockholders Cumulative Net Income Attributable to Common Stockholders Cumulative net income attributable to common stockholders. Number of properties sold Number of Properties Sold Number of Properties Sold 2025 and thereafter Finance Lease, Liability, to be Paid, after Year Four Finance Lease, Liability, to be Paid, after Year Four Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Real estate properties Real Estate Investment Property, Net [Abstract] Other operating Type of Revenue Revenue from Contract with Customer, Excluding Assessed Tax 5.63% Bonds 5.63% Bonds [Member] 5.63% Bonds [Member] Entity File Number Entity File Number Total amount funded Construction Activity, Total Amount Funded Construction Activity, Total Amount Funded Geographical [Domain] Geographical [Domain] Number of derivative instruments settled Number of Derivative Instruments Settled Number of Derivative Instruments Settled Statement [Line Items] Statement [Line Items] Net income applicable to common stockholders Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Seattle, WA Washington WASHINGTON Term of senior notes Debt Instrument, Term Document Fiscal Period Focus Document Fiscal Period Focus Real Estate Investments Acquisitions and Dispositions [Text Block] Acquisitions and dispositions. Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Notes and bonds payable Debt Instrument, Fair Value Disclosure Preferred stock, issued (shares) Preferred Stock, Shares Issued Land Land Land Total Lessor, Operating Lease, Payments to be Received Reconciliation of beginning and ending common stock outstanding Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block] Reconciliation of beginning and ending common stock outstanding. Number of properties held for sale Number of Properties Held for Sale Number of properties held for sale. Weighted Average Weighted Average [Member] Business Combinations [Abstract] Business Combinations [Abstract] OPERATING Lessee, Operating Lease, Liability, Payment, Due [Abstract] Amortization of prepaid rent Amortization of Prepaid Rent Amortization of Prepaid Rent Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Impairment of real estate assets Impairment of Real Estate Scheduled deferral payments collected in the third quarter (percent) Scheduled Deferral Payments Collected in the Quarter Percent Scheduled Deferral Payments Collected in the Quarter Percent Notes and bonds payable Debt Disclosure [Text Block] Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Amortization of straight-line rent on operating leases (lessee) Straight-line Rent Liability Straight-line rent liability. Earnings (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Amortization of straight-line rent receivable (lessor) Straight-line Rent Receivable Straight-line rent receivable. Weighted average Common Shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Summary of the activity under the incentive plan Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Debt issuance costs Debt Issuance Costs, Line of Credit Arrangements, Gross Leases Lessee, Finance Leases [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Amendment Flag Amendment Flag Repayments on notes and bonds payable Repayments of Debt Reclassification adjustments for losses included in net income (interest expense) (Gain) loss reclassified from AOCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Real estate dispositions Asset Dispositions [Table Text Block] Asset Dispositions Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Expected purchase price Real Estate Held for Sale, Sale Price Real Estate Held for Sale, Sale Price Colorado Springs, CO Colorado Springs, CO [Member] Colorado Springs, CO [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] At-the-market equity offering program, remaining authorized amount, assuming forward equity contracts settle At-the-market Equity Offering Program, Remaining Authorized Amount, Assuming Forward Equity Contracts Settle At-the-market Equity Offering Program, Remaining Authorized Amount, Assuming Forward Equity Contracts Settle Summary of employee stock purchase plan activity Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable Fair Value, by Balance Sheet Grouping [Table Text Block] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Borrowings of notes and bonds payable Proceeds from Issuance of Other Long-term Debt Liabilities of assets held for sale Liabilities of assets held for sale Disposal Group, Including Discontinued Operation, Liabilities Senior notes Senior Notes [Member] Medical office building Medical Office Building [Member] Medical Office Building [Member] Invoices accrued for construction, tenant improvements and other capitalized costs Capital Expenditures Incurred but Not yet Paid Geographical [Axis] Geographical [Axis] Local Phone Number Local Phone Number Interest rate swaps Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract] $150 million unsecured term loan due 2026 Term Loan due 2026 [Member] Term Loan due 2026 [Member] Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing. Payments to redeem unsecured senior notes Repayments of Unsecured Debt Proceeds from disposition of sales-type lease properties Proceeds from Lease Payment, Operating Activity Cumulative Dividends Cumulative Dividends [Member] Cumulative Dividends [Member]. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Employee stock purchase plan Employee Stock [Member] Income Statement Location [Axis] Income Statement Location [Axis] Los Angeles, CA Los Angeles, California [Member] Los Angeles, California [Member] Income Statement Location [Domain] Income Statement Location [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two Other Commitments [Line Items] Other Commitments [Line Items] FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Notional amount Derivative, Notional Amount Number of bonds repaid Number of Bonds Repaid Number of Bonds Repaid Lease Cost Lease, Cost [Table Text Block] Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Entity Current Reporting Status Entity Current Reporting Status Treasury Rate Locks Treasury lock Settled treasury hedges Treasury Lock [Member] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Buildings, improvements and lease intangibles Building, improvements and lease intangibles Investment Building and Building Improvements Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing. Plan Name [Axis] Plan Name [Axis] Real Estate Dispositions and Mortgage Note Repayments [Domain] Real Estate Dispositions and Mortgage Note Repayments [Domain] Real Estate Dispositions and Mortgage Note Repayments [Domain] Other liabilities Other Liabilities Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Nonvested share-based awards, net of withheld shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Net Income Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Total assets Assets Other amortization Amortization of Other Deferred Charges Forward Equity Agreement Maturing July 2021 Forward Equity Agreement 2 [Member] Forward Equity Agreement 2 Share-based awards, beginning of period Share-based awards, end of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Disposal Group Classification [Axis] Disposal Group Classification [Axis] FINANCING Finance Lease, Liability, Payment, Due [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Entity Small Business Entity Small Business 2022 Lessor, Operating Lease, Payment to be Received, Year Two Future Minimum Financing Lease Payments Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Interest expense Interest Expense Depreciation and amortization Depreciation, Depletion and Amortization Entity Filer Category Entity Filer Category Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Entity Address, City or Town Entity Address, City or Town Land and building Land and Building [Member] Gain on sales of real estate assets Gains on sales of investment real estate Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Loss recognized in AOCI on derivative Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Document Fiscal Year Focus Document Fiscal Year Focus Summary of the activity under the incentive plans Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Dividend per share to common Stockholders (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Summary of acquisitions Schedule of Business Acquisitions, by Acquisition [Table Text Block] Other assets, net Other Assets Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Construction in progress Development in Process EX-101.PRE 9 hr-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 hr-20200930_htm.xml IDEA: XBRL DOCUMENT 0000899749 2020-01-01 2020-09-30 0000899749 2020-10-30 0000899749 2020-09-30 0000899749 2019-12-31 0000899749 2020-07-01 2020-09-30 0000899749 2019-07-01 2019-09-30 0000899749 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember 2020-07-01 2020-09-30 0000899749 us-gaap:InterestRateSwapMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember 2020-01-01 2020-09-30 0000899749 us-gaap:InterestRateSwapMember 2019-01-01 2019-09-30 0000899749 us-gaap:TreasuryLockMember 2020-07-01 2020-09-30 0000899749 us-gaap:TreasuryLockMember 2019-07-01 2019-09-30 0000899749 us-gaap:TreasuryLockMember 2020-01-01 2020-09-30 0000899749 us-gaap:TreasuryLockMember 2019-01-01 2019-09-30 0000899749 us-gaap:CommonStockMember 2020-06-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000899749 hr:CumulativeNetIncomeMember 2020-06-30 0000899749 hr:CumulativeDividendsMember 2020-06-30 0000899749 2020-06-30 0000899749 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000899749 hr:CumulativeNetIncomeMember 2020-07-01 2020-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000899749 hr:CumulativeDividendsMember 2020-07-01 2020-09-30 0000899749 us-gaap:CommonStockMember 2020-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000899749 hr:CumulativeNetIncomeMember 2020-09-30 0000899749 hr:CumulativeDividendsMember 2020-09-30 0000899749 us-gaap:CommonStockMember 2019-06-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000899749 hr:CumulativeNetIncomeMember 2019-06-30 0000899749 hr:CumulativeDividendsMember 2019-06-30 0000899749 2019-06-30 0000899749 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000899749 hr:CumulativeNetIncomeMember 2019-07-01 2019-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000899749 hr:CumulativeDividendsMember 2019-07-01 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000899749 hr:CumulativeNetIncomeMember 2019-09-30 0000899749 hr:CumulativeDividendsMember 2019-09-30 0000899749 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000899749 hr:CumulativeNetIncomeMember 2019-12-31 0000899749 hr:CumulativeDividendsMember 2019-12-31 0000899749 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000899749 hr:CumulativeNetIncomeMember 2020-01-01 2020-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000899749 hr:CumulativeDividendsMember 2020-01-01 2020-09-30 0000899749 us-gaap:CommonStockMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-12-31 0000899749 hr:CumulativeDividendsMember 2018-12-31 0000899749 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000899749 hr:CumulativeNetIncomeMember 2019-01-01 2019-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000899749 hr:CumulativeDividendsMember 2019-01-01 2019-09-30 0000899749 2020-04-01 2020-09-30 0000899749 2020-04-01 2020-06-30 0000899749 hr:ParkingIncomeMember 2020-07-01 2020-09-30 0000899749 hr:ParkingIncomeMember 2019-07-01 2019-09-30 0000899749 hr:ParkingIncomeMember 2020-01-01 2020-09-30 0000899749 hr:ParkingIncomeMember 2019-01-01 2019-09-30 0000899749 hr:RentalLeaseGuarantyMember 2020-07-01 2020-09-30 0000899749 hr:RentalLeaseGuarantyMember 2019-07-01 2019-09-30 0000899749 hr:RentalLeaseGuarantyMember 2020-01-01 2020-09-30 0000899749 hr:RentalLeaseGuarantyMember 2019-01-01 2019-09-30 0000899749 hr:ManagementFeeIncomeMember 2020-07-01 2020-09-30 0000899749 hr:ManagementFeeIncomeMember 2019-07-01 2019-09-30 0000899749 hr:ManagementFeeIncomeMember 2020-01-01 2020-09-30 0000899749 hr:ManagementFeeIncomeMember 2019-01-01 2019-09-30 0000899749 hr:MiscellaneousMember 2020-07-01 2020-09-30 0000899749 hr:MiscellaneousMember 2019-07-01 2019-09-30 0000899749 hr:MiscellaneousMember 2020-01-01 2020-09-30 0000899749 hr:MiscellaneousMember 2019-01-01 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember hr:LosAngelesCaliforniaMember hr:RealEstateAcquisitionsMember 2020-01-03 2020-01-03 0000899749 hr:MedicalOfficeBuildingMember hr:LosAngelesCaliforniaMember hr:RealEstateAcquisitionsMember 2020-01-03 0000899749 hr:MedicalOfficeBuildingMember stpr:GA hr:RealEstateAcquisitionsMember 2020-02-13 2020-02-13 0000899749 hr:MedicalOfficeBuildingMember stpr:GA hr:RealEstateAcquisitionsMember 2020-02-13 0000899749 hr:MedicalOfficeBuildingMember stpr:NC hr:RealEstateAcquisitionsMember 2020-02-25 2020-02-25 0000899749 hr:MedicalOfficeBuildingMember stpr:NC hr:RealEstateAcquisitionsMember 2020-02-25 0000899749 hr:MedicalOfficeBuildingMember hr:ColoradoSpringsCOMember hr:RealEstateAcquisitionsMember 2020-03-09 2020-03-09 0000899749 hr:MedicalOfficeBuildingMember hr:ColoradoSpringsCOMember hr:RealEstateAcquisitionsMember 2020-03-09 0000899749 hr:MedicalOfficeBuildingMember hr:DenverCOMember hr:RealEstateAcquisitionsMember 2020-03-13 2020-03-13 0000899749 hr:MedicalOfficeBuildingMember hr:DenverCOMember hr:RealEstateAcquisitionsMember 2020-03-13 0000899749 hr:MedicalOfficeBuildingMember hr:SanDiegoCaliforniaMember hr:RealEstateAcquisitionsMember 2020-07-01 2020-07-01 0000899749 hr:MedicalOfficeBuildingMember hr:SanDiegoCaliforniaMember hr:RealEstateAcquisitionsMember 2020-07-01 0000899749 hr:MedicalOfficeBuildingMember hr:LosAngelesCaliforniaMember hr:RealEstateAcquisitionsMember 2020-07-17 2020-07-17 0000899749 hr:MedicalOfficeBuildingMember hr:LosAngelesCaliforniaMember hr:RealEstateAcquisitionsMember 2020-07-17 0000899749 hr:MedicalOfficeBuildingMember stpr:WA hr:RealEstateAcquisitionsMember 2020-07-23 2020-07-23 0000899749 hr:MedicalOfficeBuildingMember stpr:WA hr:RealEstateAcquisitionsMember 2020-07-23 0000899749 hr:MedicalOfficeBuildingMember stpr:GA hr:RealEstateAcquisitionsMember 2020-07-31 2020-07-31 0000899749 hr:MedicalOfficeBuildingMember stpr:GA hr:RealEstateAcquisitionsMember 2020-07-31 0000899749 hr:MedicalOfficeBuildingMember hr:HoustonTXMember hr:RealEstateAcquisitionsMember 2020-09-24 2020-09-24 0000899749 hr:MedicalOfficeBuildingMember hr:HoustonTXMember hr:RealEstateAcquisitionsMember 2020-09-24 0000899749 hr:MedicalOfficeBuildingMember hr:LosAngelesCaliforniaMember hr:RealEstateAcquisitionsMember 2020-09-28 2020-09-28 0000899749 hr:MedicalOfficeBuildingMember hr:LosAngelesCaliforniaMember hr:RealEstateAcquisitionsMember 2020-09-28 0000899749 hr:RealEstateAcquisitionsMember 2020-01-01 2020-09-30 0000899749 hr:RealEstateAcquisitionsMember 2020-09-30 0000899749 us-gaap:LandMember 2020-01-01 2020-09-30 0000899749 us-gaap:LandMember 2020-09-30 0000899749 hr:LandAcquisitionSubsequentlyDisposedMember 2020-01-01 2020-09-30 0000899749 hr:LandAcquisitionSubsequentlyDisposedMember 2020-09-30 0000899749 hr:RealEstateandLandAcquisitionsMember 2020-01-01 2020-09-30 0000899749 hr:RealEstateandLandAcquisitionsMember 2020-09-30 0000899749 hr:MedicalOfficeBuildingMember hr:DenverCOMember hr:RealEstateAcquisitionsMember 2020-03-09 2020-03-09 0000899749 hr:MedicalOfficeBuildingMember hr:ColoradoSpringsCOMember us-gaap:SubsequentEventMember 2020-10-07 0000899749 hr:MedicalOfficeBuildingMember hr:ColoradoSpringsCOMember us-gaap:SubsequentEventMember 2020-10-07 2020-10-07 0000899749 stpr:MO hr:RealEstateDispositionsMember 2020-07-30 0000899749 stpr:MO hr:RealEstateDispositionsMember 2020-07-30 2020-07-30 0000899749 stpr:OK hr:RealEstateDispositionsMember 2020-07-30 0000899749 stpr:OK hr:RealEstateDispositionsMember 2020-07-30 2020-07-30 0000899749 stpr:FL hr:RealEstateDispositionsMember 2020-09-30 0000899749 stpr:FL hr:RealEstateDispositionsMember 2020-09-30 2020-09-30 0000899749 hr:RealEstateDispositionsMember 2020-09-30 0000899749 hr:RealEstateDispositionsMember 2020-09-30 2020-09-30 0000899749 stpr:OK hr:RealEstateDispositionsMember 2020-04-01 2020-06-30 0000899749 2020-09-01 2020-09-30 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-09-30 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2019-12-31 0000899749 2020-05-01 2020-05-31 0000899749 2020-05-31 0000899749 srt:MinimumMember 2020-09-30 0000899749 srt:MaximumMember 2020-09-30 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2020-09-30 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2020-09-30 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-12-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2020-09-30 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-12-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2020-09-30 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2020-09-30 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2020-09-30 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2020-09-30 0000899749 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2020-09-30 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-12-31 0000899749 hr:TermLoandue2024Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2020-09-30 0000899749 hr:TermLoandue2024Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2020-01-01 2020-09-30 0000899749 hr:TermLoandue2026Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2020-09-30 0000899749 hr:TermLoandue2026Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2020-01-01 2020-09-30 0000899749 hr:SeniorNotesdue2025Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2020-01-01 2020-09-30 0000899749 hr:SeniorNotesdue2025Member us-gaap:TreasuryLockMember us-gaap:SeniorNotesMember 2020-01-01 2020-09-30 0000899749 us-gaap:MortgagesMember 2020-02-03 0000899749 us-gaap:MortgagesMember 2020-02-03 2020-02-03 0000899749 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2020-03-04 0000899749 hr:SeniorNotesdue2025Member us-gaap:TreasuryLockMember us-gaap:SeniorNotesMember 2020-03-04 2020-03-04 0000899749 us-gaap:MortgagesMember 2020-05-04 0000899749 us-gaap:MortgagesMember 2020-05-04 2020-05-04 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2020-05-29 2020-05-29 0000899749 us-gaap:MortgagesMember 2020-06-02 0000899749 us-gaap:MortgagesMember 2020-06-02 2020-06-02 0000899749 us-gaap:CorporateDebtSecuritiesMember 2020-06-25 0000899749 hr:A5.63BondsMember us-gaap:CorporateDebtSecuritiesMember 2020-06-25 0000899749 hr:A6.63BondsMember us-gaap:CorporateDebtSecuritiesMember 2020-06-25 0000899749 hr:A6.88BondsMember us-gaap:CorporateDebtSecuritiesMember 2020-06-25 0000899749 hr:A5.63BondsMember us-gaap:CorporateDebtSecuritiesMember 2020-06-25 2020-06-25 0000899749 hr:A6.63BondsMember us-gaap:CorporateDebtSecuritiesMember 2020-06-25 2020-06-25 0000899749 hr:A6.88BondsMember us-gaap:CorporateDebtSecuritiesMember 2020-06-25 2020-06-25 0000899749 us-gaap:MortgagesMember us-gaap:SubsequentEventMember 2020-10-01 0000899749 us-gaap:MortgagesMember us-gaap:SubsequentEventMember 2020-10-01 2020-10-01 0000899749 hr:SeniorNotesDue2031Member us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2020-10-02 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2020-10-19 2020-10-19 0000899749 us-gaap:TreasuryLockMember 2020-02-25 0000899749 us-gaap:TreasuryLockMember 2020-02-24 0000899749 us-gaap:TreasuryLockMember 2020-03-04 2020-03-04 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899749 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899749 us-gaap:InterestRateContractMember 2020-07-01 2020-09-30 0000899749 us-gaap:InterestRateContractMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000899749 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000899749 us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember 2020-01-01 2020-09-30 0000899749 us-gaap:InterestRateContractMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000899749 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000899749 us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 hr:ActiveInterestRateSwapsMember 2020-09-30 0000899749 hr:MedicalOfficeBuildingExpansionMember hr:MemphisTennesseeMember 2020-09-30 0000899749 hr:MedicalOfficeBuildingExpansionMember hr:MemphisTennesseeMember 2020-01-01 2020-09-30 0000899749 hr:MedicalOfficeBuildingMember hr:MemphisTennesseeMember us-gaap:LandAndBuildingMember 2020-01-01 2020-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:WA 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:WA 2020-09-30 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2020-02-14 0000899749 2020-02-14 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-09-30 0000899749 srt:MinimumMember hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-09-30 0000899749 srt:MaximumMember hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-09-30 0000899749 srt:WeightedAverageMember hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0000899749 srt:MinimumMember hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0000899749 srt:MaximumMember hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0000899749 srt:WeightedAverageMember hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2020-04-01 2020-06-30 0000899749 srt:MinimumMember hr:AtTheMarketEquityOfferingProgramMember 2020-04-01 2020-06-30 0000899749 srt:MaximumMember hr:AtTheMarketEquityOfferingProgramMember 2020-04-01 2020-06-30 0000899749 srt:WeightedAverageMember hr:AtTheMarketEquityOfferingProgramMember 2020-04-01 2020-06-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2020-09-30 0000899749 hr:ForwardEquityAgreement1Member 2020-04-01 2020-06-30 0000899749 hr:ForwardEquityAgreement1Member 2020-06-30 0000899749 hr:ForwardEquityAgreement2Member 2020-07-01 2020-09-30 0000899749 hr:ForwardEquityAgreement2Member 2020-09-30 0000899749 us-gaap:SubsequentEventMember hr:ForwardEquityAgreement2Member 2020-10-01 2020-11-04 0000899749 us-gaap:SubsequentEventMember hr:ForwardEquityAgreement2Member 2020-11-04 0000899749 us-gaap:SubsequentEventMember 2020-11-04 0000899749 us-gaap:SubsequentEventMember 2020-11-03 2020-11-03 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2020-07-01 2020-09-30 0000899749 hr:StockIncentivePlanMember 2020-06-30 0000899749 hr:StockIncentivePlanMember 2019-06-30 0000899749 hr:StockIncentivePlanMember 2019-12-31 0000899749 hr:StockIncentivePlanMember 2018-12-31 0000899749 hr:StockIncentivePlanMember 2020-07-01 2020-09-30 0000899749 hr:StockIncentivePlanMember 2019-07-01 2019-09-30 0000899749 hr:StockIncentivePlanMember 2020-01-01 2020-09-30 0000899749 hr:StockIncentivePlanMember 2019-01-01 2019-09-30 0000899749 hr:StockIncentivePlanMember 2020-09-30 0000899749 hr:StockIncentivePlanMember 2019-09-30 0000899749 hr:ExecutiveChairmanMember hr:StockIncentivePlanMember 2020-07-01 2020-09-30 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2020-01-01 2020-09-30 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2019-01-01 2019-09-30 0000899749 us-gaap:EmployeeStockMember 2020-06-30 0000899749 us-gaap:EmployeeStockMember 2019-06-30 0000899749 us-gaap:EmployeeStockMember 2019-12-31 0000899749 us-gaap:EmployeeStockMember 2018-12-31 0000899749 us-gaap:EmployeeStockMember 2020-07-01 2020-09-30 0000899749 us-gaap:EmployeeStockMember 2019-07-01 2019-09-30 0000899749 us-gaap:EmployeeStockMember 2020-01-01 2020-09-30 0000899749 us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0000899749 us-gaap:EmployeeStockMember 2020-09-30 0000899749 us-gaap:EmployeeStockMember 2019-09-30 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 shares iso4217:USD iso4217:USD shares hr:property hr:state utr:sqft pure hr:land_parcel hr:numberOfAgreements hr:Lease hr:derivative hr:bond hr:treasury_lock hr:swap_agreement hr:investment_bank hr:numberOfForwardEquityAgreements 0000899749 --12-31 2020 Q3 false

us-gaap:ServiceMember

10-Q true 2020-09-30 false 001-11852 HEALTHCARE REALTY TRUST INCORPORATED MD 62-1507028 3310 West End Avenue, Suite 700 Nashville TN 37203 615 269-8175 Common stock, $0.01 par value per share HR NYSE Yes Yes Large Accelerated Filer false false false 136054024

330840000

289751000

4014740000

3986326000

10962000 10538000

48731000

24647000

4381189000

4359993000

1198444000

1121102000

3182745000

3238891000

121992000

657000

60644000

20051000 37000

123807000

126177000

19776000

12667000

182436000

185426000

3711451000

3563855000

1554395000

1414069000

79528000

78517000

548000

145000

91466000

91574000

18697000

18037000

66442000

61504000

1811076000

1663846000

0.01

50000000

0.01

300000000

136054000

134706000

1361000

1347000

3532130000

3485003000

19267000

6175000

1215362000 1127304000

2829211000

2707470000

1900375000

1900009000

3711451000

3563855000

123384000

117740000

368385000

342787000

1868000

2059000

5364000

5987000

125252000

119799000

373749000

348774000

50171000

46777000

146305000

133790000

7299000

10802000

23498000

27157000

440000

501000

1621000

1227000

47143000

45137000

142331000

131725000

105053000 103217000 313755000 293899000

2177000

200000

70395000

5065000

14154000

14181000

42556000

41619000

5610000

8000

225000

-736000

-11969000

-13981000

28064000

-42900000

8230000

2601000

88058000

11975000

0.06

0.02

0.65

0.08

0.06

0.02

0.65

0.08

134309000

128090000

133662000

126571000

134357000

128169000

133736000

126657000

0.30

0.90

8230000

2601000

88058000

11975000

-1101000

-60000

-2367000

-74000

74000

2341000

11192000

7642000

4267000

1027000

-2281000

-13092000

-7568000

9257000

320000

74966000

4407000

1360000

3529559000

-20294000

1207132000

-2788396000

1929361000

1000

126000

127000

2445000

8230000

-1101000

-74000

0.30

40815000

1361000

3532130000

-19267000

1215362000

-2829211000

1900375000

1292000

3305344000

-6189000

1097493000

-2628497000

1769443000

22000

71792000

71814000

2695000

5131000

2601000

-60000

-2341000

0.30

38852000

1314000

3379572000

-8470000

1100094000

-2667349000

1805161000

1347000

3485003000

-6175000

1127304000

-2707470000

1900009000

13000

40477000

40490000

798000

1000

7448000

7449000

88058000

-2367000

-15459000

0.90

121741000

1361000

3532130000

-19267000

1215362000

-2829211000

1900375000

1253000

3180284000

-902000

1088119000

-2552112000

1716642000

61000

192414000

192475000

1000

3266000

3267000

1000

10140000

10141000

11975000

-74000

-7642000

0.90

115237000

1314000

3379572000

-8470000

1100094000

-2667349000

1805161000

88058000

11975000

142331000

131725000

3409000

2279000

7449000

10141000

2722000 1833000 1122000 1159000 70395000 5065000 5610000

-194000

-16000

193000

277000

244454000

965000

6740000

5098000

3220000

-6662000

5709000

411564000

158473000

199162000

271575000

2941000

19152000

62707000

45902000

4905000

14151000

-259905000

-322478000

-293000000

60000000

150000000

50000000

298995000

32704000

12663000

121741000

115237000

40296000

192514000

892000

2343000

4267000

3057000

4589000

3310000

249000

30320000

167433000

181979000

3428000

657000

8381000

182636000

11809000

39165000

37946000

12709000

10702000

19269000

913000

999000

<div style="margin-top:3pt">Business Overview</div><div style="margin-bottom:6pt">Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2020, the Company had gross investments of approximately $4.3 billion in 211 real estate properties located in 24 states totaling approximately 15.5 million square feet. The Company provided leasing and property management services to approximately 11.9 million square feet nationwide. Square footage and property count disclosures in these Notes to the Company's Condensed Consolidated Financial Statements are unaudited.</div><div> </div><div>Basis of Presentation</div><div style="margin-bottom:6pt">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2019. All material intercompany transactions and balances have been eliminated in consolidation.</div><div style="margin-bottom:6pt">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2020 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties, such as the impact of the COVID-19 pandemic.</div><div> </div><div>Use of Estimates in the Condensed Consolidated Financial Statements</div><div style="margin-bottom:6pt">Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.</div><div style="margin-bottom:6pt">The Company considered the impact of COVID-19 on these assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position at September 30, 2020. There can be no assurance that COVID-19 will not have a future material adverse impact on the financial results and business operations of the Company. </div><div style="margin-top:3pt"> </div><div style="margin-top:3pt">COVID-19 Update</div><div style="margin-bottom:6pt">Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.</div><div style="margin-bottom:6pt">In response to the COVID-19 pandemic, all of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants temporarily closed their offices or clinical space or operated on a reduced basis in response to government requirements or recommendations. Many of these restrictions have been lifted, but could be reimposed. In response to these disruptions, the Company provided some of its tenants with deferred rent arrangements. Such arrangements were made primarily in the second quarter of 2020, and less than $0.1 million of deferred rent arrangements originated in the third quarter. Through November 2, 2020, the Company has collected more than 99% of second and third quarter 2020 aggregate tenant billings. The Company has collected 96% of total scheduled deferral payments due in the third quarter of 2020. In addition, the Company has remaining various forms of rent deferrals outstanding representing </div><div style="margin-bottom:6pt">approximately $1.2 million, or less than 1% of second and third quarter 2020 aggregate tenant billings. The tenant deferral agreements generally require the deferred amounts to be repaid by the fourth quarter of 2020. </div><div style="margin-bottom:6pt">For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease. However, in light of the COVID-19 pandemic in which many leases are being modified, the Financial Accounting Standards Board (the "FASB") and U.S. Securities and Exchange Commission (the "SEC") have provided relief that will allow companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. The Company has elected to use this relief where applicable and therefore will have no change in the current classification of its leases in connection with many of the leases impacted by negotiations with its tenants. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. If the cash flows are substantially the same or less, there are two methods to potentially account for such rent deferrals under the relief. The first would be as if no changes to the lease contract were made. Under that accounting, a lessor would increase its lease receivable and a lessee would increase its accounts payable as receivables/payments accrue. In its income statement, a lessor would continue to recognize revenue during the deferral period. The second method would be to treat the deferred payments as variable lease payments (i.e., revenue recognized when cash received). The Company has elected the first method described above, which results in the revenue being recognized on an accrual basis.</div><div style="margin-bottom:6pt">If tenants are unable to timely repay deferred rent, or repay at all, request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads, the impact on the Company’s results of operations and financial condition could be material. In the second quarter of 2020, the Company recognized approximately $0.7 million general reserve against the deferred rent balance. Following positive collection trends in the third quarter of 2020, the Company released approximately $0.3 million of the general reserve. As of September 30, 2020, the Company had a remaining general reserve of $0.4 million against an approximate $1.7 million deferred rent balance.</div><div style="margin-bottom:6pt">Given the daily evolution of the COVID-19 pandemic and the global response to curb its spread, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for the fiscal year 2020. The Company continues to evaluate the impact of various forms of governmental assistance that may be or become available to the Company or its tenants.</div><div>Revenue from Contracts with Customers (Topic 606)</div><div style="margin-bottom:6pt">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. </div><div style="margin-bottom:6pt">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:62.385%"><tr><td style="width:1.0%"/><td style="width:33.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED September 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">in thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Type of Revenue</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Parking income</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,764 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,935 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5,042 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5,538 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Rental lease guaranty</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Management fee income</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">209 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">201 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Miscellaneous</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">120 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,868 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,059 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,364 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,987 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt">The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.</div><div style="margin-top:3pt">Cash, Cash Equivalents and Restricted Cash</div><div style="margin-bottom:6pt">Cash and cash equivalents includes short-term investments with original maturities of three months or less when purchased. Restricted cash includes cash held in escrow from the sale of a property in Oklahoma. These proceeds have been or will be disbursed as the Company acquires real estate investments in like-kind exchanges under Section 1031 of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”). The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Condensed Consolidated Balance Sheets to the combined amounts shown on the Company's Condensed Consolidated Statements of Cash Flows:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.782%"><tr><td style="width:1.0%"/><td style="width:58.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.068%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"> September 30, 2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">December 31, 2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Cash and cash equivalents</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">121,992 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">657 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Restricted cash</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">60,644 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total cash, cash equivalents and restricted cash</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">182,636 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">657 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt"> </div><div>New Accounting Pronouncements</div><div style="margin-top:3pt">Accounting Standards Update No. 2016-13</div><div style="margin-bottom:6pt">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. Operating lease receivables, representing the majority of the Company's receivables, are not within the scope of the new standard. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.</div><div> </div><div>Accounting Standards Update No. 2017-04</div><div style="margin-bottom:6pt">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.</div><div> </div><div>Accounting Standards Update No. 2020-04</div>On March 12, 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

Business OverviewHealthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2020, the Company had gross investments of approximately $4.3 billion in 211 real estate properties located in 24 states totaling approximately 15.5 million square feet. The Company provided leasing and property management services to approximately 11.9 million square feet nationwide. 4300000000 211 24

15500000

11900000

<div>Basis of Presentation</div><div style="margin-bottom:6pt">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2019. All material intercompany transactions and balances have been eliminated in consolidation.</div><div style="margin-bottom:6pt">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2020 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties, such as the impact of the COVID-19 pandemic.</div>

<div>Use of Estimates in the Condensed Consolidated Financial Statements</div><div style="margin-bottom:6pt">Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.</div><div style="margin-bottom:6pt">The Company considered the impact of COVID-19 on these assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position at September 30, 2020. There can be no assurance that COVID-19 will not have a future material adverse impact on the financial results and business operations of the Company. </div><div style="margin-top:3pt"> </div><div style="margin-top:3pt">COVID-19 Update</div><div style="margin-bottom:6pt">Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.</div><div style="margin-bottom:6pt">In response to the COVID-19 pandemic, all of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants temporarily closed their offices or clinical space or operated on a reduced basis in response to government requirements or recommendations. Many of these restrictions have been lifted, but could be reimposed. In response to these disruptions, the Company provided some of its tenants with deferred rent arrangements. Such arrangements were made primarily in the second quarter of 2020, and less than $0.1 million of deferred rent arrangements originated in the third quarter. Through November 2, 2020, the Company has collected more than 99% of second and third quarter 2020 aggregate tenant billings. The Company has collected 96% of total scheduled deferral payments due in the third quarter of 2020. In addition, the Company has remaining various forms of rent deferrals outstanding representing </div><div style="margin-bottom:6pt">approximately $1.2 million, or less than 1% of second and third quarter 2020 aggregate tenant billings. The tenant deferral agreements generally require the deferred amounts to be repaid by the fourth quarter of 2020. </div><div style="margin-bottom:6pt">For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease. However, in light of the COVID-19 pandemic in which many leases are being modified, the Financial Accounting Standards Board (the "FASB") and U.S. Securities and Exchange Commission (the "SEC") have provided relief that will allow companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. The Company has elected to use this relief where applicable and therefore will have no change in the current classification of its leases in connection with many of the leases impacted by negotiations with its tenants. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. If the cash flows are substantially the same or less, there are two methods to potentially account for such rent deferrals under the relief. The first would be as if no changes to the lease contract were made. Under that accounting, a lessor would increase its lease receivable and a lessee would increase its accounts payable as receivables/payments accrue. In its income statement, a lessor would continue to recognize revenue during the deferral period. The second method would be to treat the deferred payments as variable lease payments (i.e., revenue recognized when cash received). The Company has elected the first method described above, which results in the revenue being recognized on an accrual basis.</div><div style="margin-bottom:6pt">If tenants are unable to timely repay deferred rent, or repay at all, request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads, the impact on the Company’s results of operations and financial condition could be material. In the second quarter of 2020, the Company recognized approximately $0.7 million general reserve against the deferred rent balance. Following positive collection trends in the third quarter of 2020, the Company released approximately $0.3 million of the general reserve. As of September 30, 2020, the Company had a remaining general reserve of $0.4 million against an approximate $1.7 million deferred rent balance.</div><div style="margin-bottom:6pt">Given the daily evolution of the COVID-19 pandemic and the global response to curb its spread, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for the fiscal year 2020. The Company continues to evaluate the impact of various forms of governmental assistance that may be or become available to the Company or its tenants.</div>

100000 0.99 0.96

1200000

0.01 700000 300000 400000 1700000

<div>Revenue from Contracts with Customers (Topic 606)</div><div style="margin-bottom:6pt">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. </div><div style="margin-bottom:6pt">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:62.385%"><tr><td style="width:1.0%"/><td style="width:33.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED September 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">in thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Type of Revenue</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Parking income</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,764 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,935 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5,042 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5,538 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Rental lease guaranty</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Management fee income</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">209 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">201 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Miscellaneous</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">120 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,868 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,059 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,364 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,987 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt">The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.</div>

Below is a detail of the amounts by category:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:62.385%"><tr><td style="width:1.0%"/><td style="width:33.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED September 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">in thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Type of Revenue</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Parking income</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,764 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,935 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5,042 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5,538 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Rental lease guaranty</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Management fee income</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">209 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">201 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Miscellaneous</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">120 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,868 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,059 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,364 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,987 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>

1764000

1935000

5042000

5538000

128000

62000

69000

209000

201000

42000

55000

113000

120000

1868000

2059000

5364000

5987000

Cash, Cash Equivalents and Restricted CashCash and cash equivalents includes short-term investments with original maturities of three months or less when purchased. Restricted cash includes cash held in escrow from the sale of a property in Oklahoma. These proceeds have been or will be disbursed as the Company acquires real estate investments in like-kind exchanges under Section 1031 of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”).

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Condensed Consolidated Balance Sheets to the combined amounts shown on the Company's Condensed Consolidated Statements of Cash Flows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.782%"><tr><td style="width:1.0%"/><td style="width:58.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.068%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"> September 30, 2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">December 31, 2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Cash and cash equivalents</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">121,992 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">657 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Restricted cash</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">60,644 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total cash, cash equivalents and restricted cash</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">182,636 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">657 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table>

121992000

657000

60644000

182636000

657000

<div>New Accounting Pronouncements</div><div style="margin-top:3pt">Accounting Standards Update No. 2016-13</div><div style="margin-bottom:6pt">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. Operating lease receivables, representing the majority of the Company's receivables, are not within the scope of the new standard. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.</div><div> </div><div>Accounting Standards Update No. 2017-04</div><div style="margin-bottom:6pt">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.</div><div> </div><div>Accounting Standards Update No. 2020-04</div>On March 12, 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

Real Estate Investments<div style="margin-top:3pt">2020 Acquisitions</div><div style="margin-bottom:6pt">The following table details the Company's acquisitions for the nine months ended September 30, 2020:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.508%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in millions</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>TYPE 1</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">DATE ACQUIRED</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">PURCHASE PRICE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MORTGAGE NOTES PAYABLE</td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">CASH CONSIDERATION 2</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">REAL ESTATE</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">OTHER 3</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">SQUARE FOOTAGE</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Los Angeles, CA</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">1/3/20</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">42.0 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19.3)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">22.8 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">42.4 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(0.3)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">86,986</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Atlanta, GA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">2/13/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.3)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">64,624 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Raleigh, NC</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">2/25/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">15,964 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Colorado Springs, CO</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">3/9/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.3)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">34,210 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Denver, CO 4</div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">3/13/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">33.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">33.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">34.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.8)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">136,994 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">San Diego, CA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">7/1/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">16.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">16.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">16.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.2)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">46,083 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Los Angeles, CA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">7/17/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">35.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">37.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">37.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">49,785 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Seattle, WA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">7/23/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">10.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.4)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">21,309 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Atlanta, GA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">7/31/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">20.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">21.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">21.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">48,145 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Houston, TX</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">9/24/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">10.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.1)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">40,235 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Los Angeles, CA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">9/28/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">14.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">14.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">13.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">24,252 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total real estate acquisitions</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">210.2 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19.3)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">194.4 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">215.7 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(2.0)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">568,587 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Land acquisition 5</div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Land acquisition 6</div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">212.8 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19.3)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">197.2 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">218.5 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(2.0)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">568,587 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1MOB = medical office building.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">2Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">3Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">4Includes three properties.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">5The Company acquired land parcels under four existing buildings (previously ground leased). </div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">6The Company acquired a land parcel under an existing building (previously ground leased). The building and land were sold on September 30, 2020.</div><div> </div><div>Subsequent Acquisition</div><div style="margin-bottom:6pt">On October 7, 2020 the Company acquired a 36,720 square foot medical office building in Colorado Springs, CO for a purchase price of $8.9 million.</div><div>2020 Real Estate Asset Dispositions</div><div style="margin-bottom:6pt">The following table details the Company's dispositions for the nine months ended September 30, 2020:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.694%"><tr><td style="width:1.0%"/><td style="width:17.918%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in millions</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>TYPE 1</div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Date Disposed</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Sale Price</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Closing Adjustments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net Proceeds</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net Real Estate Investment</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Other (including receivables)2</div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gain/(Impairment)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Square Footage (Unaudited)</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div>Springfield, MO 3</div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">SF</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">7/30/20</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">138.0 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">138.0 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">92.4 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">3.9 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">41.7 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">186,000</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Oklahoma City, OK 3</div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">7/30/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">106.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">106.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">76.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">26.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">200,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Miami, FL</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">9/30/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.2)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">26,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total dispositions</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">249.5 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(0.2)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">249.3 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">171.8 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7.1 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">70.4 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">412,000 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt"> </div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1.MOB = medical office building; SF = surgical facility</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">2.Includes straight-line rent receivables, leasing commissions and lease inducements.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">3.In the second quarter of 2020, the Company entered into agreements to sell two single-tenant net leased properties, resulting in a lease modification and classification change from operating to sales-type.</div><div style="margin-bottom:3pt"> </div><div>Assets Held for Sale</div><div style="margin-bottom:6pt">In September 2020, the Company reclassified four medical office buildings and a land parcel to assets held for sale upon acceptance of an offer from a third party to purchase the properties under a single sales agreement. The contractual sales price of $23.0 million is greater than the current net investment of approximately $18.1 million. As </div><div style="margin-bottom:6pt">of September 30, 2020 and December 31, 2019, the Company had four and zero properties, respectively, classified as assets held for sale. </div><div style="margin-bottom:6pt">The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2020 and December 31, 2019:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.073%"><tr><td style="width:1.0%"/><td style="width:41.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in thousands)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">September 30, 2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">December 31, 2019</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet data:</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Land</td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,664 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Building, improvements and lease intangibles</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26,871 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Personal property</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,574 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Accumulated depreciation</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,443)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom">Real estate assets held for sale, net</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,131 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets, net</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,920 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom">Assets held for sale, net</td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">20,051 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">37 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts payable and accrued liabilities</td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">437 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">37 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom">Liabilities of assets held for sale</td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">548 </td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

<div style="margin-bottom:6pt">The following table details the Company's acquisitions for the nine months ended September 30, 2020:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.508%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in millions</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>TYPE 1</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">DATE ACQUIRED</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">PURCHASE PRICE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MORTGAGE NOTES PAYABLE</td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">CASH CONSIDERATION 2</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">REAL ESTATE</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">OTHER 3</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">SQUARE FOOTAGE</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Los Angeles, CA</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">1/3/20</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">42.0 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19.3)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">22.8 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">42.4 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(0.3)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">86,986</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Atlanta, GA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">2/13/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.3)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">64,624 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Raleigh, NC</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">2/25/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">15,964 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Colorado Springs, CO</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">3/9/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.3)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">34,210 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Denver, CO 4</div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">3/13/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">33.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">33.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">34.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.8)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">136,994 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">San Diego, CA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">7/1/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">16.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">16.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">16.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.2)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">46,083 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Los Angeles, CA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">7/17/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">35.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">37.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">37.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">49,785 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Seattle, WA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">7/23/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">10.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.4)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">21,309 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Atlanta, GA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">7/31/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">20.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">21.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">21.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">48,145 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Houston, TX</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">9/24/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">10.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">11.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.1)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">40,235 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Los Angeles, CA</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">MOB</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">9/28/20</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">14.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">14.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">13.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">24,252 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total real estate acquisitions</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">210.2 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19.3)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">194.4 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">215.7 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(2.0)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">568,587 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Land acquisition 5</div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Land acquisition 6</div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">212.8 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19.3)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">197.2 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">218.5 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(2.0)</td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">568,587 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1MOB = medical office building.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">2Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">3Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">4Includes three properties.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">5The Company acquired land parcels under four existing buildings (previously ground leased). </div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">6The Company acquired a land parcel under an existing building (previously ground leased). The building and land were sold on September 30, 2020.</div><div> </div><div>Subsequent Acquisition</div><div style="margin-bottom:6pt">On October 7, 2020 the Company acquired a 36,720 square foot medical office building in Colorado Springs, CO for a purchase price of $8.9 million.</div>

42000000.0

19300000

22800000

42400000 -300000 86986

12000000.0

11800000

12100000 -300000 64624

6300000

6500000

6500000 0 15964

8200000

8300000

8600000 -300000 34210

33500000

33200000

34000000.0 -800000 136994

16700000

16900000 -200000 46083

35000000.0

37700000

37700000 0 49785

11000000.0

10900000

11300000 -400000 21309

20500000

21600000

21300000 300000 48145

11000000.0

10900000

11000000.0 -100000 40235

14000000.0

13900000 100000 24252

210200000

19300000

194400000

215700000 -2000000.0 568587

1600000

1700000

1700000 0 0

1000000.0

1100000

1100000 0 0

212800000

19300000

197200000

218500000 -2000000.0 568587 3 4 36720

8900000

138000000.0

92400000 3900000

41700000

186000 106500000 0

106500000

76800000 3100000

26600000

200000 5000000.0 200000

4800000

2600000 100000

2100000

26000 249500000 200000

249300000

171800000 7100000

70400000

412000 2 4 23000000.0

18100000

4 0 <div style="margin-bottom:6pt">The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2020 and December 31, 2019:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.073%"><tr><td style="width:1.0%"/><td style="width:41.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in thousands)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">September 30, 2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">December 31, 2019</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet data:</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Land</td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,664 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Building, improvements and lease intangibles</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26,871 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Personal property</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,574 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Accumulated depreciation</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,443)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom">Real estate assets held for sale, net</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,131 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets, net</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,920 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom">Assets held for sale, net</td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">20,051 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">37 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts payable and accrued liabilities</td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">437 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">37 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom">Liabilities of assets held for sale</td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">548 </td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

1664000

26871000

39000 0

28574000

10443000

18131000

1920000

37000

20051000 37000

437000

37000

111000

108000

548000

145000

Leases<div style="margin-top:3pt">Lessor Accounting</div><div style="margin-bottom:6pt">The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2035. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s single-tenant net leases generally require the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</div><div style="margin-bottom:6pt">The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three and nine months ended September 30, 2020 was $123.4 million and $368.4 million, respectively. </div><div style="margin-bottom:6pt">In May 2020, the Company and Mercy Health negotiated the sale of two single-tenant net leased properties, a medical office building in Oklahoma and an orthopedic specialty hospital in Missouri, for $244.5 million. The sale was structured through amendments to the leases to allow for the early exercise of existing purchase options. The amendments resulted in the application of lease modification accounting under ASC Topic 842, which resulted in lease classification changes from operating to sales-type. During the second quarter, the Company derecognized the real estate assets on the Condensed Consolidated Balance Sheets and recognized the net investment in sales-type leases, resulting in a gain of $68.3 million. The Company disposed of these properties on July 30, 2020.</div><div>Tabular Disclosure of the Components of Sales-Type Leases</div><div style="margin-bottom:6pt">The table below presents the components of sale-type leases for the three and nine months ended September 30, 2020:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.801%"><tr><td style="width:1.0%"/><td style="width:37.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.709%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">SALES-TYPE LEASES</td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">three months ended September 30, 2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">nine months ended September 30, 2020</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Profit recognized at commencement date</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">68,267 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Gain on sales of real estate assets</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest income</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,454 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,007 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Rental income</td></tr></table></div><div style="margin-bottom:3pt"> </div><div style="margin-bottom:6pt">Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2020 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:37.461%"><tr><td style="width:1.0%"/><td style="width:42.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">Operating</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2020</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">93,722 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2021</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">352,341 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2022</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">307,166 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2023</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">261,187 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">200,578 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">555,264 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,770,258 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"> </div><div>Lessee Accounting </div><div style="margin-bottom:6pt">As of September 30, 2020, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of September 30, 2020, the Company had 103 properties totaling 8.7 million square feet that were held under ground leases. Some of the ground leases' renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2119. Any rental increases related to the Company’s ground leases are generally either stated or based on the CPI. The Company had 42 prepaid ground leases as of September 30, 2020. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately $0.2 million of the Company’s rental expense for the three months ended September 30, 2020 and 2019, respectively and $0.5 million and $0.4 million for the nine months ended September 30, 2020 and 2019, respectively.</div><div style="margin-bottom:6pt">The Company’s future lease payments (primarily for its 61 non-prepaid ground leases) as of September 30, 2020 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.165%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OPERATING</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FINANCING</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2020</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,008 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">143 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2021</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,844 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">930 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2022</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,875 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">783 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2023</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,913 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">793 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,969 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">815 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">307,665 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88,808 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total undiscounted lease payments</td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">328,274 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">92,272 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Discount</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(236,808)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(73,575)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Lease liabilities</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">91,466 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">18,697 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify">The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2020 and 2019:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.015%"><tr><td style="width:1.0%"/><td style="width:47.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED September 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease cost</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease expense</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">1,180 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">1,169 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">3,534 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">3,448 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Variable lease expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,066 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">845 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,664 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,380 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Finance lease cost</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Amortization of right-of-use assets</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">51 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">236 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">101 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest on lease liabilities</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">245 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">196 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">722 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">392 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total lease expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,579 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,261 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,156 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">6,321 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other information</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating cash flows outflows related to operating leases</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">1,440 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">1,313 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,412 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,461 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Financing cash flows outflows related to financing leases</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">143 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">3,310 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">249 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Right-of-use assets obtained in exchange for new finance lease liabilities</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">7,212 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">14,294 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average remaining lease term (excluding renewal options) - operating leases</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">48.9</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">49.7</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average remaining lease term (excluding renewal options) -finance leases</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">64.7</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">70.1</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - operating leases</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - finance leases</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.4 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div>

123400000

368400000

2 244500000 68300000

<div style="margin-bottom:6pt">The table below presents the components of sale-type leases for the three and nine months ended September 30, 2020:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.801%"><tr><td style="width:1.0%"/><td style="width:37.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.709%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">SALES-TYPE LEASES</td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">three months ended September 30, 2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">nine months ended September 30, 2020</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Profit recognized at commencement date</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">68,267 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Gain on sales of real estate assets</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest income</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,454 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,007 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Rental income</td></tr></table></div>

0 68267000

1454000

3007000

<div style="margin-bottom:6pt">Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2020 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:37.461%"><tr><td style="width:1.0%"/><td style="width:42.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">Operating</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2020</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">93,722 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2021</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">352,341 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2022</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">307,166 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2023</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">261,187 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">200,578 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">555,264 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,770,258 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr></table></div>

93722000

352341000

307166000

261187000

200578000

555264000

1770258000

103

8700000

P40Y

P99Y

42 200000 200000 500000 400000

<div style="margin-bottom:6pt">The Company’s future lease payments (primarily for its 61 non-prepaid ground leases) as of September 30, 2020 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.165%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OPERATING</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FINANCING</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2020</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,008 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">143 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2021</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,844 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">930 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2022</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,875 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">783 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2023</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,913 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">793 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,969 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">815 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">307,665 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88,808 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total undiscounted lease payments</td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">328,274 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">92,272 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Discount</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(236,808)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(73,575)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Lease liabilities</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">91,466 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">18,697 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>

1008000

143000

4844000

930000

4875000

783000

4913000

793000

4969000

815000

307665000 88808000

328274000

92272000

236808000

73575000

91466000

18697000

<div style="margin-bottom:6pt;text-align:justify">The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2020 and 2019:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.015%"><tr><td style="width:1.0%"/><td style="width:47.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED September 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease cost</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease expense</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">1,180 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">1,169 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">3,534 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">3,448 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Variable lease expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,066 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">845 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,664 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,380 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Finance lease cost</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Amortization of right-of-use assets</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">51 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">236 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">101 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest on lease liabilities</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">245 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">196 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">722 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">392 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total lease expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,579 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,261 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,156 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">6,321 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other information</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating cash flows outflows related to operating leases</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">1,440 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">1,313 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,412 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,461 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Financing cash flows outflows related to financing leases</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">143 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">3,310 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">249 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Right-of-use assets obtained in exchange for new finance lease liabilities</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">7,212 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">14,294 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average remaining lease term (excluding renewal options) - operating leases</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">48.9</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">49.7</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average remaining lease term (excluding renewal options) -finance leases</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">64.7</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">70.1</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - operating leases</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - finance leases</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.4 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div>

1180000

1169000

3534000

3448000

1066000

845000

2664000

2380000

88000

51000

236000

101000

245000

196000

722000

392000

2579000

2261000

7156000

6321000

1440000

1313000

5412000

5461000

143000

107000

3310000

249000

7212000

14294000

P48Y10M24D

P49Y8M12D

P64Y8M12D

P70Y1M6D

0.057

0.054

0.055

Notes and Bonds Payable<div style="margin-bottom:6pt;margin-top:3pt">The table below details the Company’s notes and bonds payable. </div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.847%"><tr><td style="width:1.0%"/><td style="width:38.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.117%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MATURITY DATES</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">BALANCE AS OF</td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">EFFECTIVE INTEREST RATE as of 9/30/2020</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">9/30/2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">12/31/2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div>$700 million Unsecured Credit Facility</div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">5/23</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">293,000 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">N/A</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$200 million Unsecured Term Loan Facility, net of issuance costs 1</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">5/24</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,180 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,013 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.99 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$150 million Unsecured Term Loan due 2026 2 </div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">6/26</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">149,455 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.14 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2023, net of discount and issuance costs</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">4/23</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">248,863 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">248,540 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.95 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Senior Notes due 2025, net of discount and issuance costs 3</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">5/25</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">248,711 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">248,522 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.08 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2028, net of discount and issuance costs</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">1/28</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">296,003 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">295,651 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.84 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Senior Notes due 2030, net of discount and issuance costs 4</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">3/30</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">296,384 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.71 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Mortgage notes payable, net of discounts and issuance costs and including premiums</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">1/21-4/27</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">115,799 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">129,343 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.38 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,554,395 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,414,069 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1The effective interest rate includes the impact of interest rate swaps on $75.0 million at a weighted average rate of 2.37% (plus the applicable margin rate, currently 100 basis points).</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">2The effective interest rate includes the impact of interest rate swaps on $100.0 million at a weighted average rate of 2.23% (plus the applicable margin rate, currently 160 basis points).</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">3The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets. </div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">4The effective interest rate includes the impact of the $4.3 million settlement of forward interest rate hedges that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets. </div><div> </div><div>Changes in Debt Structure</div><div style="margin-bottom:6pt">On February 3, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.10% per annum with an outstanding principal of $5.9 million. The mortgage note encumbered a 68,860 square foot property in Oklahoma.</div><div style="margin-bottom:6pt">On March 4, 2020, the Company issued $300.0 million of unsecured senior notes due 2030 (the "Senior Notes due 2030") in a registered public offering. The Senior Notes due 2030 bear interest at 2.40%, payable semi-annually on March 15 and September 15, beginning September 15, 2020, and are due on March 15, 2030, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $1.0 million and the Company incurred approximately $2.8 million in debt issuance costs. Concurrent with this transaction, the Company settled two treasury rate locks for $4.3 million. Inclusive of the discount, debt issuance costs and settlement of the treasury rate locks, the effective interest rate was 2.71%. The Senior Notes due 2030 have various financial covenants that are required to be met on a quarterly and annual basis.</div><div style="margin-bottom:6pt">On May 4, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.74% per annum with an outstanding principal of $0.3 million. The mortgage note encumbered an 83,318 square foot property in Iowa.</div><div style="margin-bottom:6pt;margin-top:3pt">On May 29, 2020, the Company borrowed $150.0 million pursuant to its unsecured term loan due 2026. </div><div style="margin-bottom:6pt">On June 2, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.44% per annum with an outstanding principal of $12.6 million. The mortgage note encumbered a 67,510 square foot property in Washington.</div><div style="margin-bottom:6pt">On June 25, 2020, the Company repaid in full three mortgage notes bearing interest at rates of 5.63%, 6.63% and 6.88% per annum with outstanding principal of $0.5 million, $2.8 million, and $7.0 million, respectively. The mortgage notes encumbered a 60,476 square foot property in Minnesota.</div><div>Subsequent Changes in Debt Structure</div><div style="margin-bottom:6pt">On October 1, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.47% per annum with an outstanding principal of $4.2 million. The mortgage note encumbered a 40,171 square foot property in Georgia.</div>On October 2, 2020, the Company issued $300.0 million of unsecured senior notes due 2031 (the "Senior Notes due 2031") in a registered public offering. The Senior Notes due 2031 bear interest at 2.05%, payable semi-annually on March 15 and September 15, beginning March 15, 2021, and are due on March 15, 2031, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $2.4 million and the Company incurred approximately $2.8 million in debt issuance costs. Inclusive of the discount and debt issuance costs, the effective interest rate was 2.24%. The Senior Notes due 2031 have various financial covenants that are required to be met on a quarterly and annual basis.On October 19, 2020, the Company redeemed its unsecured senior notes due 2023 (the "Senior Notes due 2023"). The aggregate redemption price of $270.5 million consisted of outstanding principal of $250.0 million, accrued interest of $0.1 million, and a "make-whole" amount of approximately $20.4 million for the early extinguishment of debt. The unaccreted discount and unamortized costs on these notes of $1.1 million was written off upon redemption. In October 2020, the Company recognized a loss on early extinguishment of debt of approximately $21.5 million related to this redemption.

<div style="margin-bottom:6pt;margin-top:3pt">The table below details the Company’s notes and bonds payable. </div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.847%"><tr><td style="width:1.0%"/><td style="width:38.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.117%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MATURITY DATES</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">BALANCE AS OF</td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">EFFECTIVE INTEREST RATE as of 9/30/2020</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">9/30/2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">12/31/2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div>$700 million Unsecured Credit Facility</div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">5/23</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">293,000 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">N/A</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$200 million Unsecured Term Loan Facility, net of issuance costs 1</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">5/24</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,180 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,013 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.99 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$150 million Unsecured Term Loan due 2026 2 </div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">6/26</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">149,455 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.14 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2023, net of discount and issuance costs</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">4/23</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">248,863 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">248,540 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.95 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Senior Notes due 2025, net of discount and issuance costs 3</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">5/25</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">248,711 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">248,522 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.08 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2028, net of discount and issuance costs</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">1/28</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">296,003 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">295,651 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.84 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Senior Notes due 2030, net of discount and issuance costs 4</div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">3/30</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">296,384 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.71 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Mortgage notes payable, net of discounts and issuance costs and including premiums</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">1/21-4/27</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">115,799 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">129,343 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.38 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,554,395 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,414,069 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1The effective interest rate includes the impact of interest rate swaps on $75.0 million at a weighted average rate of 2.37% (plus the applicable margin rate, currently 100 basis points).</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">2The effective interest rate includes the impact of interest rate swaps on $100.0 million at a weighted average rate of 2.23% (plus the applicable margin rate, currently 160 basis points).</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">3The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets. </div>4The effective interest rate includes the impact of the $4.3 million settlement of forward interest rate hedges that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.

700000000

293000000

200000000

199180000

199013000

0.0199

150000000

149455000

0.0314

248863000

248540000

0.0395

248711000

248522000

0.0408

296003000

295651000

0.0384

296384000

0.0271

115799000

129343000

0.0438

1554395000

1414069000

75000000.0

0.0237

100000000.0

0.0223

1.60

-1700000

-4300000

0.0610

5900000

68860

300000000.0

0.0240

1000000.0

2800000

-4300000

0.0271

0.0574

300000

83318

150000000.0

0.0644

12600000

67510

0.0563

0.0663

0.0688

500000

2800000

7000000.0

60476

0.0547

4200000

40171

300000000.0

0.0205

2400000

2800000

0.0224

270500000

250000000.0

100000 20400000

1100000

-21500000

Derivative Financial Instruments<div style="margin-top:3pt">Risk Management Objective of Using Derivatives</div><div style="margin-bottom:6pt">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.</div><div> </div><div>Cash Flow Hedges of Interest Rate Risk</div><div style="margin-bottom:6pt">The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.</div><div style="margin-bottom:6pt">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. </div><div style="margin-bottom:6pt">On February 24 and 25, 2020, the Company entered into two treasury rate locks totaling $75.0 million and $40.0 million, respectively. The treasury rate locks were settled for an aggregate amount of $4.3 million on March 4, 2020 concurrent with the Company's issuance of its Senior Notes due 2030. The settlement will be amortized over the 10-year term of the notes.</div><div style="margin-bottom:6pt">As of September 30, 2020, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.318%"><tr><td style="width:1.0%"/><td style="width:39.722%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.950%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">DERIVATIVE INSTRUMENT</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">NUMBER OF INSTRUMENTS</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">NOTIONAL AMOUNT in millions</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swaps</td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">$175.0</td></tr></table></div><div>Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet</div><div style="margin-bottom:6pt">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2020.</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.394%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;padding:2px 1pt;text-align:center;vertical-align:bottom">BALANCE AT SEPTEMBER 30, 2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">BALANCE SHEET LOCATION</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Derivatives designated as hedging instruments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other liabilities</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">14,460 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Total derivatives designated as hedging instruments</td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">14,460 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div> </div><div>Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)</div><div style="margin-bottom:6pt">The table below presents the effect of cash flow hedge accounting on AOCI during the three and nine months ended September 30, 2020 and 2019 related to the Company's outstanding interest rate swaps.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.694%"><tr><td style="width:1.0%"/><td style="width:24.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.940%"/><td style="width:0.1%"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended September 30,</td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended September 30,</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,341 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">952 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">18 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled treasury hedges</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled interest rate swaps</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">42 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">42 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> </td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,341 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Total interest expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,101 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">60 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.694%"><tr><td style="width:1.0%"/><td style="width:24.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.940%"/><td style="width:0.1%"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">LOSS RECOGNIZED IN AOCI ON DERIVATIVE nine months ended September 30,</td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME nine months ended September 30,</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">11,192 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,642 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,012 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(52)</td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled treasury hedges</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,267 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">229 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled interest rate swaps</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> </td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">15,459 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,642 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Total interest expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,367 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt">The Company estimates that $4.4 million will be reclassified from AOCI to interest expense over the next 12 months.</div><div>Credit-risk-related Contingent Features</div><div style="margin-bottom:6pt">The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.</div><div style="margin-bottom:6pt">As of September 30, 2020, the fair value of derivatives in a net liability position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was $15.1 million. As of September 30, 2020, the Company has not posted any collateral related to these agreements and was not in breach of any agreement.</div>

75000000.0

40000000.0

-4300000

P10Y

<div style="margin-bottom:6pt">As of September 30, 2020, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.318%"><tr><td style="width:1.0%"/><td style="width:39.722%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.950%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">DERIVATIVE INSTRUMENT</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">NUMBER OF INSTRUMENTS</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">NOTIONAL AMOUNT in millions</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swaps</td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">$175.0</td></tr></table></div><div style="margin-bottom:6pt">The table below presents the effect of cash flow hedge accounting on AOCI during the three and nine months ended September 30, 2020 and 2019 related to the Company's outstanding interest rate swaps.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.694%"><tr><td style="width:1.0%"/><td style="width:24.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.940%"/><td style="width:0.1%"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended September 30,</td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended September 30,</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,341 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">952 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">18 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled treasury hedges</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled interest rate swaps</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">42 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">42 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> </td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,341 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Total interest expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,101 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">60 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.694%"><tr><td style="width:1.0%"/><td style="width:24.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.940%"/><td style="width:0.1%"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">LOSS RECOGNIZED IN AOCI ON DERIVATIVE nine months ended September 30,</td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME nine months ended September 30,</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">11,192 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,642 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,012 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(52)</td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled treasury hedges</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,267 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">229 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled interest rate swaps</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> </td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">15,459 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,642 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle">Total interest expense</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,367 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>

175000000.0

<div style="margin-bottom:6pt">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2020.</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.394%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;padding:2px 1pt;text-align:center;vertical-align:bottom">BALANCE AT SEPTEMBER 30, 2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">BALANCE SHEET LOCATION</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Derivatives designated as hedging instruments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other liabilities</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">14,460 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Total derivatives designated as hedging instruments</td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">14,460 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>

14460000

74000

2341000

952000

18000

107000

42000

74000

2341000

1101000

60000

11192000

7642000

2012000

-52000

4267000

229000

126000

15459000

7642000

2367000

74000

4400000

15100000

Commitments and Contingencies<div style="margin-top:3pt">Legal Proceedings</div><div style="margin-bottom:6pt">The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.</div><div> </div><div>Redevelopment Activity</div><div style="margin-bottom:6pt">The Company initiated the redevelopment of a 110,883 square foot medical office building in Memphis, Tennessee ("Memphis Redevelopment") in December 2019. As of September 30, 2020, the Company funded approximately $5.7 million in project costs, excluding the purchase price of $8.7 million for the land and building. The building will continue to operate with in-place leases during construction. The core and shell portion of the Memphis Redevelopment is expected to be completed in the first quarter of 2021, with construction of tenant spaces to be completed throughout the remainder of 2021.</div><div>Development Activity</div><div style="margin-bottom:6pt">In the first quarter of 2020, the Company completed the construction of the core and shell of a 151,031 square foot medical office building in Seattle, Washington. As of September 30, 2020, the Company had funded approximately $59.1 million towards the development and additional tenant improvements. The Company expects to fund an additional amount of approximately $5.0 million for additional tenant improvements associated with this project. The first tenant commenced rent payment in the first quarter of 2020.</div>

110883

5700000 8700000

151031

59100000 5000000.0

Stockholders' Equity<div style="margin-top:3pt">Common Stock </div><div style="margin-bottom:6pt">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2020 and the year ended December 31, 2019:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.840%"><tr><td style="width:1.0%"/><td style="width:56.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">SEPTEMBER 30, 2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">DECEMBER 31, 2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Balance, beginning of period</td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,706,154 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">125,279,455 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Issuance of common stock</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,292,324 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">9,251,440 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Nonvested share-based awards, net of withheld shares </td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">55,462 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">175,259 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Balance, end of period</td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">136,053,940 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,706,154 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div> </div><div>At-The-Market Equity Offering Program</div><div style="margin-bottom:6pt">On February 14, 2020, the Company entered into sales agreements with six investment banks to allow sales under its at-the-market equity offering program of up to an aggregate of $500.0 million of common stock. The Company sold 1,268,237 shares under the Company's at-the market equity offering program during the nine months ended September 30, 2020. The sales generated $39.9 million in net proceeds at prices to the public ranging from $30.50 to $36.15 per share (weighted average of $31.86 per share). The sales occurred during the following time periods:</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">•During the first quarter of 2020, the Company sold 196,250 shares generating approximately $7.0 million in net proceeds at prices to the public ranging from $33.00 to $36.15 per share (weighted average of $36.09 per share). </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">•During the second quarter of 2020, the Company sold 1,071,987 shares generating approximately $32.9 million in net proceeds at prices to the public ranging from $30.50 to $31.29 per share (weighted average of $31.08 per share). </div><div style="margin-bottom:6pt">In addition, the Company has entered into three forward equity agreements totaling 3.6 million shares at a weighted average price of $31.30 per share:</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">•In the second quarter of 2020, the Company entered into a forward equity agreement for a total of 1,579,371 shares at a weighted average price of $31.66 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in June 2021. </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">•In the third quarter of 2020, the Company entered into a forward equity agreement for a total of 764,472 shares at a weighted average price of $31.84 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in July 2021. </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">•In the fourth quarter of 2020, the Company entered into a forward equity agreement for a total of 1,235,129 shares at a weighted average price of $30.52 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in October 2021.</div><div style="margin-bottom:6pt">After taking into account the forward equity contracts discussed above, the Company has approximately $347.6 million remaining available to be sold under the current sales agreements at the date of this filing.</div><div>Common Stock Dividends</div><div style="margin-bottom:6pt">During the nine months ended September 30, 2020, the Company declared and paid common stock dividends totaling $0.90 per share. On November 3, 2020, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on December 1, 2020 to stockholders of record on November 16, 2020.</div><div>Earnings Per Common Share</div><div style="margin-bottom:6pt">The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. </div><div style="margin-bottom:6pt">During the nine months ended September 30, 2020, the Company entered into forward sale agreements to sell approximately 2.3 million shares of common stock through the Company's at-the-market equity offering program. The Company considered the accounting guidance governing financial instruments and derivatives to account for these agreements and concluded that it was not a liability as it did not embody obligations to repurchase our shares of common stock nor did it embody obligations to issue a variable number of shares for which the monetary value was predominately fixed, varying with something other than the fair value of the shares, or varying inversely in relation to the shares. In addition, the Company evaluated whether the agreements met the derivative and hedging guidance scope exception to be accounted for as an equity instrument and concluded that the agreements can be classified as equity.</div><div style="margin-bottom:6pt">The Company used the treasury method to determine the dilution from the forward equity agreements during the period of time prior to settlement. The number of weighted-average shares outstanding used in the computation of earnings per common share for the three and nine months ended September 30, 2020 included the effect from the assumed issuance of 2.3 million shares of common stock pursuant to the settlement of the forward equity agreements at the contractual price, less the assumed repurchase of the common stock at the average market price using the proceeds of approximately $72.7 million, adjusted for costs to borrow. For the three and nine months ended September 30, 2020, 137,757 and 51,133 weighted-average incremental shares of common stock were excluded from the computation of weighted-average common shares outstanding - diluted, as the impact was anti-dilutive.</div><div style="margin-bottom:6pt">The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2020 and 2019.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.847%"><tr><td style="width:1.0%"/><td style="width:47.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED SEPTEMBER 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED SEPTEMBER 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands, except per share data</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">136,048,781 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">129,865,985 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">135,393,798 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">128,348,638 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Non-vested shares</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,739,364)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,775,911)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,731,658)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,777,743)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - basic</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,309,417 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">128,090,074 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">133,662,140 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126,570,895 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - basic</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,309,417 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">128,090,074 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">133,662,140 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126,570,895 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of forward equity shares</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of employee stock purchase plan</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">47,810 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">78,610 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">74,029 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">85,690 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - diluted</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,357,227 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">128,168,684 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">133,736,169 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126,656,585 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Net Income</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">8,230 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">2,601 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">88,058 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">11,975 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dividends paid on nonvested share-based awards</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(522)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(534)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,561)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,603)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Net income applicable to common stockholders</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,708 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,067 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">86,497 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">10,372 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Basic earnings per common share - net income </td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.06 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.02 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.65 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.08 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Diluted earnings per common share - net income </td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.06 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.02 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.65 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.08 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">Incentive Plans</div><div style="margin-bottom:6pt">A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2020 and 2019 is included in the table below.</div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.847%"><tr><td style="width:1.0%"/><td style="width:47.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED SEPTEMBER 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED SEPTEMBER 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Share-based awards, beginning of period</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,739,258 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,778,134 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,754,066 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,769,863 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Granted</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">188 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">79,025 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">89,767 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Vested 1</div></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(204,548)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(93,645)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(286,044)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Share-based awards, end of period</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,739,446 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,573,586 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,739,446 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,573,586 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of 204,548 outstanding nonvested share-based awards. </div><div style="margin-bottom:6pt;margin-top:9pt">During the nine months ended September 30, 2020 and 2019, the Company withheld 23,563 and 100,036 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested. </div><div style="margin-bottom:6pt">In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2020 and 2019 is included in the table below.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.847%"><tr><td style="width:1.0%"/><td style="width:47.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED SEPTEMBER 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED SEPTEMBER 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Outstanding and exercisable, beginning of period</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">361,719 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">363,218 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">332,659 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">328,533 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Granted</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">212,716 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">235,572 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Exercised</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(3,504)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(9,927)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(17,871)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(28,943)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Forfeited</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(6,659)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(11,762)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(36,154)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(51,559)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Expired</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(139,794)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(142,074)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Outstanding and exercisable, end of period</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">351,556 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">341,529 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">351,556 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">341,529 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>

<div style="margin-bottom:6pt">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2020 and the year ended December 31, 2019:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.840%"><tr><td style="width:1.0%"/><td style="width:56.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">SEPTEMBER 30, 2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">DECEMBER 31, 2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Balance, beginning of period</td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,706,154 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">125,279,455 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Issuance of common stock</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,292,324 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">9,251,440 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Nonvested share-based awards, net of withheld shares </td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">55,462 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">175,259 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Balance, end of period</td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">136,053,940 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,706,154 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>

134706154

125279455

1292324

9251440

55462

175259

136053940

134706154

6 500000000.0

1268237

39900000

30.50 36.15 31.86

196250

7000000.0

33.00 36.15 36.09

1071987

32900000

30.50 31.29 31.08 3 3600000

31.30

1579371

31.66

764472

31.84

1235129

30.52

347600000

0.90

0.30

2300000

72700000 72700000

137757

51133

<div style="margin-bottom:6pt">The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2020 and 2019.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.847%"><tr><td style="width:1.0%"/><td style="width:47.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED SEPTEMBER 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED SEPTEMBER 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands, except per share data</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">136,048,781 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">129,865,985 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">135,393,798 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">128,348,638 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Non-vested shares</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,739,364)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,775,911)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,731,658)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,777,743)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - basic</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,309,417 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">128,090,074 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">133,662,140 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126,570,895 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - basic</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,309,417 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">128,090,074 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">133,662,140 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126,570,895 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of forward equity shares</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of employee stock purchase plan</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">47,810 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">78,610 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">74,029 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">85,690 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - diluted</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">134,357,227 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">128,168,684 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">133,736,169 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">126,656,585 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Net Income</td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">8,230 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">2,601 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">88,058 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">11,975 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dividends paid on nonvested share-based awards</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(522)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(534)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,561)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,603)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Net income applicable to common stockholders</td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,708 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,067 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">86,497 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">10,372 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Basic earnings per common share - net income </td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.06 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.02 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.65 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.08 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Diluted earnings per common share - net income </td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.06 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.02 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.65 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">0.08 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>

136048781

129865985

135393798

128348638

1739364

1775911

1731658

1777743

134309417

128090074

133662140

126570895

134309417

128090074

133662140

126570895

47810 78610 74029 85690

134357227

128168684

133736169

126656585

8230000

2601000

88058000

11975000

522000

534000

1561000

1603000

7708000 2067000 86497000 10372000

0.06

0.02

0.65

0.08

0.06

0.02

0.65

0.08

<div style="margin-bottom:6pt">A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2020 and 2019 is included in the table below.</div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.847%"><tr><td style="width:1.0%"/><td style="width:47.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED SEPTEMBER 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED SEPTEMBER 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Share-based awards, beginning of period</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,739,258 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,778,134 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,754,066 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,769,863 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Granted</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">188 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">79,025 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">89,767 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Vested 1</div></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(204,548)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(93,645)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(286,044)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Share-based awards, end of period</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,739,446 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,573,586 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,739,446 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,573,586 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>1The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of 204,548 outstanding nonvested share-based awards.

1739258

1778134

1754066

1769863

188

79025

89767

204548

93645

286044

1739446

1573586

1739446

1573586

204548

23563

100036

A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2020 and 2019 is included in the table below.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.847%"><tr><td style="width:1.0%"/><td style="width:47.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED SEPTEMBER 30,</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">NINE MONTHS ENDED SEPTEMBER 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2020</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Outstanding and exercisable, beginning of period</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">361,719 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">363,218 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">332,659 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">328,533 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Granted</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">212,716 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">235,572 </td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Exercised</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(3,504)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(9,927)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(17,871)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(28,943)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Forfeited</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(6,659)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(11,762)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(36,154)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(51,559)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Expired</td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(139,794)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(142,074)</td><td style="border-right:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Outstanding and exercisable, end of period</td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">351,556 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">341,529 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">351,556 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">341,529 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table>

361719

363218

332659

328533

212716

235572

3504

9927

17871

28943

6659

11762

36154

51559

139794

142074

351556

341529

351556

341529

Fair Value of Financial Instruments<div style="margin-bottom:6pt">The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.</div><div style="padding-left:18pt;text-indent:-18pt">•Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments. </div><div style="padding-left:18pt;text-indent:-18pt">•Borrowings under the Unsecured Credit Facility and the Term Loans Due 2024 and 2026 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.</div><div style="padding-left:18pt;text-indent:-18pt">•Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.</div><div style="padding-left:18pt;text-indent:-18pt">•Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.</div><div style="margin-bottom:6pt;margin-top:9pt">The table below details the fair values and carrying values for notes and bonds payable at September 30, 2020 and December 31, 2019.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.406%"><tr><td style="width:1.0%"/><td style="width:32.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2020</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2019</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in millions</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Notes and bonds payable 1</div></td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,554.4 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,621.7 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,414.1 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,425.8 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.</div>

<div style="margin-bottom:6pt;margin-top:9pt">The table below details the fair values and carrying values for notes and bonds payable at September 30, 2020 and December 31, 2019.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.406%"><tr><td style="width:1.0%"/><td style="width:32.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="6" style="background-color:#000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2020</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2019</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in millions</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE</td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Notes and bonds payable 1</div></td><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,554.4 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,621.7 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,414.1 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,425.8 </td><td style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.</div>

1554400000

1621700000

1414100000

1425800000

XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2020	Oct. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-11852
Entity Registrant Name	HEALTHCARE REALTY TRUST INCORPORATED
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	62-1507028
Entity Address, Address Line One	3310 West End Avenue, Suite 700
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37203
City Area Code	615
Local Phone Number	269-8175
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	HR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		136,054,024
Entity Central Index Key	0000899749
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Real estate properties
Land	$ 330,840	$ 289,751
Buildings, improvements and lease intangibles	4,014,740	3,986,326
Personal property	10,962	10,538
Construction in progress	0	48,731
Land held for development	24,647	24,647
Total real estate properties	4,381,189	4,359,993
Less accumulated depreciation and amortization	(1,198,444)	(1,121,102)
Total real estate properties, net	3,182,745	3,238,891
Cash and cash equivalents	121,992	657
Restricted cash	60,644	0
Assets held for sale, net	20,051	37
Operating lease right-of-use assets	123,807	126,177
Financing lease right-of-use assets	19,776	12,667
Other assets, net	182,436	185,426
Total assets	3,711,451	3,563,855
Liabilities
Notes and bonds payable	1,554,395	1,414,069
Accounts payable and accrued liabilities	79,528	78,517
Liabilities of assets held for sale	548	145
Operating lease liabilities	91,466	91,574
Financing lease liabilities	18,697	18,037
Other liabilities	66,442	61,504
Total liabilities	1,811,076	1,663,846
Commitments and contingencies
Stockholders' equity
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding	0	0
Common stock, $.01 par value per share; 300,000 shares authorized; 136,054 and 134,706 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	1,361	1,347
Additional paid-in capital	3,532,130	3,485,003
Accumulated other comprehensive loss	(19,267)	(6,175)
Cumulative net income attributable to common stockholders	1,215,362	1,127,304
Cumulative dividends	(2,829,211)	(2,707,470)
Total stockholders' equity	1,900,375	1,900,009
Total liabilities and stockholders' equity	$ 3,711,451	$ 3,563,855
Preferred Stock, Shares Outstanding	0	0

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (shares)	50,000,000	50,000,000
Preferred stock, issued (shares)	0	0
Preferred stock, outstanding (shares)	0	0
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (shares)	300,000,000	300,000,000
Common stock, issued (shares)	136,054,000	134,706,000
Common stock, outstanding (shares)	136,054,000	134,706,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues
Rental income	$ 123,384	$ 117,740	$ 368,385	$ 342,787
Other operating	1,868	2,059	5,364	5,987
Revenues	125,252	119,799	373,749	348,774
Expenses
Property operating	50,171	46,777	146,305	133,790
General and administrative	7,299	10,802	23,498	27,157
Acquisition and pursuit costs	440	501	1,621	1,227
Depreciation and amortization	47,143	45,137	142,331	131,725
Expenses	105,053	103,217	313,755	293,899
Other Income (Expense)
Gain on sales of real estate assets	2,177	200	70,395	5,065
Interest expense	(14,154)	(14,181)	(42,556)	(41,619)
Impairment of real estate assets				(5,610)
Interest and other income (expense), net	8		225	(736)
Total other income (expense)	(11,969)	(13,981)	28,064	(42,900)
Net Income	$ 8,230	$ 2,601	$ 88,058	$ 11,975
Basic earnings per common share (in dollars per share)	$ 0.06	$ 0.02	$ 0.65	$ 0.08
Diluted earnings per common share (in dollars per share)	$ 0.06	$ 0.02	$ 0.65	$ 0.08
Weighted average common shares outstanding - basic	134,309,417	128,090,074	133,662,140	126,570,895
Weighted average common shares outstanding - diluted	134,357,227	128,168,684	133,736,169	126,656,585
Dividends declared, per common share, during the period (in dollars per share)	$ 0.30	$ 0.30	$ 0.90	$ 0.90
Revenue, Product and Service [Extensible List]	us-gaap:ServiceMember	us-gaap:ServiceMember	us-gaap:ServiceMember	us-gaap:ServiceMember

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net income	$ 8,230	$ 2,601	$ 88,058	$ 11,975
Interest rate swaps
Reclassification adjustments for losses included in net income (interest expense)	1,101	60	2,367	74
Losses arising during the period on interest rate swaps	74	2,341	15,459	7,642
Other comprehensive income (loss)	1,027	(2,281)	(13,092)	(7,568)
Comprehensive income	9,257	320	74,966	4,407
Interest Rate Swaps
Interest rate swaps
Losses arising during the period on interest rate swaps	(74)	(2,341)	(11,192)	(7,642)
Treasury Rate Locks
Interest rate swaps
Losses arising during the period on interest rate swaps	$ 0	$ 0	$ (4,267)	$ 0

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Equity (Unaudited) Statement - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Cumulative Net Income	Cumulative Dividends
Beginning balance at Dec. 31, 2018	$ 1,716,642	$ 1,253	$ 3,180,284	$ (902)	$ 1,088,119	$ (2,552,112)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs	192,475	61	192,414
Common stock redemptions	(3,267)	(1)	(3,266)
Share-based compensation	10,141	1	10,140
Net income	11,975				11,975
Reclassification adjustments for losses included in net income (interest expense)	74			74
Losses arising during the period on interest rate swaps and treasury rate locks	(7,642)			(7,642)
Dividends to common stockholders (in usd per share)	(115,237)					(115,237)
Ending balance at Sep. 30, 2019	1,805,161	1,314	3,379,572	(8,470)	1,100,094	(2,667,349)
Beginning balance at Jun. 30, 2019	1,769,443	1,292	3,305,344	(6,189)	1,097,493	(2,628,497)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs	71,814	22	71,792
Common stock redemptions	(2,695)		(2,695)
Share-based compensation	5,131		5,131
Net income	2,601				2,601
Reclassification adjustments for losses included in net income (interest expense)	60			60
Losses arising during the period on interest rate swaps and treasury rate locks	(2,341)			(2,341)
Dividends to common stockholders (in usd per share)	(38,852)					(38,852)
Ending balance at Sep. 30, 2019	1,805,161	1,314	3,379,572	(8,470)	1,100,094	(2,667,349)
Beginning balance at Dec. 31, 2019	1,900,009	1,347	3,485,003	(6,175)	1,127,304	(2,707,470)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs	40,490	13	40,477
Common stock redemptions	(798)		(798)
Share-based compensation	7,449		7,448
Net income	88,058				88,058
Reclassification adjustments for losses included in net income (interest expense)	2,367			2,367
Losses arising during the period on interest rate swaps and treasury rate locks	(15,459)			(15,459)
Dividends to common stockholders (in usd per share)	(121,741)					(121,741)
Ending balance at Sep. 30, 2020	1,900,375	1,361	3,532,130	(19,267)	1,215,362	(2,829,211)
Beginning balance at Jun. 30, 2020	1,929,361	1,360	3,529,559	(20,294)	1,207,132	(2,788,396)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs	127	1	126
Share-based compensation	2,445		2,445
Net income	8,230				8,230
Reclassification adjustments for losses included in net income (interest expense)	1,101			1,101
Losses arising during the period on interest rate swaps and treasury rate locks	(74)			(74)
Dividends to common stockholders (in usd per share)	(40,815)					(40,815)
Ending balance at Sep. 30, 2020	$ 1,900,375	$ 1,361	$ 3,532,130	$ (19,267)	$ 1,215,362	$ (2,829,211)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Stockholders' Equity [Abstract]
Dividend per share to common Stockholders (in dollars per share)	$ 0.30	$ 0.30	$ 0.90	$ 0.90

XML 18 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
OPERATING ACTIVITIES
Net income	$ 88,058	$ 11,975
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	142,331	131,725
Other amortization	3,409	2,279
Share-based compensation	7,449	10,141
Amortization of straight-line rent receivable (lessor)	(2,722)	(1,833)
Amortization of straight-line rent on operating leases (lessee)	1,122	1,159
Gain on sales of real estate assets	(70,395)	(5,065)
Impairment of real estate assets		5,610
Loss from unconsolidated joint ventures	194	16
Distributions from unconsolidated joint ventures	193	277
Proceeds from disposition of sales-type lease properties	244,454	0
Changes in operating assets and liabilities:
Other assets, including right-of-use-assets	(965)	(6,740)
Accounts payable and accrued liabilities	5,098	3,220
Other liabilities	(6,662)	5,709
Net cash provided by operating activities	411,564	158,473
INVESTING ACTIVITIES
Acquisitions of real estate	(199,162)	(271,575)
Development of real estate	(2,941)	(19,152)
Additional long-lived assets	(62,707)	(45,902)
Proceeds from sales of real estate assets	4,905	14,151
Net cash used in investing activities	(259,905)	(322,478)
FINANCING ACTIVITIES
Net (repayments) borrowings on unsecured credit facility	(293,000)	60,000
Borrowings on term loan	150,000	50,000
Borrowings of notes and bonds payable	298,995
Repayments on notes and bonds payable	(32,704)	(12,663)
Dividends paid	(121,741)	(115,237)
Net proceeds from issuance of common stock	40,296	192,514
Common stock redemptions	(892)	(2,343)
Settlement of treasury rate locks	(4,267)
Debt issuance and assumption costs	(3,057)	(4,589)
Payments made on finance leases	(3,310)	(249)
Net cash provided by financing activities	30,320	167,433
Increase in cash, cash equivalents and restricted cash	181,979	3,428
Cash and cash equivalents at beginning of period	657	8,381
Cash, cash equivalents and restricted cash at end of period	182,636	11,809
Supplemental Cash Flow Information
Interest paid	39,165	37,946
Invoices accrued for construction, tenant improvements and other capitalized costs	12,709	10,702
Mortgage notes payable assumed upon acquisition (adjusted to fair value)	19,269
Capitalized interest	$ 913	$ 999

XML 19 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of significant accounting policies

Business Overview

Basis of Presentation

Use of Estimates in the Condensed Consolidated Financial Statements

COVID-19 Update

Revenue from Contracts with Customers (Topic 606)


	THREE MONTHS ENDED September 30,				NINE MONTHS ENDED September 30,
in thousands	2020		2019		2020		2019
Type of Revenue
Parking income	$	1,764	$	1,935	$	5,042	$	5,538
Rental lease guaranty	—		—		—		128
Management fee income	62		69		209		201
Miscellaneous	42		55		113		120
	$	1,868	$	2,059	$	5,364	$	5,987

Cash, Cash Equivalents and Restricted Cash


In thousands	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	121,992	$	657
Restricted cash	60,644		—
Total cash, cash equivalents and restricted cash	$	182,636	$	657

New Accounting Pronouncements

Accounting Standards Update No. 2016-13

Accounting Standards Update No. 2017-04

Accounting Standards Update No. 2020-04

XML 20 R10.htm IDEA: XBRL DOCUMENT

Real Estate Investments

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Real Estate Investments

2020 Acquisitions

The following table details the Company's acquisitions for the nine months ended September 30, 2020:


Dollars in millions	TYPE 1	DATE ACQUIRED	PURCHASE PRICE		MORTGAGE NOTES PAYABLE		CASH CONSIDERATION 2		REAL ESTATE		OTHER 3		SQUARE FOOTAGE
Los Angeles, CA	MOB	1/3/20	$	42.0	$	(19.3)	$	22.8	$	42.4	$	(0.3)	86,986
Atlanta, GA	MOB	2/13/20	12.0		—		11.8		12.1		(0.3)		64,624
Raleigh, NC	MOB	2/25/20	6.3		—		6.5		6.5		—		15,964
Colorado Springs, CO	MOB	3/9/20	8.2		—		8.3		8.6		(0.3)		34,210
Denver, CO 4	MOB	3/13/20	33.5		—		33.2		34.0		(0.8)		136,994
San Diego, CA	MOB	7/1/20	16.7		—		16.7		16.9		(0.2)		46,083
Los Angeles, CA	MOB	7/17/20	35.0		—		37.7		37.7		—		49,785
Seattle, WA	MOB	7/23/20	11.0		—		10.9		11.3		(0.4)		21,309
Atlanta, GA	MOB	7/31/20	20.5		—		21.6		21.3		0.3		48,145
Houston, TX	MOB	9/24/20	11.0		—		10.9		11.0		(0.1)		40,235
Los Angeles, CA	MOB	9/28/20	14.0		—		14.0		13.9		0.1		24,252

Total real estate acquisitions			$	210.2	$	(19.3)	$	194.4	$	215.7	$	(2.0)	568,587
Land acquisition 5			1.6		—		1.7		1.7		—		—
Land acquisition 6			1.0		—		1.1		1.1		—		—
			$	212.8	$	(19.3)	$	197.2	$	218.5	$	(2.0)	568,587

1MOB = medical office building.

2Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.

3Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.

4Includes three properties.

5The Company acquired land parcels under four existing buildings (previously ground leased).

6The Company acquired a land parcel under an existing building (previously ground leased). The building and land were sold on September 30, 2020.

Subsequent Acquisition

On October 7, 2020 the Company acquired a 36,720 square foot medical office building in Colorado Springs, CO for a purchase price of $8.9 million.

2020 Real Estate Asset Dispositions

The following table details the Company's dispositions for the nine months ended September 30, 2020:


Dollars in millions	TYPE 1	Date Disposed	Sale Price		Closing Adjustments		Net Proceeds		Net Real Estate Investment		Other (including receivables)2		Gain/(Impairment)		Square Footage (Unaudited)
Springfield, MO 3	SF	7/30/20	$	138.0	$	—	$	138.0	$	92.4	$	3.9	$	41.7	186,000
Oklahoma City, OK 3	MOB	7/30/20	106.5		—		106.5		76.8		3.1		26.6		200,000
Miami, FL	MOB	9/30/20	5.0		(0.2)		4.8		2.6		0.1		2.1		26,000

Total dispositions			$	249.5	$	(0.2)	$	249.3	$	171.8	$	7.1	$	70.4	412,000

1.MOB = medical office building; SF = surgical facility

2.Includes straight-line rent receivables, leasing commissions and lease inducements.

Assets Held for Sale

of September 30, 2020 and December 31, 2019, the Company had four and zero properties, respectively, classified as assets held for sale.

The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2020 and December 31, 2019:


(Dollars in thousands)	September 30, 2020		December 31, 2019
Balance Sheet data:
Land	$	1,664	$	—
Building, improvements and lease intangibles	26,871		—
Personal property	39		—
	28,574		—
Accumulated depreciation	(10,443)		—
Real estate assets held for sale, net	18,131		—
Other assets, net	1,920		37
Assets held for sale, net	$	20,051	$	37

Accounts payable and accrued liabilities	$	437	$	37
Other liabilities	111		108
Liabilities of assets held for sale	$	548	$	145

XML 21 R11.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Leases

Lessor Accounting

Tabular Disclosure of the Components of Sales-Type Leases

The table below presents the components of sale-type leases for the three and nine months ended September 30, 2020:


	SALES-TYPE LEASES
In thousands	three months ended September 30, 2020		nine months ended September 30, 2020
Profit recognized at commencement date	$	—	$	68,267	Gain on sales of real estate assets
Interest income	1,454		3,007		Rental income

Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2020 were as follows:


In thousands	Operating
2020	$	93,722
2021	352,341
2022	307,166
2023	261,187
2024	200,578
2025 and thereafter	555,264
	$	1,770,258

Lessee Accounting

The Company’s future lease payments (primarily for its 61 non-prepaid ground leases) as of September 30, 2020 were as follows:


In thousands	OPERATING		FINANCING
2020	$	1,008	$	143
2021	4,844		930
2022	4,875		783
2023	4,913		793
2024	4,969		815
2025 and thereafter	307,665		88,808
Total undiscounted lease payments	328,274		92,272
Discount	(236,808)		(73,575)
Lease liabilities	$	91,466	$	18,697

The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2020 and 2019:


	THREE MONTHS ENDED September 30,						NINE MONTHS ENDED September 30,
In thousands	2020			2019			2020		2019
Operating lease cost
Operating lease expense	$	1,180		$	1,169		$	3,534	$	3,448
Variable lease expense	1,066			845			2,664		2,380

Finance lease cost
Amortization of right-of-use assets	88			51			236		101
Interest on lease liabilities	245			196			722		392
Total lease expense	$	2,579		$	2,261		$	7,156	$	6,321

Other information
Operating cash flows outflows related to operating leases	$	1,440		$	1,313		$	5,412	$	5,461
Financing cash flows outflows related to financing leases	$	143		$	107		$	3,310	$	249
Right-of-use assets obtained in exchange for new finance lease liabilities	$	—		$	—		$	7,212	$	14,294

Weighted-average remaining lease term (excluding renewal options) - operating leases	48.9			49.7
Weighted-average remaining lease term (excluding renewal options) -finance leases	64.7			70.1
Weighted-average discount rate - operating leases	5.7		%	5.7		%
Weighted-average discount rate - finance leases	5.4		%	5.5		%

Leases

Lessor Accounting

Tabular Disclosure of the Components of Sales-Type Leases

The table below presents the components of sale-type leases for the three and nine months ended September 30, 2020:


	SALES-TYPE LEASES
In thousands	three months ended September 30, 2020		nine months ended September 30, 2020
Profit recognized at commencement date	$	—	$	68,267	Gain on sales of real estate assets
Interest income	1,454		3,007		Rental income

Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2020 were as follows:


In thousands	Operating
2020	$	93,722
2021	352,341
2022	307,166
2023	261,187
2024	200,578
2025 and thereafter	555,264
	$	1,770,258

Lessee Accounting

The Company’s future lease payments (primarily for its 61 non-prepaid ground leases) as of September 30, 2020 were as follows:


In thousands	OPERATING		FINANCING
2020	$	1,008	$	143
2021	4,844		930
2022	4,875		783
2023	4,913		793
2024	4,969		815
2025 and thereafter	307,665		88,808
Total undiscounted lease payments	328,274		92,272
Discount	(236,808)		(73,575)
Lease liabilities	$	91,466	$	18,697

The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2020 and 2019:


	THREE MONTHS ENDED September 30,						NINE MONTHS ENDED September 30,
In thousands	2020			2019			2020		2019
Operating lease cost
Operating lease expense	$	1,180		$	1,169		$	3,534	$	3,448
Variable lease expense	1,066			845			2,664		2,380

Finance lease cost
Amortization of right-of-use assets	88			51			236		101
Interest on lease liabilities	245			196			722		392
Total lease expense	$	2,579		$	2,261		$	7,156	$	6,321

Other information
Operating cash flows outflows related to operating leases	$	1,440		$	1,313		$	5,412	$	5,461
Financing cash flows outflows related to financing leases	$	143		$	107		$	3,310	$	249
Right-of-use assets obtained in exchange for new finance lease liabilities	$	—		$	—		$	7,212	$	14,294

Weighted-average remaining lease term (excluding renewal options) - operating leases	48.9			49.7
Weighted-average remaining lease term (excluding renewal options) -finance leases	64.7			70.1
Weighted-average discount rate - operating leases	5.7		%	5.7		%
Weighted-average discount rate - finance leases	5.4		%	5.5		%

XML 22 R12.htm IDEA: XBRL DOCUMENT

Notes and Bonds Payable

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Notes and bonds payable

Notes and Bonds Payable

The table below details the Company’s notes and bonds payable.


	MATURITY DATES	BALANCE AS OF				EFFECTIVE INTEREST RATE as of 9/30/2020
Dollars in thousands		9/30/2020		12/31/2019
$700 million Unsecured Credit Facility	5/23	$	—	$	293,000	N/A
$200 million Unsecured Term Loan Facility, net of issuance costs 1	5/24	199,180		199,013		1.99	%
$150 million Unsecured Term Loan due 2026 2	6/26	149,455		—		3.14	%
Senior Notes due 2023, net of discount and issuance costs	4/23	248,863		248,540		3.95	%
Senior Notes due 2025, net of discount and issuance costs 3	5/25	248,711		248,522		4.08	%
Senior Notes due 2028, net of discount and issuance costs	1/28	296,003		295,651		3.84	%
Senior Notes due 2030, net of discount and issuance costs 4	3/30	296,384		—		2.71	%
Mortgage notes payable, net of discounts and issuance costs and including premiums	1/21-4/27	115,799		129,343		4.38	%
		$	1,554,395	$	1,414,069

1The effective interest rate includes the impact of interest rate swaps on $75.0 million at a weighted average rate of 2.37% (plus the applicable margin rate, currently 100 basis points).

2The effective interest rate includes the impact of interest rate swaps on $100.0 million at a weighted average rate of 2.23% (plus the applicable margin rate, currently 160 basis points).

Changes in Debt Structure

On May 29, 2020, the Company borrowed $150.0 million pursuant to its unsecured term loan due 2026.

Subsequent Changes in Debt Structure

On October 2, 2020, the Company issued $300.0 million of unsecured senior notes due 2031 (the "Senior Notes due 2031") in a registered public offering. The Senior Notes due 2031 bear interest at 2.05%, payable semi-annually on March 15 and September 15, beginning March 15, 2021, and are due on March 15, 2031, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $2.4 million and the Company incurred approximately $2.8 million in debt issuance costs. Inclusive of the discount and debt issuance costs, the effective interest rate was 2.24%. The Senior Notes due 2031 have various financial covenants that are required to be met on a quarterly and annual basis.On October 19, 2020, the Company redeemed its unsecured senior notes due 2023 (the "Senior Notes due 2023"). The aggregate redemption price of $270.5 million consisted of outstanding principal of $250.0 million, accrued interest of $0.1 million, and a "make-whole" amount of approximately $20.4 million for the early extinguishment of debt. The unaccreted discount and unamortized costs on these notes of $1.1 million was written off upon redemption. In October 2020, the Company recognized a loss on early extinguishment of debt of approximately $21.5 million related to this redemption.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments

9 Months Ended

Sep. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative financial instruments

Derivative Financial Instruments

Risk Management Objective of Using Derivatives

Cash Flow Hedges of Interest Rate Risk

As of September 30, 2020, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:


DERIVATIVE INSTRUMENT	NUMBER OF INSTRUMENTS	NOTIONAL AMOUNT in millions
Interest rate swaps	8	$175.0

Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet

The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2020.


	BALANCE AT SEPTEMBER 30, 2020
In thousands	BALANCE SHEET LOCATION	FAIR VALUE
Derivatives designated as hedging instruments
Interest rate swaps	Other liabilities	$	14,460
Total derivatives designated as hedging instruments		$	14,460

Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)

The table below presents the effect of cash flow hedge accounting on AOCI during the three and nine months ended September 30, 2020 and 2019 related to the Company's outstanding interest rate swaps.


	LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended September 30,					(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended September 30,
In thousands	2020		2019			2020		2019
Interest rate swaps	$	74	$	2,341	Interest expense	$	952	$	18
Settled treasury hedges	—		—		Interest expense	107		—
Settled interest rate swaps	—		—		Interest expense	42		42
	$	74	$	2,341	Total interest expense	$	1,101	$	60


	LOSS RECOGNIZED IN AOCI ON DERIVATIVE nine months ended September 30,					(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME nine months ended September 30,
In thousands	2020		2019			2020		2019
Interest rate swaps	$	11,192	$	7,642	Interest expense	$	2,012	$	(52)
Settled treasury hedges	4,267		—		Interest expense	229		—
Settled interest rate swaps	—		—		Interest expense	126		126
	$	15,459	$	7,642	Total interest expense	$	2,367	$	74

The Company estimates that $4.4 million will be reclassified from AOCI to interest expense over the next 12 months.

Credit-risk-related Contingent Features

XML 24 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and Contingencies Legal Proceedings The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. Redevelopment Activity The Company initiated the redevelopment of a 110,883 square foot medical office building in Memphis, Tennessee ("Memphis Redevelopment") in December 2019. As of September 30, 2020, the Company funded approximately $5.7 million in project costs, excluding the purchase price of $8.7 million for the land and building. The building will continue to operate with in-place leases during construction. The core and shell portion of the Memphis Redevelopment is expected to be completed in the first quarter of 2021, with construction of tenant spaces to be completed throughout the remainder of 2021. Development Activity In the first quarter of 2020, the Company completed the construction of the core and shell of a 151,031 square foot medical office building in Seattle, Washington. As of September 30, 2020, the Company had funded approximately $59.1 million towards the development and additional tenant improvements. The Company expects to fund an additional amount of approximately $5.0 million for additional tenant improvements associated with this project. The first tenant commenced rent payment in the first quarter of 2020.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Stockholders' equity

Stockholders' Equity

Common Stock

The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2020 and the year ended December 31, 2019:


	SEPTEMBER 30, 2020	DECEMBER 31, 2019
Balance, beginning of period	134,706,154	125,279,455
Issuance of common stock	1,292,324	9,251,440
Nonvested share-based awards, net of withheld shares	55,462	175,259
Balance, end of period	136,053,940	134,706,154

At-The-Market Equity Offering Program

In addition, the Company has entered into three forward equity agreements totaling 3.6 million shares at a weighted average price of $31.30 per share:

Common Stock Dividends

Earnings Per Common Share

The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method.

The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2020 and 2019.


	THREE MONTHS ENDED SEPTEMBER 30,				NINE MONTHS ENDED SEPTEMBER 30,
Dollars in thousands, except per share data	2020		2019		2020		2019
Weighted average common shares outstanding
Weighted average common shares outstanding	136,048,781		129,865,985		135,393,798		128,348,638
Non-vested shares	(1,739,364)		(1,775,911)		(1,731,658)		(1,777,743)
Weighted average common shares outstanding - basic	134,309,417		128,090,074		133,662,140		126,570,895

Weighted average common shares outstanding - basic	134,309,417		128,090,074		133,662,140		126,570,895
Dilutive effect of forward equity shares	—		—		—		—
Dilutive effect of employee stock purchase plan	47,810		78,610		74,029		85,690
Weighted average common shares outstanding - diluted	134,357,227		128,168,684		133,736,169		126,656,585

Net Income	$	8,230	$	2,601	$	88,058	$	11,975
Dividends paid on nonvested share-based awards	(522)		(534)		(1,561)		(1,603)
Net income applicable to common stockholders	$	7,708	$	2,067	$	86,497	$	10,372





Basic earnings per common share - net income	$	0.06	$	0.02	$	0.65	$	0.08


Diluted earnings per common share - net income	$	0.06	$	0.02	$	0.65	$	0.08

Incentive Plans

A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2020 and 2019 is included in the table below.


	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,
	2020	2019	2020	2019
Share-based awards, beginning of period	1,739,258	1,778,134	1,754,066	1,769,863
Granted	188	—	79,025	89,767
Vested 1	—	(204,548)	(93,645)	(286,044)

Share-based awards, end of period	1,739,446	1,573,586	1,739,446	1,573,586

1The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of 204,548 outstanding nonvested share-based awards.


	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,
	2020	2019	2020	2019
Outstanding and exercisable, beginning of period	361,719	363,218	332,659	328,533
Granted	—	—	212,716	235,572
Exercised	(3,504)	(9,927)	(17,871)	(28,943)
Forfeited	(6,659)	(11,762)	(36,154)	(51,559)
Expired	—	—	(139,794)	(142,074)
Outstanding and exercisable, end of period	351,556	341,529	351,556	341,529

XML 26 R16.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair value of financial instruments

Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

•Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.

The table below details the fair values and carrying values for notes and bonds payable at September 30, 2020 and December 31, 2019.


	September 30, 2020				December 31, 2019
Dollars in millions	CARRYING VALUE		FAIR VALUE		CARRYING VALUE		FAIR VALUE
Notes and bonds payable 1	$	1,554.4	$	1,621.7	$	1,414.1	$	1,425.8

1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Business overview

Basis of presentation

Basis of Presentation

Use of estimates in the condensed consolidated financial statements

Use of Estimates in the Condensed Consolidated Financial Statements

COVID-19 Update

Revenue from contract with customers (topic 606)

Revenue from Contracts with Customers (Topic 606)


	THREE MONTHS ENDED September 30,				NINE MONTHS ENDED September 30,
in thousands	2020		2019		2020		2019
Type of Revenue
Parking income	$	1,764	$	1,935	$	5,042	$	5,538
Rental lease guaranty	—		—		—		128
Management fee income	62		69		209		201
Miscellaneous	42		55		113		120
	$	1,868	$	2,059	$	5,364	$	5,987

Cash, cash equivalents and restricted cash

New accounting pronouncements

New Accounting Pronouncements

Accounting Standards Update No. 2016-13

Accounting Standards Update No. 2017-04

Accounting Standards Update No. 2020-04

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

+ Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Disaggreation of revenue

Below is a detail of the amounts by category:


	THREE MONTHS ENDED September 30,				NINE MONTHS ENDED September 30,
in thousands	2020		2019		2020		2019
Type of Revenue
Parking income	$	1,764	$	1,935	$	5,042	$	5,538
Rental lease guaranty	—		—		—		128
Management fee income	62		69		209		201
Miscellaneous	42		55		113		120
	$	1,868	$	2,059	$	5,364	$	5,987

Cash, cash equivalents and restricted cash


In thousands	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	121,992	$	657
Restricted cash	60,644		—
Total cash, cash equivalents and restricted cash	$	182,636	$	657

XML 29 R19.htm IDEA: XBRL DOCUMENT

Real Estate Investments (Tables)

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Summary of acquisitions

The following table details the Company's acquisitions for the nine months ended September 30, 2020:


Dollars in millions	TYPE 1	DATE ACQUIRED	PURCHASE PRICE		MORTGAGE NOTES PAYABLE		CASH CONSIDERATION 2		REAL ESTATE		OTHER 3		SQUARE FOOTAGE
Los Angeles, CA	MOB	1/3/20	$	42.0	$	(19.3)	$	22.8	$	42.4	$	(0.3)	86,986
Atlanta, GA	MOB	2/13/20	12.0		—		11.8		12.1		(0.3)		64,624
Raleigh, NC	MOB	2/25/20	6.3		—		6.5		6.5		—		15,964
Colorado Springs, CO	MOB	3/9/20	8.2		—		8.3		8.6		(0.3)		34,210
Denver, CO 4	MOB	3/13/20	33.5		—		33.2		34.0		(0.8)		136,994
San Diego, CA	MOB	7/1/20	16.7		—		16.7		16.9		(0.2)		46,083
Los Angeles, CA	MOB	7/17/20	35.0		—		37.7		37.7		—		49,785
Seattle, WA	MOB	7/23/20	11.0		—		10.9		11.3		(0.4)		21,309
Atlanta, GA	MOB	7/31/20	20.5		—		21.6		21.3		0.3		48,145
Houston, TX	MOB	9/24/20	11.0		—		10.9		11.0		(0.1)		40,235
Los Angeles, CA	MOB	9/28/20	14.0		—		14.0		13.9		0.1		24,252

Total real estate acquisitions			$	210.2	$	(19.3)	$	194.4	$	215.7	$	(2.0)	568,587
Land acquisition 5			1.6		—		1.7		1.7		—		—
Land acquisition 6			1.0		—		1.1		1.1		—		—
			$	212.8	$	(19.3)	$	197.2	$	218.5	$	(2.0)	568,587

1MOB = medical office building.

2Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.

3Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.

4Includes three properties.

5The Company acquired land parcels under four existing buildings (previously ground leased).

6The Company acquired a land parcel under an existing building (previously ground leased). The building and land were sold on September 30, 2020.

Subsequent Acquisition

On October 7, 2020 the Company acquired a 36,720 square foot medical office building in Colorado Springs, CO for a purchase price of $8.9 million.

Real estate dispositions

The following table details the Company's dispositions for the nine months ended September 30, 2020:


Dollars in millions	TYPE 1	Date Disposed	Sale Price		Closing Adjustments		Net Proceeds		Net Real Estate Investment		Other (including receivables)2		Gain/(Impairment)		Square Footage (Unaudited)
Springfield, MO 3	SF	7/30/20	$	138.0	$	—	$	138.0	$	92.4	$	3.9	$	41.7	186,000
Oklahoma City, OK 3	MOB	7/30/20	106.5		—		106.5		76.8		3.1		26.6		200,000
Miami, FL	MOB	9/30/20	5.0		(0.2)		4.8		2.6		0.1		2.1		26,000

Total dispositions			$	249.5	$	(0.2)	$	249.3	$	171.8	$	7.1	$	70.4	412,000

1.MOB = medical office building; SF = surgical facility

2.Includes straight-line rent receivables, leasing commissions and lease inducements.

Schedule of assets and liabilities held for sale

The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2020 and December 31, 2019:


(Dollars in thousands)	September 30, 2020		December 31, 2019
Balance Sheet data:
Land	$	1,664	$	—
Building, improvements and lease intangibles	26,871		—
Personal property	39		—
	28,574		—
Accumulated depreciation	(10,443)		—
Real estate assets held for sale, net	18,131		—
Other assets, net	1,920		37
Assets held for sale, net	$	20,051	$	37

Accounts payable and accrued liabilities	$	437	$	37
Other liabilities	111		108
Liabilities of assets held for sale	$	548	$	145

XML 30 R20.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Components of Sales-type Leases

The table below presents the components of sale-type leases for the three and nine months ended September 30, 2020:


	SALES-TYPE LEASES
In thousands	three months ended September 30, 2020		nine months ended September 30, 2020
Profit recognized at commencement date	$	—	$	68,267	Gain on sales of real estate assets
Interest income	1,454		3,007		Rental income

Future Minimum Operating Lease Payments Receivable

Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2020 were as follows:


In thousands	Operating
2020	$	93,722
2021	352,341
2022	307,166
2023	261,187
2024	200,578
2025 and thereafter	555,264
	$	1,770,258

Future Minimum Operating Lease Payments

The Company’s future lease payments (primarily for its 61 non-prepaid ground leases) as of September 30, 2020 were as follows:


In thousands	OPERATING		FINANCING
2020	$	1,008	$	143
2021	4,844		930
2022	4,875		783
2023	4,913		793
2024	4,969		815
2025 and thereafter	307,665		88,808
Total undiscounted lease payments	328,274		92,272
Discount	(236,808)		(73,575)
Lease liabilities	$	91,466	$	18,697

Future Minimum Financing Lease Payments

The Company’s future lease payments (primarily for its 61 non-prepaid ground leases) as of September 30, 2020 were as follows:


In thousands	OPERATING		FINANCING
2020	$	1,008	$	143
2021	4,844		930
2022	4,875		783
2023	4,913		793
2024	4,969		815
2025 and thereafter	307,665		88,808
Total undiscounted lease payments	328,274		92,272
Discount	(236,808)		(73,575)
Lease liabilities	$	91,466	$	18,697

Lease Cost

The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2020 and 2019:


	THREE MONTHS ENDED September 30,						NINE MONTHS ENDED September 30,
In thousands	2020			2019			2020		2019
Operating lease cost
Operating lease expense	$	1,180		$	1,169		$	3,534	$	3,448
Variable lease expense	1,066			845			2,664		2,380

Finance lease cost
Amortization of right-of-use assets	88			51			236		101
Interest on lease liabilities	245			196			722		392
Total lease expense	$	2,579		$	2,261		$	7,156	$	6,321

Other information
Operating cash flows outflows related to operating leases	$	1,440		$	1,313		$	5,412	$	5,461
Financing cash flows outflows related to financing leases	$	143		$	107		$	3,310	$	249
Right-of-use assets obtained in exchange for new finance lease liabilities	$	—		$	—		$	7,212	$	14,294

Weighted-average remaining lease term (excluding renewal options) - operating leases	48.9			49.7
Weighted-average remaining lease term (excluding renewal options) -finance leases	64.7			70.1
Weighted-average discount rate - operating leases	5.7		%	5.7		%
Weighted-average discount rate - finance leases	5.4		%	5.5		%

XML 31 R21.htm IDEA: XBRL DOCUMENT

Notes and Bonds Payable (Tables)

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Schedule of debt

The table below details the Company’s notes and bonds payable.


	MATURITY DATES	BALANCE AS OF				EFFECTIVE INTEREST RATE as of 9/30/2020
Dollars in thousands		9/30/2020		12/31/2019
$700 million Unsecured Credit Facility	5/23	$	—	$	293,000	N/A
$200 million Unsecured Term Loan Facility, net of issuance costs 1	5/24	199,180		199,013		1.99	%
$150 million Unsecured Term Loan due 2026 2	6/26	149,455		—		3.14	%
Senior Notes due 2023, net of discount and issuance costs	4/23	248,863		248,540		3.95	%
Senior Notes due 2025, net of discount and issuance costs 3	5/25	248,711		248,522		4.08	%
Senior Notes due 2028, net of discount and issuance costs	1/28	296,003		295,651		3.84	%
Senior Notes due 2030, net of discount and issuance costs 4	3/30	296,384		—		2.71	%
Mortgage notes payable, net of discounts and issuance costs and including premiums	1/21-4/27	115,799		129,343		4.38	%
		$	1,554,395	$	1,414,069

1The effective interest rate includes the impact of interest rate swaps on $75.0 million at a weighted average rate of 2.37% (plus the applicable margin rate, currently 100 basis points).

2The effective interest rate includes the impact of interest rate swaps on $100.0 million at a weighted average rate of 2.23% (plus the applicable margin rate, currently 160 basis points).

XML 32 R22.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of cash flow hedges included in accumulated other comprehensive income (loss)

As of September 30, 2020, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:


DERIVATIVE INSTRUMENT	NUMBER OF INSTRUMENTS	NOTIONAL AMOUNT in millions
Interest rate swaps	8	$175.0

The table below presents the effect of cash flow hedge accounting on AOCI during the three and nine months ended September 30, 2020 and 2019 related to the Company's outstanding interest rate swaps.


	LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended September 30,					(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended September 30,
In thousands	2020		2019			2020		2019
Interest rate swaps	$	74	$	2,341	Interest expense	$	952	$	18
Settled treasury hedges	—		—		Interest expense	107		—
Settled interest rate swaps	—		—		Interest expense	42		42
	$	74	$	2,341	Total interest expense	$	1,101	$	60


	LOSS RECOGNIZED IN AOCI ON DERIVATIVE nine months ended September 30,					(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME nine months ended September 30,
In thousands	2020		2019			2020		2019
Interest rate swaps	$	11,192	$	7,642	Interest expense	$	2,012	$	(52)
Settled treasury hedges	4,267		—		Interest expense	229		—
Settled interest rate swaps	—		—		Interest expense	126		126
	$	15,459	$	7,642	Total interest expense	$	2,367	$	74

Schedule of derivative instruments in statement of financial position, fair value

The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2020.


	BALANCE AT SEPTEMBER 30, 2020
In thousands	BALANCE SHEET LOCATION	FAIR VALUE
Derivatives designated as hedging instruments
Interest rate swaps	Other liabilities	$	14,460
Total derivatives designated as hedging instruments		$	14,460

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Reconciliation of beginning and ending common stock outstanding

The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2020 and the year ended December 31, 2019:


	SEPTEMBER 30, 2020	DECEMBER 31, 2019
Balance, beginning of period	134,706,154	125,279,455
Issuance of common stock	1,292,324	9,251,440
Nonvested share-based awards, net of withheld shares	55,462	175,259
Balance, end of period	136,053,940	134,706,154

Earnings (loss) per share

The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2020 and 2019.


	THREE MONTHS ENDED SEPTEMBER 30,				NINE MONTHS ENDED SEPTEMBER 30,
Dollars in thousands, except per share data	2020		2019		2020		2019
Weighted average common shares outstanding
Weighted average common shares outstanding	136,048,781		129,865,985		135,393,798		128,348,638
Non-vested shares	(1,739,364)		(1,775,911)		(1,731,658)		(1,777,743)
Weighted average common shares outstanding - basic	134,309,417		128,090,074		133,662,140		126,570,895

Weighted average common shares outstanding - basic	134,309,417		128,090,074		133,662,140		126,570,895
Dilutive effect of forward equity shares	—		—		—		—
Dilutive effect of employee stock purchase plan	47,810		78,610		74,029		85,690
Weighted average common shares outstanding - diluted	134,357,227		128,168,684		133,736,169		126,656,585

Net Income	$	8,230	$	2,601	$	88,058	$	11,975
Dividends paid on nonvested share-based awards	(522)		(534)		(1,561)		(1,603)
Net income applicable to common stockholders	$	7,708	$	2,067	$	86,497	$	10,372





Basic earnings per common share - net income	$	0.06	$	0.02	$	0.65	$	0.08


Diluted earnings per common share - net income	$	0.06	$	0.02	$	0.65	$	0.08

Summary of the activity under the incentive plan

A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2020 and 2019 is included in the table below.


	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,
	2020	2019	2020	2019
Share-based awards, beginning of period	1,739,258	1,778,134	1,754,066	1,769,863
Granted	188	—	79,025	89,767
Vested 1	—	(204,548)	(93,645)	(286,044)

Share-based awards, end of period	1,739,446	1,573,586	1,739,446	1,573,586

1The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of 204,548 outstanding nonvested share-based awards.

Summary of employee stock purchase plan activity

A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2020 and 2019 is included in the table below.


	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,
	2020	2019	2020	2019
Outstanding and exercisable, beginning of period	361,719	363,218	332,659	328,533
Granted	—	—	212,716	235,572
Exercised	(3,504)	(9,927)	(17,871)	(28,943)
Forfeited	(6,659)	(11,762)	(36,154)	(51,559)
Expired	—	—	(139,794)	(142,074)
Outstanding and exercisable, end of period	351,556	341,529	351,556	341,529

XML 34 R24.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable

The table below details the fair values and carrying values for notes and bonds payable at September 30, 2020 and December 31, 2019.


	September 30, 2020				December 31, 2019
Dollars in millions	CARRYING VALUE		FAIR VALUE		CARRYING VALUE		FAIR VALUE
Notes and bonds payable 1	$	1,554.4	$	1,621.7	$	1,414.1	$	1,425.8

1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.

XML 35 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) $ in Thousands, ft² in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2020 USD ($) ft² property state	Jun. 30, 2020 USD ($)	Sep. 30, 2020 USD ($) ft² property state
Business Overview:
Gross investment amount, total	$ 4,300,000		$ 4,300,000
Number of real estate properties \| property	211		211
Number of states that the company owns real estate in, whole units \| state	24		24
Square footage of owned real estate properties \| ft²	15.5		15.5
Approximate square feet for which Nationwide property management services provided by company \| ft²	11.9		11.9
Deferred rent arrangements for the quarter	$ 100
Aggregate second quarter 2020 tenant billings collected (percent)			99.00%
Scheduled deferral payments collected in the third quarter (percent)	96.00%
Deferred rent receivable, net	$ 1,200		$ 1,200
Second and third quarter 2020 tenant billings deferred under rent deferral agreements (percent)			1.00%
Deferred rent reserve recognized in the period	300	$ 700
Deferred rent, general reserve	400		$ 400
Deferred rent receivable, gross	$ 1,700		$ 1,700

XML 36 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Type of Revenue	$ 1,868	$ 2,059	$ 5,364	$ 5,987
Parking income
Disaggregation of Revenue [Line Items]
Type of Revenue	1,764	1,935	5,042	5,538
Rental lease guaranty
Disaggregation of Revenue [Line Items]
Type of Revenue	0	0	0	128
Management fee income
Disaggregation of Revenue [Line Items]
Type of Revenue	62	69	209	201
Miscellaneous
Disaggregation of Revenue [Line Items]
Type of Revenue	$ 42	$ 55	$ 113	$ 120

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 37 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 121,992	$ 657
Restricted cash	60,644	0
Total cash, cash equivalents and restricted cash	$ 182,636	$ 657	$ 11,809	$ 8,381

XML 38 R28.htm IDEA: XBRL DOCUMENT

Real Estate Investments - Acquisitions (Details) $ in Thousands													9 Months Ended
	Oct. 07, 2020 USD ($) ft²	Sep. 28, 2020 USD ($) ft²	Sep. 24, 2020 USD ($) ft²	Jul. 31, 2020 USD ($) ft²	Jul. 23, 2020 USD ($) ft²	Jul. 17, 2020 USD ($) ft²	Jul. 01, 2020 USD ($) ft²	Mar. 13, 2020 USD ($) ft²	Mar. 09, 2020 USD ($) ft² property	Feb. 25, 2020 USD ($) ft²	Feb. 13, 2020 USD ($) ft²	Jan. 03, 2020 USD ($) ft²	Sep. 30, 2020 USD ($) ft² land_parcel
Business Acquisition [Line Items]
Number of land parcels acquired \| land_parcel													4
Total real estate acquisitions
Business Acquisition [Line Items]
Purchase price													$ 210,200
Mortgage notes payable													(19,300)
Cash consideration													194,400
Real estate													215,700
Other													$ (2,000)
Square footage \| ft²													568,587
Land Acquisition
Business Acquisition [Line Items]
Purchase price													$ 1,600
Mortgage notes payable													0
Cash consideration													1,700
Real estate													1,700
Other													$ 0
Square footage \| ft²													0
Land Acquisition, Subsequently Disposed
Business Acquisition [Line Items]
Purchase price													$ 1,000
Mortgage notes payable													0
Cash consideration													1,100
Real estate													1,100
Other													$ 0
Square footage \| ft²													0
Real Estate and Land Acquisitions
Business Acquisition [Line Items]
Purchase price													$ 212,800
Mortgage notes payable													(19,300)
Cash consideration													197,200
Real estate													218,500
Other													$ (2,000)
Square footage \| ft²													568,587
Medical office building \| Los Angeles, CA \| Total real estate acquisitions
Business Acquisition [Line Items]
Purchase price		$ 14,000				$ 35,000						$ 42,000
Mortgage notes payable		0				0						(19,300)
Cash consideration		14,000				37,700						22,800
Real estate		13,900				37,700						42,400
Other		$ 100				$ 0						$ (300)
Square footage \| ft²		24,252				49,785						86,986
Medical office building \| Atlanta, GA \| Total real estate acquisitions
Business Acquisition [Line Items]
Purchase price				$ 20,500							$ 12,000
Mortgage notes payable				0							0
Cash consideration				21,600							11,800
Real estate				21,300							12,100
Other				$ 300							$ (300)
Square footage \| ft²				48,145							64,624
Medical office building \| Raleigh, NC \| Total real estate acquisitions
Business Acquisition [Line Items]
Purchase price										$ 6,300
Mortgage notes payable										0
Cash consideration										6,500
Real estate										6,500
Other										$ 0
Square footage \| ft²										15,964
Medical office building \| Colorado Springs, CO \| Total real estate acquisitions
Business Acquisition [Line Items]
Purchase price									$ 8,200
Mortgage notes payable									0
Cash consideration									8,300
Real estate									8,600
Other									$ (300)
Square footage \| ft²									34,210
Medical office building \| Denver, CO \| Total real estate acquisitions
Business Acquisition [Line Items]
Number of properties acquired \| property									3
Purchase price								$ 33,500
Mortgage notes payable								0
Cash consideration								33,200
Real estate								34,000
Other								$ (800)
Square footage \| ft²								136,994
Medical office building \| San Diego, CA \| Total real estate acquisitions
Business Acquisition [Line Items]
Purchase price							$ 16,700
Mortgage notes payable							0
Cash consideration							16,700
Real estate							16,900
Other							$ (200)
Square footage \| ft²							46,083
Medical office building \| Seattle, WA \| Total real estate acquisitions
Business Acquisition [Line Items]
Purchase price					$ 11,000
Mortgage notes payable					0
Cash consideration					10,900
Real estate					11,300
Other					$ (400)
Square footage \| ft²					21,309
Medical office building \| Houston, TX \| Total real estate acquisitions
Business Acquisition [Line Items]
Purchase price			$ 11,000
Mortgage notes payable			0
Cash consideration			10,900
Real estate			11,000
Other			$ (100)
Square footage \| ft²			40,235
Subsequent event \| Medical office building \| Colorado Springs, CO
Business Acquisition [Line Items]
Purchase price	$ 8,900
Square footage \| ft²	36,720

XML 39 R29.htm IDEA: XBRL DOCUMENT

Real Estate Investments - Dispositions (Details) ft² in Thousands, $ in Thousands			3 Months Ended
	Sep. 30, 2020 USD ($) ft²	Jul. 30, 2020 USD ($) ft²	Jun. 30, 2020 numberOfAgreements	May 31, 2020 USD ($)
Real Estate Dispositions [Line Items]
Sales price				$ 244,500
Real Estate Dispositions
Real Estate Dispositions [Line Items]
Sales price	$ 249,500
Closing adjustments	(200)
Net proceeds	249,300
Net Real Estate Investment	171,800
Real estate other	7,100
Gain/(impairment)	$ 70,400
Square footage \| ft²	412
Real Estate Dispositions \| Springfield, MO
Real Estate Dispositions [Line Items]
Sales price		$ 138,000
Closing adjustments		0
Net proceeds		138,000
Net Real Estate Investment		92,400
Real estate other		3,900
Gain/(impairment)		$ 41,700
Square footage \| ft²		186
Real Estate Dispositions \| Oklahoma City, OK
Real Estate Dispositions [Line Items]
Sales price		$ 106,500
Closing adjustments		0
Net proceeds		106,500
Net Real Estate Investment		76,800
Real estate other		3,100
Gain/(impairment)		$ 26,600
Square footage \| ft²		200
Number of agreements to sell leased properties \| numberOfAgreements			2
Real Estate Dispositions \| Miami, FL
Real Estate Dispositions [Line Items]
Sales price	$ 5,000
Closing adjustments	(200)
Net proceeds	4,800
Net Real Estate Investment	2,600
Real estate other	100
Gain/(impairment)	$ 2,100
Square footage \| ft²	26

XML 40 R30.htm IDEA: XBRL DOCUMENT

Real Estate Investments - Assets Held for Sale (Details) $ in Thousands	1 Months Ended
	Sep. 30, 2020 USD ($) property	Dec. 31, 2019 USD ($) property
Long Lived Assets Held-for-sale [Line Items]
Number of properties reclassified to held for sale \| property	4
Expected purchase price	$ 23,000
Net investment in property held for sale	$ 18,100
Number of properties held for sale \| property	4	0
Balance Sheet Related Disclosures [Abstract]
Land	$ 330,840	$ 289,751
Building, improvements and lease intangibles	4,014,740	3,986,326
Personal property	10,962	10,538
Total real estate properties	4,381,189	4,359,993
Accumulated depreciation	(1,198,444)	(1,121,102)
Total real estate properties, net	3,182,745	3,238,891
Assets held for sale, net	20,051	37
Liabilities of assets held for sale	548	145
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Balance Sheet Related Disclosures [Abstract]
Land	1,664	0
Building, improvements and lease intangibles	26,871	0
Personal property	39	0
Total real estate properties	28,574	0
Accumulated depreciation	(10,443)	0
Total real estate properties, net	18,131	0
Other assets, net	1,920	37
Assets held for sale, net	20,051	37
Accounts payable and accrued liabilities	437	37
Other liabilities	111	108
Liabilities of assets held for sale	$ 548	$ 145

XML 41 R31.htm IDEA: XBRL DOCUMENT

Leases - Lease Income (Details) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
Leases - Lease Income (Details) $ in Thousands	May 31, 2020 USD ($) property	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)
Leases [Abstract]
Rental income		$ 123,384		$ 117,740	$ 368,385	$ 342,787
Number of properties sold \| property	2
Sales price	$ 244,500
Gains on sales of investment real estate			$ 68,300		70,395	$ 5,065
Profit recognized at commencement date		0			68,267
Interest income		$ 1,454			$ 3,007

XML 42 R32.htm IDEA: XBRL DOCUMENT

Leases - Lessor Accounting (Details) $ in Thousands	Sep. 30, 2020 USD ($)
Future Operating Lease Payments Receivable [Abstract]
2020	$ 93,722
2021	352,341
2022	307,166
2023	261,187
2024	200,578
2025 and thereafter	555,264
Total	$ 1,770,258

XML 43 R33.htm IDEA: XBRL DOCUMENT

Leases - Ground Leases (Details) ft² in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020 USD ($) Lease property	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) ft² Lease property	Sep. 30, 2019 USD ($)
Lessee, Lease, Description [Line Items]
Number of properties subject to ground leases \| property	103		103
Square feet subject to ground leases \| ft²			8.7
Number of prepaid ground leases			42
Amortization of prepaid rent \| $	$ 0.2	$ 0.2	$ 0.5	$ 0.4
Number of non-prepaid ground leases	61		61
Minimum
Lessee, Lease, Description [Line Items]
Ground lease, initial term	40 years		40 years
Maximum
Lessee, Lease, Description [Line Items]
Ground lease, initial term	99 years		99 years

XML 44 R34.htm IDEA: XBRL DOCUMENT

Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
OPERATING
2020	$ 1,008
2021	4,844
2022	4,875
2023	4,913
2024	4,969
2025 and thereafter	307,665
Total undiscounted lease payments	328,274
Discount	(236,808)
Lease liabilities	91,466	$ 91,574
FINANCING
2020	143
2021	930
2022	783
2023	793
2024	815
2025 and thereafter	88,808
Total undiscounted lease payments	92,272
Discount	(73,575)
Lease liabilities	$ 18,697	$ 18,037

XML 45 R35.htm IDEA: XBRL DOCUMENT

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Leases - Lease Cost (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating lease cost
Operating lease expense	$ 1,180	$ 1,169	$ 3,534	$ 3,448
Variable lease expense	1,066	845	2,664	2,380
Finance lease cost
Amortization of right-of-use assets	88	51	236	101
Interest on lease liabilities	245	196	722	392
Total lease expense	2,579	2,261	7,156	6,321
Other information
Operating cash flows outflows related to operating leases	1,440	1,313	5,412	5,461
Financing cash flows outflows related to financing leases	143	107	3,310	249
Right-of-use assets obtained in exchange for new finance lease liabilities	$ 0	$ 0	$ 7,212	$ 14,294
Weighted-average remaining lease term (excluding renewal options) - operating leases	48 years 10 months 24 days	49 years 8 months 12 days	48 years 10 months 24 days	49 years 8 months 12 days
Weighted-average remaining lease term (excluding renewal options) -finance leases	64 years 8 months 12 days	70 years 1 month 6 days	64 years 8 months 12 days	70 years 1 month 6 days
Weighted-average discount rate - operating leases	5.70%	5.70%	5.70%	5.70%
Weighted-average discount rate - finance leases	5.40%	5.50%	5.40%	5.50%

XML 46 R36.htm IDEA: XBRL DOCUMENT

Notes and Bonds Payable (Details)									3 Months Ended		9 Months Ended
Notes and Bonds Payable (Details)	Oct. 19, 2020 USD ($)	Oct. 01, 2020 USD ($) ft²	Jun. 25, 2020 USD ($) ft² bond	Jun. 02, 2020 USD ($) ft²	May 29, 2020 USD ($)	May 04, 2020 USD ($) ft²	Mar. 04, 2020 USD ($) derivative	Feb. 03, 2020 USD ($) ft²	Sep. 30, 2020 USD ($) ft²	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) ft²	Sep. 30, 2019 USD ($)	Oct. 02, 2020 USD ($)	Feb. 25, 2020 USD ($)	Feb. 24, 2020 USD ($)	Dec. 31, 2019 USD ($)
Debt Instrument [Line Items]
Notes and bonds payable									$ 1,554,395,000		$ 1,554,395,000					$ 1,414,069,000
Impact of settlement of forward-starting interest rate swap									$ 74,000	$ 2,341,000	$ 15,459,000	$ 7,642,000
Area of real estate property \| ft²									15,500,000		15,500,000
Borrowings on term loan											$ 150,000,000	50,000,000
Line of credit \| $700 million Unsecured Credit Facility
Debt Instrument [Line Items]
Notes and bonds payable									$ 0		0					293,000,000
Credit facility									700,000,000		700,000,000
Medium-term notes \| $200 million unsecured term loan facility, net of issuance costs
Debt Instrument [Line Items]
Notes and bonds payable									$ 199,180,000		$ 199,180,000					199,013,000
Effective interest rate									1.99%		1.99%
Term-loan facility									$ 200,000,000		$ 200,000,000
Medium-term notes \| $150 million unsecured term loan due 2026
Debt Instrument [Line Items]
Notes and bonds payable									$ 149,455,000		$ 149,455,000					0
Effective interest rate									3.14%		3.14%
Borrowings on term loan					$ 150,000,000.0
Term-loan facility									$ 150,000,000		$ 150,000,000
Senior notes \| Senior Notes due 2023, net of discount and issuance costs
Debt Instrument [Line Items]
Notes and bonds payable									$ 248,863,000		$ 248,863,000					248,540,000
Effective interest rate									3.95%		3.95%
Senior notes \| Senior Notes due 2023, net of discount and issuance costs \| Subsequent event
Debt Instrument [Line Items]
Outstanding principal repaid	$ 250,000,000.0
Payments to redeem unsecured senior notes	270,500,000
Debt redeemed, accrued interest	100,000
Debt redeemed, make whole amount	20,400,000
Write off of Deferred Debt Issuance Cost	1,100,000
Loss on early extinguishment of debt	$ 21,500,000
Senior notes \| Senior notes due 2025, net of discount and issuance costs
Debt Instrument [Line Items]
Notes and bonds payable									$ 248,711,000		$ 248,711,000					248,522,000
Effective interest rate									4.08%		4.08%
Senior notes \| Senior Notes due 2028, net of discount and issuance costs
Debt Instrument [Line Items]
Notes and bonds payable									$ 296,003,000		$ 296,003,000					295,651,000
Effective interest rate									3.84%		3.84%
Senior notes \| Senior notes due 2030, net of discount and issuance costs
Debt Instrument [Line Items]
Notes and bonds payable									$ 296,384,000		$ 296,384,000					0
Effective interest rate							2.71%		2.71%		2.71%
Fixed interest rate (percent)							2.40%
Term-loan facility							$ 300,000,000.0
Debt discount							1,000,000.0
Debt issuance costs							$ 2,800,000
Number of derivative instruments settled \| derivative							2
Senior notes \| Senior notes due 2031 \| Subsequent event
Debt Instrument [Line Items]
Effective interest rate													2.24%
Fixed interest rate (percent)													2.05%
Term-loan facility													$ 300,000,000.0
Debt discount													2,400,000
Debt issuance costs													$ 2,800,000
Mortgages \| Mortgage notes payable, net of discounts and issuance costs and including premiums
Debt Instrument [Line Items]
Notes and bonds payable									$ 115,799,000		$ 115,799,000					$ 129,343,000
Effective interest rate									4.38%		4.38%
Settled interest rate swaps
Debt Instrument [Line Items]
Impact of settlement of forward-starting interest rate swap									$ (74,000)	(2,341,000)	$ (11,192,000)	(7,642,000)
Settled interest rate swaps \| Medium-term notes \| $200 million unsecured term loan facility, net of issuance costs
Debt Instrument [Line Items]
Notional amount									$ 75,000,000.0		$ 75,000,000.0
Weighted average interest rate (percent)									2.37%		2.37%
Basis spread on variable rate											100.00%
Settled interest rate swaps \| Medium-term notes \| $150 million unsecured term loan due 2026
Debt Instrument [Line Items]
Notional amount									$ 100,000,000.0		$ 100,000,000.0
Weighted average interest rate (percent)									2.23%		2.23%
Basis spread on variable rate											160.00%
Settled interest rate swaps \| Senior notes \| Senior notes due 2025, net of discount and issuance costs
Debt Instrument [Line Items]
Impact of settlement of forward-starting interest rate swap											$ 1,700,000
Treasury lock
Debt Instrument [Line Items]
Notional amount														$ 40,000,000.0	$ 75,000,000.0
Impact of settlement of forward-starting interest rate swap							$ 4,300,000		$ 0	$ 0	(4,267,000)	$ 0
Treasury lock \| Senior notes \| Senior notes due 2025, net of discount and issuance costs
Debt Instrument [Line Items]
Impact of settlement of forward-starting interest rate swap							$ 4,300,000				$ 4,300,000
Mortgages
Debt Instrument [Line Items]
Fixed interest rate (percent)				6.44%		5.74%		6.10%
Outstanding principal repaid				$ 12,600,000		$ 300,000		$ 5,900,000
Area of real estate property \| ft²				67,510		83,318		68,860
Mortgages \| Subsequent event
Debt Instrument [Line Items]
Fixed interest rate (percent)		5.47%
Outstanding principal repaid		$ 4,200,000
Area of real estate property \| ft²		40,171
Bonds
Debt Instrument [Line Items]
Area of real estate property \| ft²			60,476
Number of bonds repaid \| bond			3
Bonds \| 5.63% Bonds
Debt Instrument [Line Items]
Fixed interest rate (percent)			5.63%
Outstanding principal repaid			$ 500,000
Bonds \| 6.63% Bonds
Debt Instrument [Line Items]
Fixed interest rate (percent)			6.63%
Outstanding principal repaid			$ 2,800,000
Bonds \| 6.88% Bonds
Debt Instrument [Line Items]
Fixed interest rate (percent)			6.88%
Outstanding principal repaid			$ 7,000,000.0

XML 47 R37.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) $ in Thousands		3 Months Ended		9 Months Ended
	Mar. 04, 2020 USD ($)	Sep. 30, 2020 USD ($) swap_agreement	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) swap_agreement	Sep. 30, 2019 USD ($)	Feb. 25, 2020 USD ($) treasury_lock	Feb. 24, 2020 USD ($)
Derivative [Line Items]
Impact of settlement of forward-starting interest rate swap		$ 74	$ 2,341	$ 15,459	$ 7,642
Derivatives in net liability position		15,100		15,100
Treasury lock
Derivative [Line Items]
Number of instruments \| treasury_lock						2
Notional amount						$ 40,000	$ 75,000
Impact of settlement of forward-starting interest rate swap	$ 4,300	0	0	(4,267)	0
Term of senior notes	10 years
Settled interest rate swaps
Derivative [Line Items]
Impact of settlement of forward-starting interest rate swap		(74)	$ (2,341)	(11,192)	$ (7,642)
Active Interest Rate Swap
Derivative [Line Items]
Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months		$ 4,400		$ 4,400
Cash flow hedging \| Designated as hedging instrument \| Settled interest rate swaps
Derivative [Line Items]
Number of instruments \| swap_agreement		8		8
Notional amount		$ 175,000		$ 175,000

XML 48 R38.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) - Designated as hedging instrument - Settled interest rate swaps $ in Thousands	Sep. 30, 2020 USD ($)
Derivative [Line Items]
Liability derivatives	$ 14,460
Other liabilities
Derivative [Line Items]
Liability derivatives	$ 14,460

XML 49 R39.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative [Line Items]
Loss recognized in AOCI on derivative	$ 74	$ 2,341	$ 15,459	$ 7,642
(Gain) loss reclassified from AOCI into income	(1,101)	(60)	(2,367)	(74)
Interest rate swaps
Derivative [Line Items]
Loss recognized in AOCI on derivative	74	2,341	11,192	7,642
Settled treasury hedges
Derivative [Line Items]
Loss recognized in AOCI on derivative	0	0	4,267	0
Settled interest rate swaps
Derivative [Line Items]
Loss recognized in AOCI on derivative	0	0	0	0
Total interest expense
Derivative [Line Items]
(Gain) loss reclassified from AOCI into income	1,101	60	2,367	74
Total interest expense \| Interest rate swaps
Derivative [Line Items]
(Gain) loss reclassified from AOCI into income	952	18	2,012	(52)
Total interest expense \| Settled treasury hedges
Derivative [Line Items]
(Gain) loss reclassified from AOCI into income	107	0	229	0
Total interest expense \| Settled interest rate swaps
Derivative [Line Items]
(Gain) loss reclassified from AOCI into income	$ 42	$ 42	$ 126	$ 126

XML 50 R40.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Construction Activity (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($) ft²	Mar. 31, 2020 ft²
Other Commitments [Line Items]
Approximate square feet \| ft²	15,500,000
Medical office building expansion \| Memphis, Tennessee
Other Commitments [Line Items]
Approximate square feet \| ft²	110,883
Construction activity, total funding during the period, excluding purchase of land and building	$ 5,700
Medical office building \| Washington
Other Commitments [Line Items]
Approximate square feet \| ft²		151,031
Total amount funded	59,100
Estimated amount to complete project	5,000
Land and building \| Medical office building \| Memphis, Tennessee
Other Commitments [Line Items]
Construction activity, total funding during the period	$ 8,700

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Reconciliation of the beginning and ending common stock outstanding
Balance, beginning of period	134,706,000
Balance, end of period	136,054,000	134,706,000
Common Stock
Reconciliation of the beginning and ending common stock outstanding
Balance, beginning of period	134,706,154	125,279,455
Issuance of common stock	1,292,324	9,251,440
Nonvested share-based awards, net of withheld shares	55,462	175,259
Balance, end of period	136,053,940	134,706,154

XML 52 R42.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Stock Transactions - Narrative) (Details)		1 Months Ended	3 Months Ended				9 Months Ended
	Nov. 03, 2020 $ / shares	Nov. 04, 2020 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares shares	Mar. 31, 2020 USD ($) $ / shares shares	Sep. 30, 2019 $ / shares shares	Sep. 30, 2020 USD ($) numberOfForwardEquityAgreements $ / shares shares	Sep. 30, 2019 USD ($) $ / shares shares	Feb. 14, 2020 USD ($) investment_bank
Class of Stock [Line Items]
At-the-market equity offering program, authorized amount \| $									$ 500,000,000.0
Net proceeds from issuance of common stock \| $							$ 40,296,000	$ 192,514,000
Proceeds from issuance of common stock, adjusted for costs to borrow \| $			$ 72,700,000				$ 72,700,000
Dividends declared per common share, during the period (in dollars per share)			$ 0.30			$ 0.30	$ 0.90	$ 0.90
Dilutive effect of forward equity shares (in shares) \| shares			0			0	0	0
Weighted-average incremental shares of common stock excluded from the computation (shares) \| shares			137,757				51,133
At the market equity offering program
Class of Stock [Line Items]
Number of investment banks included in the program \| investment_bank									6
Issuance of common stock (in shares) \| shares				1,071,987	196,250		1,268,237
Net proceeds from issuance of common stock \| $				$ 32,900,000	$ 7,000,000.0		$ 39,900,000
Number of forward equity agreements \| numberOfForwardEquityAgreements							3
Forward equity agreement (in shares) \| shares							3,600,000
Stock price, per share to be subsequently sold (in USD per share)			$ 31.30				$ 31.30
Dilutive effect of forward equity shares (in shares) \| shares			2,300,000				2,300,000
Forward Equity Agreement Maturing June 2021
Class of Stock [Line Items]
Forward equity agreement (in shares) \| shares				1,579,371
Stock price, per share to be subsequently sold (in USD per share)				$ 31.66
Forward Equity Agreement Maturing July 2021
Class of Stock [Line Items]
Forward equity agreement (in shares) \| shares			764,472
Stock price, per share to be subsequently sold (in USD per share)			$ 31.84				$ 31.84
Subsequent event
Class of Stock [Line Items]
At-the-market equity offering program, remaining authorized amount, assuming forward equity contracts settle \| $		$ 347,600,000
Dividends declared per common share, during the period (in dollars per share)	$ 0.30
Subsequent event \| Forward Equity Agreement Maturing July 2021
Class of Stock [Line Items]
Forward equity agreement (in shares) \| shares		1,235,129
Stock price, per share to be subsequently sold (in USD per share)		$ 30.52
Minimum \| At the market equity offering program
Class of Stock [Line Items]
Shares issued during period, price per share (in dollars per share)				30.50	$ 33.00		30.50
Maximum \| At the market equity offering program
Class of Stock [Line Items]
Shares issued during period, price per share (in dollars per share)				31.29	36.15		36.15
Weighted Average \| At the market equity offering program
Class of Stock [Line Items]
Shares issued during period, price per share (in dollars per share)				$ 31.08	$ 36.09		$ 31.86

XML 53 R43.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Weighted average Common Shares outstanding
Weighted average common shares outstanding (in shares)	136,048,781	129,865,985	135,393,798	128,348,638
Non-vested shares	(1,739,364)	(1,775,911)	(1,731,658)	(1,777,743)
Weighted average common shares outstanding - basic (in shares)	134,309,417	128,090,074	133,662,140	126,570,895
Dilutive effect of forward equity shares (in shares)	0	0	0	0
Dilutive effect of employee stock purchase plan (in shares)	47,810	78,610	74,029	85,690
Weighted average common shares outstanding - diluted (in shares)	134,357,227	128,168,684	133,736,169	126,656,585
Net Income	$ 8,230	$ 2,601	$ 88,058	$ 11,975
Dividends paid on nonvested share-based awards	(522)	(534)	(1,561)	(1,603)
Net income applicable to common stockholders	$ 7,708	$ 2,067	$ 86,497	$ 10,372
Basic earnings per common share (in dollars per share)	$ 0.06	$ 0.02	$ 0.65	$ 0.08
Diluted earnings per common share (in dollars per share)	$ 0.06	$ 0.02	$ 0.65	$ 0.08

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) - Stock incentive plan - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Summary of the activity under the incentive plans
Share-based awards, beginning of period	1,739,258	1,778,134	1,754,066	1,769,863
Granted (shares)	188	0	79,025	89,767
Vested (shares)	0	204,548	93,645	286,044
Share-based awards, end of period	1,739,446	1,573,586	1,739,446	1,573,586
Executive Chairman
Summary of the activity under the incentive plans
Vested (shares)	204,548
Restricted stock
Summary of the activity under the incentive plans
Shares withheld to pay estimated withholding taxes			23,563	100,036

XML 55 R45.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) - Employee stock purchase plan - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Summary of the Employee Stock Purchase Plan activity
Outstanding and exercisable, beginning of period (in shares)	361,719	363,218	332,659	328,533
Granted (in shares)	0	0	212,716	235,572
Exercised (in shares)	(3,504)	(9,927)	(17,871)	(28,943)
Forfeited (in shares)	(6,659)	(11,762)	(36,154)	(51,559)
Expired (in shares)	0	0	(139,794)	(142,074)
Outstanding and exercisable, end of period (in shares)	351,556	341,529	351,556	341,529

XML 56 R46.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
CARRYING VALUE
Derivative [Line Items]
Notes and bonds payable	$ 1,554.4	$ 1,414.1
FAIR VALUE
Derivative [Line Items]
Notes and bonds payable	$ 1,621.7	$ 1,425.8

EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 262 366 1 false 69 0 false 16 false false R1.htm 0001001 - Document - Cover Page Sheet http://healthcarerealty.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Statement Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement Condensed Consolidated Statements of Equity (Unaudited) Statement Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedParenthetical Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 2101101 - Disclosure - Summary of Significant Accounting Policies Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2107102 - Disclosure - Real Estate Investments Sheet http://healthcarerealty.com/role/RealEstateInvestments Real Estate Investments Notes 10 false false R11.htm 2112103 - Disclosure - Leases Sheet http://healthcarerealty.com/role/Leases Leases Notes 11 false false R12.htm 2119104 - Disclosure - Notes and Bonds Payable Notes http://healthcarerealty.com/role/NotesandBondsPayable Notes and Bonds Payable Notes 12 false false R13.htm 2122105 - Disclosure - Derivative Financial Instruments Sheet http://healthcarerealty.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 13 false false R14.htm 2127106 - Disclosure - Commitments and Contingencies Sheet http://healthcarerealty.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 14 false false R15.htm 2129107 - Disclosure - Stockholders' Equity Sheet http://healthcarerealty.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 2136108 - Disclosure - Fair Value of Financial Instruments Sheet http://healthcarerealty.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 16 false false R17.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies 17 false false R18.htm 2303301 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies 18 false false R19.htm 2308302 - Disclosure - Real Estate Investments (Tables) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsTables Real Estate Investments (Tables) Tables http://healthcarerealty.com/role/RealEstateInvestments 19 false false R20.htm 2313303 - Disclosure - Leases (Tables) Sheet http://healthcarerealty.com/role/LeasesTables Leases (Tables) Tables http://healthcarerealty.com/role/Leases 20 false false R21.htm 2320304 - Disclosure - Notes and Bonds Payable (Tables) Notes http://healthcarerealty.com/role/NotesandBondsPayableTables Notes and Bonds Payable (Tables) Tables http://healthcarerealty.com/role/NotesandBondsPayable 21 false false R22.htm 2323305 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://healthcarerealty.com/role/DerivativeFinancialInstruments 22 false false R23.htm 2330306 - Disclosure - Stockholders' Equity (Tables) Sheet http://healthcarerealty.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://healthcarerealty.com/role/StockholdersEquity 23 false false R24.htm 2337307 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://healthcarerealty.com/role/FairValueofFinancialInstruments 24 false false R25.htm 2404401 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables 25 false false R26.htm 2405402 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 26 false false R27.htm 2406403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Details 27 false false R28.htm 2409404 - Disclosure - Real Estate Investments - Acquisitions (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails Real Estate Investments - Acquisitions (Details) Details 28 false false R29.htm 2410405 - Disclosure - Real Estate Investments - Dispositions (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails Real Estate Investments - Dispositions (Details) Details 29 false false R30.htm 2411406 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails Real Estate Investments - Assets Held for Sale (Details) Details 30 false false R31.htm 2414407 - Disclosure - Leases - Lease Income (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseIncomeDetails Leases - Lease Income (Details) Details 31 false false R32.htm 2415408 - Disclosure - Leases - Lessor Accounting (Details) Sheet http://healthcarerealty.com/role/LeasesLessorAccountingDetails Leases - Lessor Accounting (Details) Details 32 false false R33.htm 2416409 - Disclosure - Leases - Ground Leases (Details) Sheet http://healthcarerealty.com/role/LeasesGroundLeasesDetails Leases - Ground Leases (Details) Details 33 false false R34.htm 2417410 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 34 false false R35.htm 2418411 - Disclosure - Leases - Lease Cost (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 35 false false R36.htm 2421412 - Disclosure - Notes and Bonds Payable (Details) Notes http://healthcarerealty.com/role/NotesandBondsPayableDetails Notes and Bonds Payable (Details) Details http://healthcarerealty.com/role/NotesandBondsPayableTables 36 false false R37.htm 2424413 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Details 37 false false R38.htm 2425414 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Details 38 false false R39.htm 2426415 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Details 39 false false R40.htm 2428416 - Disclosure - Commitments and Contingencies - Construction Activity (Details) Sheet http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails Commitments and Contingencies - Construction Activity (Details) Details 40 false false R41.htm 2431417 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Details 41 false false R42.htm 2432418 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails Stockholders' Equity (Stock Transactions - Narrative) (Details) Details http://healthcarerealty.com/role/StockholdersEquityTables 42 false false R43.htm 2433419 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Details 43 false false R44.htm 2434420 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Details 44 false false R45.htm 2435421 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Details 45 false false R46.htm 2438422 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://healthcarerealty.com/role/FairValueofFinancialInstrumentsTables 46 false false All Reports Book All Reports hr-20200930.htm hr-20200930.xsd hr-20200930_cal.xml hr-20200930_def.xml hr-20200930_lab.xml hr-20200930_pre.xml hr-2020930xex311.htm hr-2020930xex312.htm hr-2020930xex32.htm http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hr-20200930.htm": { "axisCustom": 3, "axisStandard": 20, "contextCount": 262, "dts": { "calculationLink": { "local": [ "hr-20200930_cal.xml" ] }, "definitionLink": { "local": [ "hr-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "hr-20200930.htm" ] }, "labelLink": { "local": [ "hr-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "hr-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "hr-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 480, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 4, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 9 }, "keyCustom": 64, "keyStandard": 302, "memberCustom": 36, "memberStandard": 32, "nsprefix": "hr", "nsuri": "http://healthcarerealty.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://healthcarerealty.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107102 - Disclosure - Real Estate Investments", "role": "http://healthcarerealty.com/role/RealEstateInvestments", "shortName": "Real Estate Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112103 - Disclosure - Leases", "role": "http://healthcarerealty.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119104 - Disclosure - Notes and Bonds Payable", "role": "http://healthcarerealty.com/role/NotesandBondsPayable", "shortName": "Notes and Bonds Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122105 - Disclosure - Derivative Financial Instruments", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127106 - Disclosure - Commitments and Contingencies", "role": "http://healthcarerealty.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129107 - Disclosure - Stockholders' Equity", "role": "http://healthcarerealty.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136108 - Disclosure - Fair Value of Financial Instruments", "role": "http://healthcarerealty.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - Real Estate Investments (Tables)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsTables", "shortName": "Real Estate Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DevelopmentInProcess", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Leases (Tables)", "role": "http://healthcarerealty.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - Notes and Bonds Payable (Tables)", "role": "http://healthcarerealty.com/role/NotesandBondsPayableTables", "shortName": "Notes and Bonds Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323305 - Disclosure - Derivative Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables", "shortName": "Derivative Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330306 - Disclosure - Stockholders' Equity (Tables)", "role": "http://healthcarerealty.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337307 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-8", "first": true, "lang": "en-US", "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:UseOfEstimates", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "hr:DeferredRentArrangementsAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i6fb95ad4f166467993ed5e7e752be13c_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "hr:NumberofLandParcelsAcquired", "reportCount": 1, "unique": true, "unitRef": "land_parcel", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Real Estate Investments - Acquisitions (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "shortName": "Real Estate Investments - Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "hr:NumberofLandParcelsAcquired", "reportCount": 1, "unique": true, "unitRef": "land_parcel", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic1e9d521953148c187a0383f5c15475f_I20200531", "decimals": "-5", "first": true, "lang": "en-US", "name": "hr:DispositionSalesPrice", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Real Estate Investments - Dispositions (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails", "shortName": "Real Estate Investments - Dispositions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hr:AssetDispositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i763a4c8d0e6e4aa5b1208ec3da967a86_I20200930", "decimals": "-3", "lang": "en-US", "name": "hr:DispositionSalesPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76183c15fea846f19aaaf3ad99486322_D20200901-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "hr:PropertiesReclassifiedToHeldForSale", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Real Estate Investments - Assets Held for Sale (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails", "shortName": "Real Estate Investments - Assets Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76183c15fea846f19aaaf3ad99486322_D20200901-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "hr:PropertiesReclassifiedToHeldForSale", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Leases - Lease Income (Details)", "role": "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails", "shortName": "Leases - Lease Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i682aa73b72df49429a56f070eff7d7d1_D20200501-20200531", "decimals": "INF", "lang": "en-US", "name": "hr:NumberofPropertiesSold", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Leases - Lessor Accounting (Details)", "role": "http://healthcarerealty.com/role/LeasesLessorAccountingDetails", "shortName": "Leases - Lessor Accounting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfPropertiesSubjectToGroundLeases", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Leases - Ground Leases (Details)", "role": "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "shortName": "Leases - Ground Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": "-5", "lang": "en-US", "name": "hr:SquareFeetSubjecttoGroundLeases", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417410 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "role": "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418411 - Disclosure - Leases - Lease Cost (Details)", "role": "http://healthcarerealty.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421412 - Disclosure - Notes and Bonds Payable (Details)", "role": "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "shortName": "Notes and Bonds Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i6ef9a4f330f84597831d96a28593c3b5_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "shortName": "Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i9bf8d06212a94defbb60f17918dc3be3_I20200225", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "treasury_lock", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i01fc1a69d27b4f3cb596898eecd15863_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425414 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails", "shortName": "Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i01fc1a69d27b4f3cb596898eecd15863_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426415 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "shortName": "Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i76c840461e8347219d0fd1317e9e1010_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unitRef": "sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Commitments and Contingencies - Construction Activity (Details)", "role": "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails", "shortName": "Commitments and Contingencies - Construction Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i4b3c061fc30342aeb307c12c5638a6ba_I20200930", "decimals": "0", "lang": "en-US", "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ibb136a01fd824b72879855d1a07e14ab_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431417 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails", "shortName": "Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i494d3fdf04eb4629b82e372045fd2b2c_I20181231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ia552c0bf9d4e47298e359c954f24d3c6_I20200214", "decimals": "INF", "first": true, "lang": "en-US", "name": "hr:AtthemarketEquityOfferingProgramAuthorizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432418 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "shortName": "Stockholders' Equity (Stock Transactions - Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ia552c0bf9d4e47298e359c954f24d3c6_I20200214", "decimals": "INF", "first": true, "lang": "en-US", "name": "hr:AtthemarketEquityOfferingProgramAuthorizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433419 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails", "shortName": "Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ibfaa6e8933674131ab25eab6425d1af8_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434420 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails", "shortName": "Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ibfaa6e8933674131ab25eab6425d1af8_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ibf913d14e0374e548ce3b2e1c692b365_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435421 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails", "shortName": "Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ibf913d14e0374e548ce3b2e1c692b365_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i12164f6988914dc0ae322ae1a9d9ba91_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438422 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "i12164f6988914dc0ae322ae1a9d9ba91_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "iac4ee9a81fec49059fd3dbbe0a34782f_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Statement", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement", "shortName": "Condensed Consolidated Statements of Equity (Unaudited) Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "iac4ee9a81fec49059fd3dbbe0a34782f_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "id8f051123ff04a89a7081afc5ce3b030_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies", "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hr-20200930.htm", "contextRef": "ic9929cebecc246c490b0b07ae049f976_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 69, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r404" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r400" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hr_A5.63BondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "5.63% Bonds [Member]", "label": "5.63% Bonds [Member]", "terseLabel": "5.63% Bonds" } } }, "localname": "A5.63BondsMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_A6.63BondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "6.63% Bonds [Member]", "label": "6.63% Bonds [Member]", "terseLabel": "6.63% Bonds" } } }, "localname": "A6.63BondsMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_A6.88BondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "6.88% Bonds [Member]", "label": "6.88% Bonds [Member]", "terseLabel": "6.88% Bonds" } } }, "localname": "A6.88BondsMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_AcquisitionsAndDispositionsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisitions and dispositions.", "label": "Acquisitions and Dispositions [Text Block]", "verboseLabel": "Real Estate Investments" } } }, "localname": "AcquisitionsAndDispositionsTextBlock", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestments" ], "xbrltype": "textBlockItemType" }, "hr_ActiveInterestRateSwapsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Active Interest Rate Swaps [Member]", "label": "Active Interest Rate Swaps [Member]", "terseLabel": "Active Interest Rate Swap" } } }, "localname": "ActiveInterestRateSwapsMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "hr_AggregateTenantBillingsCollectedforPeriodPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate Tenant Billings Collected for Period, Percent", "label": "Aggregate Tenant Billings Collected for Period, Percent", "terseLabel": "Aggregate second quarter 2020 tenant billings collected (percent)" } } }, "localname": "AggregateTenantBillingsCollectedforPeriodPercent", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "hr_AmortizationofPrepaidRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Prepaid Rent", "label": "Amortization of Prepaid Rent", "terseLabel": "Amortization of prepaid rent" } } }, "localname": "AmortizationofPrepaidRent", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "monetaryItemType" }, "hr_ApproximateSquareFeetProvidedByCompany": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Approximate square feet for which Nationwide property management services provided by company", "label": "Approximate Square Feet Provided by Company", "verboseLabel": "Approximate square feet for which Nationwide property management services provided by company" } } }, "localname": "ApproximateSquareFeetProvidedByCompany", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "hr_AreaCoveredUnderRealEstateInvestmentSoldInMeasurementUnits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area covered under real estate investment sold in measurement units.", "label": "Area Covered Under Real Estate Investment Sold in Measurement Units", "terseLabel": "Square footage" } } }, "localname": "AreaCoveredUnderRealEstateInvestmentSoldInMeasurementUnits", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "areaItemType" }, "hr_AssetDispositionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Dispositions", "label": "Asset Dispositions [Table Text Block]", "terseLabel": "Real estate dispositions" } } }, "localname": "AssetDispositionsTableTextBlock", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Assets held for sale and discontinued operations, net.", "label": "Assets Held-for-sale and Discontinued Operations Net", "verboseLabel": "Assets held for sale, net" } } }, "localname": "AssetsHeldForSaleAndDiscontinuedOperationsNet", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "hr_AtTheMarketEquityOfferingProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At The Market Equity Offering Program [Member]", "label": "At The Market Equity Offering Program [Member]", "terseLabel": "At the market equity offering program" } } }, "localname": "AtTheMarketEquityOfferingProgramMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_AtthemarketEquityOfferingProgramAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "At-the-market Equity Offering Program, Authorized Amount", "label": "At-the-market Equity Offering Program, Authorized Amount", "terseLabel": "At-the-market equity offering program, authorized amount" } } }, "localname": "AtthemarketEquityOfferingProgramAuthorizedAmount", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hr_AtthemarketEquityOfferingProgramRemainingAuthorizedAmountAssumingForwardEquityContractsSettle": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "At-the-market Equity Offering Program, Remaining Authorized Amount, Assuming Forward Equity Contracts Settle", "label": "At-the-market Equity Offering Program, Remaining Authorized Amount, Assuming Forward Equity Contracts Settle", "terseLabel": "At-the-market equity offering program, remaining authorized amount, assuming forward equity contracts settle" } } }, "localname": "AtthemarketEquityOfferingProgramRemainingAuthorizedAmountAssumingForwardEquityContractsSettle", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessAcquisitionPurchasePriceAllocationSquareFootage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition Purchase Price Allocation Square Footage.", "label": "Business Acquisition Purchase Price Allocation Square Footage", "verboseLabel": "Square footage" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationSquareFootage", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "areaItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "terseLabel": "Real estate" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "terseLabel": "Other" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessOverviewAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Overview [Abstract]", "label": "Business Overview [Abstract]", "terseLabel": "Business Overview:" } } }, "localname": "BusinessOverviewAbstract", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "hr_ClosingAdjustmentsDisposedEntity": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Closing Adjustments Disposed Entity, including closing costs and other adjustments to the sales price.", "label": "Closing Adjustments Disposed Entity", "negatedTerseLabel": "Closing adjustments" } } }, "localname": "ClosingAdjustmentsDisposedEntity", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_ColoradoSpringsCOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Colorado Springs, CO [Member]", "label": "Colorado Springs, CO [Member]", "terseLabel": "Colorado Springs, CO" } } }, "localname": "ColoradoSpringsCOMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_ConstructionActivityEstimatedRemainingFundings": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Estimated Remaining Fundings", "label": "Construction Activity, Estimated Remaining Fundings", "terseLabel": "Estimated amount to complete project" } } }, "localname": "ConstructionActivityEstimatedRemainingFundings", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_ConstructionActivityTotalAmountFunded": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Total Amount Funded", "label": "Construction Activity, Total Amount Funded", "terseLabel": "Total amount funded" } } }, "localname": "ConstructionActivityTotalAmountFunded", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_ConstructionActivityTotalFundingDuringthePeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Total Funding During the Period", "label": "Construction Activity, Total Funding During the Period", "terseLabel": "Construction activity, total funding during the period" } } }, "localname": "ConstructionActivityTotalFundingDuringthePeriod", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_ConstructionActivityTotalFundingDuringthePeriodExcludingPurchaseofLandandBuilding": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Total Funding During the Period, Excluding Purchase of Land and Building", "label": "Construction Activity, Total Funding During the Period, Excluding Purchase of Land and Building", "terseLabel": "Construction activity, total funding during the period, excluding purchase of land and building" } } }, "localname": "ConstructionActivityTotalFundingDuringthePeriodExcludingPurchaseofLandandBuilding", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_ContractWithCustomerAssetPastDueGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Asset, Past Due, Gross", "label": "Contract with Customer, Asset, Past Due, Gross", "terseLabel": "Deferred rent receivable, gross" } } }, "localname": "ContractWithCustomerAssetPastDueGross", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hr_ContractwithCustomerLiabilityReserveRecognizedinPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Liability, Reserve Recognized in Period", "label": "Contract with Customer, Liability, Reserve Recognized in Period", "terseLabel": "Deferred rent reserve recognized in the period" } } }, "localname": "ContractwithCustomerLiabilityReserveRecognizedinPeriod", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeDividendsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Dividends [Member].", "label": "Cumulative Dividends [Member]", "terseLabel": "Cumulative Dividends" } } }, "localname": "CumulativeDividendsMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_CumulativeNetIncomeAttributableToCommonStockholders": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cumulative net income attributable to common stockholders.", "label": "Cumulative Net Income Attributable to Common Stockholders", "verboseLabel": "Cumulative net income attributable to common stockholders" } } }, "localname": "CumulativeNetIncomeAttributableToCommonStockholders", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeNetIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Net Income [Member].", "label": "Cumulative Net Income [Member]", "terseLabel": "Cumulative Net Income" } } }, "localname": "CumulativeNetIncomeMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_DebtInstrumentPrepaymentPenaltyAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Prepayment Penalty, Amount", "label": "Debt Instrument, Prepayment Penalty, Amount", "terseLabel": "Debt redeemed, make whole amount" } } }, "localname": "DebtInstrumentPrepaymentPenaltyAmount", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "hr_DeferredRentArrangementsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Rent Arrangements, Amount", "label": "Deferred Rent Arrangements, Amount", "terseLabel": "Deferred rent arrangements for the quarter" } } }, "localname": "DeferredRentArrangementsAmount", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hr_DeferredRentReserve": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Rent Reserve", "label": "Deferred Rent Reserve", "terseLabel": "Deferred rent, general reserve" } } }, "localname": "DeferredRentReserve", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hr_DenverCOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Denver, CO [Member]", "label": "Denver, CO [Member]", "terseLabel": "Denver, CO" } } }, "localname": "DenverCOMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_DispositionSalesPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposition Sales Price", "label": "Disposition Sales Price", "terseLabel": "Sales price" } } }, "localname": "DispositionSalesPrice", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_ExecutiveChairmanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Executive Chairman", "label": "Executive Chairman [Member]", "terseLabel": "Executive Chairman" } } }, "localname": "ExecutiveChairmanMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "domainItemType" }, "hr_ExtinguishmentOfDebtAccruedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Extinguishment of Debt, Accrued Interest", "label": "Extinguishment of Debt, Accrued Interest", "terseLabel": "Debt redeemed, accrued interest" } } }, "localname": "ExtinguishmentOfDebtAccruedInterest", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "hr_FinanceLeaseLiabilitytobePaidafterYearFour": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Liability, to be Paid, after Year Four", "label": "Finance Lease, Liability, to be Paid, after Year Four", "terseLabel": "2025 and thereafter" } } }, "localname": "FinanceLeaseLiabilitytobePaidafterYearFour", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "hr_ForwardEquityAgreement1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward Equity Agreement 1", "label": "Forward Equity Agreement 1 [Member]", "terseLabel": "Forward Equity Agreement Maturing June 2021" } } }, "localname": "ForwardEquityAgreement1Member", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_ForwardEquityAgreement2Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward Equity Agreement 2", "label": "Forward Equity Agreement 2 [Member]", "terseLabel": "Forward Equity Agreement Maturing July 2021" } } }, "localname": "ForwardEquityAgreement2Member", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_ForwardEquityAgreementShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward Equity Agreement, Shares", "label": "Forward Equity Agreement, Shares", "terseLabel": "Forward equity agreement (in shares)" } } }, "localname": "ForwardEquityAgreementShares", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hr_GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "label": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "negatedLabel": "Gain on sales of real estate assets", "terseLabel": "Gains on sales of investment real estate" } } }, "localname": "GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "hr_GainsLossesonSalesofInvestmentRealEstateSalesTypeLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gains (Losses) on Sales of Investment Real Estate, Sales-Type Leases", "label": "Gains (Losses) on Sales of Investment Real Estate, Sales-Type Leases", "terseLabel": "Profit recognized at commencement date" } } }, "localname": "GainsLossesonSalesofInvestmentRealEstateSalesTypeLeases", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "hr_HoustonTXMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Houston, TX", "label": "Houston, TX [Member]", "terseLabel": "Houston, TX" } } }, "localname": "HoustonTXMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_ImpairmentOfRealEstateContinuingAndDiscontinuedOperations": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Impairment of Real Estate, Continuing and Discontinued Operations", "label": "Impairment of Real Estate, Continuing and Discontinued Operations", "terseLabel": "Impairment of real estate assets" } } }, "localname": "ImpairmentOfRealEstateContinuingAndDiscontinuedOperations", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to dilutive effect of employee stock purchase plan.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan", "verboseLabel": "Dilutive effect of employee stock purchase plan (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "sharesItemType" }, "hr_InvestmentInRealEstatePropertiesAndMortgageNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in real estate properties and mortgage notes.", "label": "Investment in Real Estate Properties and Mortgage Notes", "terseLabel": "Gross investment amount, total" } } }, "localname": "InvestmentInRealEstatePropertiesAndMortgageNotes", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hr_LandAcquisitionSubsequentlyDisposedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Land Acquisition, Subsequently Disposed", "label": "Land Acquisition, Subsequently Disposed [Member]", "terseLabel": "Land Acquisition, Subsequently Disposed" } } }, "localname": "LandAcquisitionSubsequentlyDisposedMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_LesseeOperatingLeaseLiabilitytobePaidafterYearFour": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "verboseLabel": "2025 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilitytobePaidafterYearFour", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "hr_LessorOperatingLeasePaymenttobeReceivedafterYearFour": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessor, Operating Lease, Payment to be Received, after Year Four", "label": "Lessor, Operating Lease, Payment to be Received, after Year Four", "terseLabel": "2025 and thereafter" } } }, "localname": "LessorOperatingLeasePaymenttobeReceivedafterYearFour", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "hr_LosAngelesCaliforniaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Los Angeles, California [Member]", "label": "Los Angeles, California [Member]", "terseLabel": "Los Angeles, CA" } } }, "localname": "LosAngelesCaliforniaMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_ManagementFeeIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Management Fee Income [Member]", "label": "Management Fee Income [Member]", "terseLabel": "Management fee income" } } }, "localname": "ManagementFeeIncomeMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingExpansionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building Expansion [Member]", "label": "Medical Office Building Expansion [Member]", "terseLabel": "Medical office building expansion" } } }, "localname": "MedicalOfficeBuildingExpansionMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building [Member]", "label": "Medical Office Building [Member]", "terseLabel": "Medical office building" } } }, "localname": "MedicalOfficeBuildingMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_MemphisTennesseeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Memphis, Tennessee [Member]", "label": "Memphis, Tennessee [Member]", "terseLabel": "Memphis, Tennessee" } } }, "localname": "MemphisTennesseeMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "hr_MiscellaneousMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Miscellaneous [Member]", "label": "Miscellaneous [Member]", "terseLabel": "Miscellaneous" } } }, "localname": "MiscellaneousMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MortgageNotesPayableNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mortgage Notes Payable, Net [Member]", "label": "Mortgage Notes Payable, Net [Member]", "terseLabel": "Mortgage notes payable, net of discounts and issuance costs and including premiums" } } }, "localname": "MortgageNotesPayableNetMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nature Of Operations Policy.", "label": "Nature of Operations [Policy Text Block]", "terseLabel": "Business overview" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "label": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "totalLabel": "Net income applicable to common stockholders" } } }, "localname": "NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "monetaryItemType" }, "hr_NumberOfAgreementsToSellLeasedProperties": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Agreements to Sell Leased Properties", "label": "Number of Agreements to Sell Leased Properties", "terseLabel": "Number of agreements to sell leased properties" } } }, "localname": "NumberOfAgreementsToSellLeasedProperties", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberOfForwardEquityAgreements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Forward Equity Agreements", "label": "Number of Forward Equity Agreements", "terseLabel": "Number of forward equity agreements" } } }, "localname": "NumberOfForwardEquityAgreements", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "hr_NumberOfPropertiesHeldForSale": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of properties held for sale.", "label": "Number of Properties Held for Sale", "terseLabel": "Number of properties held for sale" } } }, "localname": "NumberOfPropertiesHeldForSale", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "integerItemType" }, "hr_NumberOfRealEstateInvestments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of real estate investments.", "label": "Number of Real Estate Investments", "terseLabel": "Number of real estate properties" } } }, "localname": "NumberOfRealEstateInvestments", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofBondsRepaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Bonds Repaid", "label": "Number of Bonds Repaid", "terseLabel": "Number of bonds repaid" } } }, "localname": "NumberofBondsRepaid", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofDerivativeInstrumentsSettled": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Derivative Instruments Settled", "label": "Number of Derivative Instruments Settled", "terseLabel": "Number of derivative instruments settled" } } }, "localname": "NumberofDerivativeInstrumentsSettled", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofGroundLeasesExcludingPrepaidLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Ground Leases, Excluding Prepaid Leases", "label": "Number of Ground Leases, Excluding Prepaid Leases", "terseLabel": "Number of non-prepaid ground leases" } } }, "localname": "NumberofGroundLeasesExcludingPrepaidLeases", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofGroundLeasesPrepaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Ground Leases Prepaid", "label": "Number of Ground Leases Prepaid", "terseLabel": "Number of prepaid ground leases" } } }, "localname": "NumberofGroundLeasesPrepaid", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofInvestmentBanks": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Investment Banks", "label": "Number of Investment Banks", "terseLabel": "Number of investment banks included in the program" } } }, "localname": "NumberofInvestmentBanks", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofLandParcelsAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Land Parcels Acquired", "label": "Number of Land Parcels Acquired", "terseLabel": "Number of land parcels acquired" } } }, "localname": "NumberofLandParcelsAcquired", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofPropertiesAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Properties Acquired", "label": "Number of Properties Acquired", "terseLabel": "Number of properties acquired" } } }, "localname": "NumberofPropertiesAcquired", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofPropertiesSold": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Properties Sold", "label": "Number of Properties Sold", "terseLabel": "Number of properties sold" } } }, "localname": "NumberofPropertiesSold", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "xbrltype": "integerItemType" }, "hr_OperatingExpensesandCostofGoodsSold": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Expenses and Cost of Goods Sold", "label": "Operating Expenses and Cost of Goods Sold", "totalLabel": "Expenses" } } }, "localname": "OperatingExpensesandCostofGoodsSold", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_ParkingIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Parking Income [Member]", "label": "Parking Income [Member]", "terseLabel": "Parking income" } } }, "localname": "ParkingIncomeMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_PersonalProperty": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Personal property.", "label": "Personal Property", "terseLabel": "Personal property" } } }, "localname": "PersonalProperty", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "hr_ProceedsfromIssuanceofCommonStockAdjustedforCoststoBorrow": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from Issuance of Common Stock, Adjusted for Costs to Borrow", "label": "Proceeds from Issuance of Common Stock, Adjusted for Costs to Borrow", "terseLabel": "Proceeds from issuance of common stock, adjusted for costs to borrow" } } }, "localname": "ProceedsfromIssuanceofCommonStockAdjustedforCoststoBorrow", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hr_PropertiesReclassifiedToHeldForSale": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Properties Reclassified to Held for Sale", "label": "Properties Reclassified to Held for Sale", "terseLabel": "Number of properties reclassified to held for sale" } } }, "localname": "PropertiesReclassifiedToHeldForSale", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "integerItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Axis]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Axis]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingAxis", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Domain]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Domain]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingDomain", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateAcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate acquisitions.", "label": "Real Estate Acquisitions [Member]", "terseLabel": "Total real estate acquisitions" } } }, "localname": "RealEstateAcquisitionsMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateDispositionsAndMortgageNoteRepaymentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions and Mortgage Note Repayments [Axis]", "label": "Real Estate Dispositions and Mortgage Note Repayments [Axis]", "terseLabel": "Real Estate Dispositions and Mortgage Note Repayments [Axis]" } } }, "localname": "RealEstateDispositionsAndMortgageNoteRepaymentsAxis", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateDispositionsAndMortgageNoteRepaymentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions and Mortgage Note Repayments [Domain]", "label": "Real Estate Dispositions and Mortgage Note Repayments [Domain]", "terseLabel": "Real Estate Dispositions and Mortgage Note Repayments [Domain]" } } }, "localname": "RealEstateDispositionsAndMortgageNoteRepaymentsDomain", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateDispositionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate dispositions.", "label": "Real Estate Dispositions [Line Items]", "terseLabel": "Real Estate Dispositions [Line Items]" } } }, "localname": "RealEstateDispositionsLineItems", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateDispositionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions [Member]", "label": "Real Estate Dispositions [Member]", "terseLabel": "Real Estate Dispositions" } } }, "localname": "RealEstateDispositionsMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateHeldforSaleSalePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Real Estate Held for Sale, Sale Price", "label": "Real Estate Held for Sale, Sale Price", "terseLabel": "Expected purchase price" } } }, "localname": "RealEstateHeldforSaleSalePrice", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateInvestmentNetDisposedOfDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Real estate investment net disposed of during the Period.", "label": "Real Estate Investment Net Disposed of During Period", "terseLabel": "Net Real Estate Investment" } } }, "localname": "RealEstateInvestmentNetDisposedOfDuringPeriod", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateInvestmentsPropertyOwnedInNumberOfStates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate investments property owned in number of states.", "label": "Real Estate Investments Property Owned in Number of States", "verboseLabel": "Number of states that the company owns real estate in, whole units" } } }, "localname": "RealEstateInvestmentsPropertyOwnedInNumberOfStates", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_RealEstateOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Real estate other.", "label": "Real Estate Other", "terseLabel": "Real estate other" } } }, "localname": "RealEstateOther", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateandLandAcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate and Land Acquisitions [Member]", "label": "Real Estate and Land Acquisitions [Member]", "terseLabel": "Real Estate and Land Acquisitions" } } }, "localname": "RealEstateandLandAcquisitionsMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of the beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward]", "verboseLabel": "Reconciliation of the beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails" ], "xbrltype": "stringItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block]", "terseLabel": "Reconciliation of beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "hr_RentalLeaseGuarantyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rental Lease Guaranty [Member]", "label": "Rental Lease Guaranty [Member]", "terseLabel": "Rental lease guaranty" } } }, "localname": "RentalLeaseGuarantyMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_SanDiegoCaliforniaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "San Diego, California [Member]", "label": "San Diego, California [Member]", "terseLabel": "San Diego, CA" } } }, "localname": "SanDiegoCaliforniaMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Assets and Liabilities Held for Sale", "label": "Schedule of Assets and Liabilities Held for Sale [Table Text Block]", "terseLabel": "Schedule of assets and liabilities held for sale" } } }, "localname": "ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "hr_ScheduleOfRealEstateDispositionsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of real estate dispositions.", "label": "Schedule of Real Estate Dispositions [Table]", "terseLabel": "Schedule of Real Estate Dispositions [Table]" } } }, "localname": "ScheduleOfRealEstateDispositionsTable", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_ScheduledDeferralPaymentsCollectedInTheQuarterPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Scheduled Deferral Payments Collected in the Quarter Percent", "label": "Scheduled Deferral Payments Collected in the Quarter Percent", "terseLabel": "Scheduled deferral payments collected in the third quarter (percent)" } } }, "localname": "ScheduledDeferralPaymentsCollectedInTheQuarterPercent", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "hr_SeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2031", "label": "Senior Notes due 2031 [Member]", "terseLabel": "Senior notes due 2031" } } }, "localname": "SeniorNotesDue2031Member", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2023 [Member]", "label": "Senior Notes due 2023 [Member]", "terseLabel": "Senior Notes due 2023, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2023Member", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2025 [Member]", "label": "Senior Notes due 2025 [Member]", "terseLabel": "Senior notes due 2025, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2025Member", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2028 [Member]", "label": "Senior Notes due 2028 [Member]", "terseLabel": "Senior Notes due 2028, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2028Member", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2030Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2030 [Member]", "label": "Senior Notes due 2030 [Member]", "terseLabel": "Senior notes due 2030, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2030Member", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SharesIssuedDuringPeriodPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares Issued During Period, Price Per Share", "label": "Shares Issued During Period, Price Per Share", "terseLabel": "Shares issued during period, price per share (in dollars per share)" } } }, "localname": "SharesIssuedDuringPeriodPricePerShare", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "hr_SquareFeetSubjecttoGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Square Feet Subject to Ground Leases", "label": "Square Feet Subject to Ground Leases", "terseLabel": "Square feet subject to ground leases" } } }, "localname": "SquareFeetSubjecttoGroundLeases", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "areaItemType" }, "hr_StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Incentive Plan [Member]", "label": "Stock Incentive Plan [Member]", "terseLabel": "Stock incentive plan" } } }, "localname": "StockIncentivePlanMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "domainItemType" }, "hr_StockIssuanceProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Axis]", "terseLabel": "Stock Issuance Program [Axis]" } } }, "localname": "StockIssuanceProgramAxis", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "hr_StockIssuanceProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Domain]", "terseLabel": "Stock Issuance Program [Domain]" } } }, "localname": "StockIssuanceProgramDomain", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_StraightLineRentReceivable": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent receivable.", "label": "Straight-line Rent Receivable", "negatedLabel": "Amortization of straight-line rent receivable (lessor)" } } }, "localname": "StraightLineRentReceivable", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_StraightlineRentLiability": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent liability.", "label": "Straight-line Rent Liability", "terseLabel": "Amortization of straight-line rent on operating leases (lessee)" } } }, "localname": "StraightlineRentLiability", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_TenantBillingsDeferredunderRentDeferralAgreementsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tenant Billings Deferred under Rent Deferral Agreements, Percent", "label": "Tenant Billings Deferred under Rent Deferral Agreements, Percent", "terseLabel": "Second and third quarter 2020 tenant billings deferred under rent deferral agreements (percent)" } } }, "localname": "TenantBillingsDeferredunderRentDeferralAgreementsPercent", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "hr_TermLoandue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan due 2024 [Member]", "label": "Term Loan due 2024 [Member]", "terseLabel": "$200 million unsecured term loan facility, net of issuance costs" } } }, "localname": "TermLoandue2024Member", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_TermLoandue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan due 2026 [Member]", "label": "Term Loan due 2026 [Member]", "terseLabel": "$150 million unsecured term loan due 2026" } } }, "localname": "TermLoandue2026Member", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_UnsecuredCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unsecured Credit Facility [Member]", "label": "Unsecured Credit Facility [Member]", "terseLabel": "$700 million Unsecured Credit Facility" } } }, "localname": "UnsecuredCreditFacilityMember", "nsuri": "http://healthcarerealty.com/20200930", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r213", "r214", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r381", "r384" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r213", "r214", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r381", "r384" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ], "lang": { "en-US": { "role": { "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [ "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397" ], "lang": { "en-US": { "role": { "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r147", "r200", "r201", "r337", "r380", "r382" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r147", "r200", "r201", "r337", "r380", "r382" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r209", "r213", "r214", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r381", "r384" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r209", "r213", "r214", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r381", "r384" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r148", "r149", "r200", "r202", "r383", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397" ], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r148", "r149", "r200", "r202", "r383", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r151", "r327" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r329", "r331", "r334" ], "lang": { "en-US": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_FL": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "FLORIDA", "terseLabel": "Miami, FL" } } }, "localname": "FL", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_GA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "GEORGIA", "terseLabel": "Atlanta, GA" } } }, "localname": "GA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_MO": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "MISSOURI", "terseLabel": "Springfield, MO" } } }, "localname": "MO", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_NC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NORTH CAROLINA", "verboseLabel": "Raleigh, NC" } } }, "localname": "NC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_OK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "OKLAHOMA", "terseLabel": "Oklahoma City, OK" } } }, "localname": "OK", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_WA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "WASHINGTON", "terseLabel": "Washington", "verboseLabel": "Seattle, WA" } } }, "localname": "WA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r346", "r370" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r33", "r36", "r211" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r34", "r36", "r38", "r95", "r96", "r97", "r247", "r385", "r386" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AcquisitionCosts": { "auth_ref": [ "r338", "r339" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 4.0, "parentTag": "hr_OperatingExpensesandCostofGoodsSold", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.", "label": "Acquisition Costs, Period Cost", "terseLabel": "Acquisition and pursuit costs" } } }, "localname": "AcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r95", "r96", "r97", "r229", "r230", "r231" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r215", "r217", "r232", "r233" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Weighted-average incremental shares of common stock excluded from the computation (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "netLabel": "Approximate square feet", "terseLabel": "Area of real estate property", "verboseLabel": "Square footage of owned real estate properties" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r91", "r136", "r139", "r145", "r154", "r245", "r248", "r286", "r342", "r360" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r218", "r228" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r257", "r262" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r239", "r240", "r241" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "verboseLabel": "Purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r238", "r239", "r240", "r243" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "negatedTerseLabel": "Mortgage notes payable" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r83", "r84", "r85" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "verboseLabel": "Invoices accrued for construction, tenant improvements and other capitalized costs" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r284", "r285" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "CARRYING VALUE" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r6", "r20", "r80" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r8", "r81", "r87", "r340" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r73", "r80", "r86" ], "calculation": { "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r73", "r287" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash flow hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r27", "r170", "r348", "r365" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r167", "r168", "r169", "r171" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "verboseLabel": "Dividend per share to common Stockholders (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per common share, during the period (in dollars per share)", "verboseLabel": "Dividends declared, per common share, during the period (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r95", "r96" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r182" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "verboseLabel": "Common stock, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $.01 par value per share; 300,000 shares authorized; 136,054 and 134,706 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r41", "r43", "r44", "r52", "r353", "r374" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetPastDue": { "auth_ref": [ "r156" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, past due.", "label": "Contract with Customer, Asset, Past Due", "terseLabel": "Deferred rent receivable, net" } } }, "localname": "ContractWithCustomerAssetPastDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r210", "r212", "r388" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeDividends": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative cash dividends distributed to shareholders.", "label": "Cumulative Dividends", "negatedLabel": "Cumulative dividends" } } }, "localname": "CumulativeDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Notes and bonds payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r12", "r13", "r343", "r344", "r358" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r298", "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Term-loan facility" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r283" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "verboseLabel": "Notes and bonds payable" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r25", "r174", "r298" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Fixed interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r26", "r92", "r183", "r186", "r187", "r188", "r297", "r298", "r300", "r357" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Term of senior notes" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r297", "r300" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r78", "r159" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 3.0, "parentTag": "hr_OperatingExpensesandCostofGoodsSold", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r78", "r134" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r30", "r31", "r260", "r335" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Liability derivatives" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Weighted average interest rate (percent)" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r258", "r261", "r266", "r269" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative financial instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r255", "r258", "r266" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": { "auth_ref": [ "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.", "label": "Derivative, Net Liability Position, Aggregate Fair Value", "terseLabel": "Derivatives in net liability position" } } }, "localname": "DerivativeNetLiabilityPositionAggregateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r251", "r253" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r250", "r252", "r253", "r255", "r256", "r263", "r266", "r272", "r273", "r276" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopmentInProcess": { "auth_ref": [ "r369" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current amount of expenditures for a real estate project that has not yet been completed.", "label": "Development in Process", "terseLabel": "Construction in progress" } } }, "localname": "DevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment": { "auth_ref": [ "r49" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 2.0, "parentTag": "hr_OperatingExpensesandCostofGoodsSold", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense incurred and directly related to generating revenue by lessor from operating lease of rented property and equipment.", "label": "Direct Costs of Leased and Rented Property or Equipment", "verboseLabel": "Property operating" } } }, "localname": "DirectCostsOfLeasedAndRentedPropertyOrEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggreation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r218", "r228" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of the activity under the incentive plan" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r4", "r157", "r166" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r0", "r1", "r3", "r165" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "auth_ref": [ "r0", "r1", "r3", "r165" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Other assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r0", "r1", "r3", "r165" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends to common stockholders (in usd per share)" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsShareBasedCompensation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails": { "order": 2.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind dividends declared for award under share-based payment arrangement.", "label": "Dividend, Share-based Payment Arrangement", "negatedTerseLabel": "Dividends paid on nonvested share-based awards" } } }, "localname": "DividendsShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r53", "r100", "r101", "r102", "r103", "r104", "r108", "r111", "r114", "r115", "r116", "r118", "r119", "r354", "r375" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r53", "r100", "r101", "r102", "r103", "r104", "r111", "r114", "r115", "r116", "r118", "r119", "r354", "r375" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "verboseLabel": "Employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r95", "r96", "r97", "r99", "r105", "r107", "r121", "r155", "r182", "r189", "r229", "r230", "r231", "r234", "r235", "r288", "r289", "r290", "r291", "r292", "r294", "r385", "r386", "r387" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r48", "r72", "r78", "r371" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Distributions from unconsolidated joint ventures" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "FAIR VALUE" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Outstanding principal repaid" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]", "terseLabel": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment of Debt, Type [Domain]", "terseLabel": "Extinguishment of Debt, Type [Domain]" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r279", "r284" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r279", "r281" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r304", "r309", "r318" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "FINANCING" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r303", "r317" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Financing lease liabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Future Minimum Financing Lease Payments" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Discount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r305", "r312" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments made on finance leases", "terseLabel": "Financing cash flows outflows related to financing leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r302" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Financing lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r304", "r309", "r318" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r315", "r318" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r314", "r318" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (excluding renewal options) -finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r78", "r158", "r163" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "netLabel": "Gain/(impairment)" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r78", "r175", "r176" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on early extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r54", "r55", "r78", "r350", "r376", "r377", "r378", "r379" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "terseLabel": "Gain on sales of real estate assets" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 1.0, "parentTag": "hr_OperatingExpensesandCostofGoodsSold", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r255", "r270" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfRealEstate": { "auth_ref": [ "r78", "r162" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.", "label": "Impairment of Real Estate", "negatedLabel": "Impairment of real estate assets" } } }, "localname": "ImpairmentOfRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r56", "r79", "r100", "r101", "r102", "r103", "r113", "r116", "r244" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails": { "order": 1.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net Income" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r48", "r78", "r135", "r153", "r349", "r371" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Loss from unconsolidated joint ventures" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r77" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r77" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets, including right-of-use-assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r77" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements": { "auth_ref": [ "r112", "r116" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shared included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity forward arrangements using the reverse treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements", "terseLabel": "Dilutive effect of forward equity shares (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToEquityForwardAgreements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r46", "r133", "r296", "r299", "r355" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Total interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidCapitalized": { "auth_ref": [ "r64", "r82" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.", "label": "Interest Paid, Capitalized, Investing Activities", "terseLabel": "Capitalized interest" } } }, "localname": "InterestPaidCapitalized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r71", "r74", "r82" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r210", "r267" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest rate swaps" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Settled interest rate swaps", "verboseLabel": "Interest Rate Swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "auth_ref": [ "r367" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.", "label": "Investment Building and Building Improvements", "terseLabel": "Building, improvements and lease intangibles", "verboseLabel": "Buildings, improvements and lease intangibles" } } }, "localname": "InvestmentBuildingAndBuildingImprovements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r7", "r21" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land", "verboseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAndBuildingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities.", "label": "Land and Building [Member]", "terseLabel": "Land and building" } } }, "localname": "LandAndBuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandAvailableForDevelopment": { "auth_ref": [ "r364" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of land available for development.", "label": "Land Available for Development", "terseLabel": "Land held for development" } } }, "localname": "LandAvailableForDevelopment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land Acquisition" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r316", "r318" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Operating lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases, Operating [Abstract]", "terseLabel": "Other information" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Finance Lease, Description [Abstract]", "terseLabel": "Finance lease cost" } } }, "localname": "LesseeFinanceLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future Minimum Operating Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r317" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Ground lease, initial term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Operating Lease Payments Receivable [Abstract]" } } }, "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r324" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r324" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Future Minimum Operating Lease Payments Receivable" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r324" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2021" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r324" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r324" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r324" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r91", "r140", "r154", "r246", "r248", "r249", "r286" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r91", "r154", "r286", "r345", "r363" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r3", "r4", "r5", "r165" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Liabilities of assets held for sale", "verboseLabel": "Liabilities of assets held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsHeldForSaleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long Lived Assets Held-for-sale [Line Items]", "terseLabel": "Long Lived Assets Held-for-sale [Line Items]" } } }, "localname": "LongLivedAssetsHeldForSaleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r173", "r344", "r361" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Notes and bonds payable", "verboseLabel": "Notes and bonds payable" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r26", "r172" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Medium-term notes" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgages" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r73" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r73" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r73", "r75", "r79" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r39", "r42", "r50", "r79", "r91", "r98", "r100", "r101", "r102", "r103", "r106", "r107", "r113", "r136", "r138", "r141", "r144", "r146", "r154", "r286", "r351", "r372" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net Income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAssumed1": { "auth_ref": [ "r83", "r84", "r85" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of notes assumed in noncash investing or financing activities.", "label": "Notes Assumed", "terseLabel": "Mortgage notes payable assumed upon acquisition (adjusted to fair value)" } } }, "localname": "NotesAssumed1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r251", "r253" ], "lang": { "en-US": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "terseLabel": "Number of instruments" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfPropertiesSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of separate real estate development properties located on land subject to ground leases.", "label": "Number of Properties Subject to Ground Leases", "terseLabel": "Number of properties subject to ground leases" } } }, "localname": "NumberOfPropertiesSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r310", "r318" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r120", "r321", "r326" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Rental income" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "OPERATING" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r303" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r306", "r312" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows outflows related to operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r302" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r315", "r318" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r314", "r318" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (excluding renewal options) - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAmortizationOfDeferredCharges": { "auth_ref": [ "r57", "r78" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization of other deferred costs recognized in the income statement.", "label": "Amortization of Other Deferred Charges", "terseLabel": "Other amortization" } } }, "localname": "OtherAmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r10", "r341", "r359" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "verboseLabel": "Other assets, net" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]", "terseLabel": "Interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r32", "r35" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "negatedLabel": "Impact of settlement of forward-starting interest rate swap", "negatedTerseLabel": "Losses arising during the period on interest rate swaps", "verboseLabel": "Losses arising during the period on interest rate swaps and treasury rate locks" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r32", "r35", "r259", "r264", "r275" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Loss recognized in AOCI on derivative" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r35", "r37" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedLabel": "Reclassification adjustments for losses included in net income (interest expense)", "terseLabel": "(Gain) loss reclassified from AOCI into income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r40", "r43", "r45", "r51", "r182", "r288", "r293", "r294", "r352", "r373" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r347" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r257", "r274" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest and other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForHedgeFinancingActivities": { "auth_ref": [ "r70", "r76" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.", "label": "Payments for Hedge, Financing Activities", "negatedLabel": "Settlement of treasury rate locks" } } }, "localname": "PaymentsForHedgeFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r67" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Common stock redemptions" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r69" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance and assumption costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r67" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r63", "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r64" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Additional long-lived assets" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRealEstate": { "auth_ref": [ "r64" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.", "label": "Payments to Acquire Real Estate", "negatedTerseLabel": "Acquisitions of real estate" } } }, "localname": "PaymentsToAcquireRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopRealEstateAssets": { "auth_ref": [ "r64" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to develop real estate assets is the process of adding improvements on or to a parcel of land. Such improvements may include drainage, utilities, subdividing, access, buildings, and any combination of these elements; and are generally classified as cash flow from investing activities.", "label": "Payments to Develop Real Estate Assets", "negatedLabel": "Development of real estate" } } }, "localname": "PaymentsToDevelopRealEstateAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r218", "r228" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, issued (shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r65" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": { "auth_ref": [ "r66" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.", "label": "Proceeds from Issuance of Medium-term Notes", "terseLabel": "Borrowings on term loan" } } }, "localname": "ProceedsFromIssuanceOfMediumTermNotes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "auth_ref": [ "r66" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.", "label": "Proceeds from Issuance of Other Long-term Debt", "terseLabel": "Borrowings of notes and bonds payable" } } }, "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLeasePayments": { "auth_ref": [ "r322", "r323" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from lease payment, classified as operating activity.", "label": "Proceeds from Lease Payment, Operating Activity", "terseLabel": "Proceeds from disposition of sales-type lease properties" } } }, "localname": "ProceedsFromLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r93" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net (repayments) borrowings on unsecured credit facility" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": { "auth_ref": [ "r62" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.", "label": "Proceeds from Sale of Property Held-for-sale", "terseLabel": "Proceeds from sales of real estate assets" } } }, "localname": "ProceedsFromSaleOfPropertyHeldForSale", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period.", "label": "Proceeds from Sale of Real Estate Held-for-investment", "terseLabel": "Net proceeds" } } }, "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r22", "r161" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r160" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstateHeldforsale": { "auth_ref": [ "r368" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of investments in land and buildings held for sale, excluding real estate considered to be inventory of the entity.", "label": "Real Estate Held-for-sale", "terseLabel": "Net investment in property held for sale" } } }, "localname": "RealEstateHeldforsale", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r366" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedLabel": "Less accumulated depreciation and amortization", "negatedNetLabel": "Accumulated depreciation" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r367" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "totalLabel": "Total real estate properties" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r367" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "terseLabel": "Total real estate properties, net", "totalLabel": "Total real estate properties, net" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate Investment Property, Net [Abstract]", "verboseLabel": "Real estate properties" } } }, "localname": "RealEstateInvestmentPropertyNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r68" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Repayments on notes and bonds payable" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfUnsecuredDebt": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.", "label": "Repayments of Unsecured Debt", "terseLabel": "Payments to redeem unsecured senior notes" } } }, "localname": "RepaymentsOfUnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r86", "r340", "r362" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r131", "r132", "r137", "r142", "r143", "r147", "r148", "r150", "r199", "r200", "r337" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Type of Revenue", "verboseLabel": "Other operating" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r88", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r208" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from contract with customers (topic 606)" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r47", "r91", "r131", "r132", "r137", "r142", "r143", "r147", "r148", "r150", "r154", "r286", "r356" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r313", "r318" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeLeaseInterestIncome": { "auth_ref": [ "r120", "r320", "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest income from net investment in sales-type lease.", "label": "Sales-type Lease, Interest Income", "terseLabel": "Interest income" } } }, "localname": "SalesTypeLeaseInterestIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r120", "r326" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of components of income from sales-type lease.", "label": "Sales-type Lease, Lease Income [Table Text Block]", "terseLabel": "Components of Sales-type Leases" } } }, "localname": "SalesTypeLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r236", "r237" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r236", "r237" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Summary of acquisitions" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of cash flow hedges included in accumulated other comprehensive income (loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of derivative instruments in statement of financial position, fair value" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": { "auth_ref": [ "r2", "r166" ], "lang": { "en-US": { "role": { "documentation": "Description and amounts of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Schedule of Long Lived Assets Held-for-sale [Table]", "terseLabel": "Schedule of Long Lived Assets Held-for-sale [Table]" } } }, "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r218", "r228" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Summary of employee stock purchase plan activity" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r28", "r89", "r122", "r123", "r179", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r77" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Share-based awards, end of period", "periodStartLabel": "Share-based awards, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "verboseLabel": "Summary of the activity under the incentive plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r220", "r228" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding and exercisable, end of period (in shares)", "periodStartLabel": "Outstanding and exercisable, beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Summary of the Employee Stock Purchase Plan activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r216", "r219" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Stock price, per share to be subsequently sold (in USD per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares withheld to pay estimated withholding taxes", "verboseLabel": "Shares withheld to pay taxes" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderstockbasedincentiveplansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r29", "r95", "r96", "r97", "r99", "r105", "r107", "r121", "r155", "r182", "r189", "r229", "r230", "r231", "r234", "r235", "r288", "r289", "r290", "r291", "r292", "r294", "r385", "r386", "r387" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r95", "r96", "r97", "r121", "r337" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r182", "r189" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (in shares)", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r14", "r15", "r182", "r189" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Nonvested share-based awards, net of withheld shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofbeginningandendingcommonstockoutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r182", "r189", "r221" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryofactivityunderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r182", "r189" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r14", "r15", "r182", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Common stock redemptions" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r17", "r18", "r91", "r152", "r154", "r286" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r90", "r189", "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r295", "r328" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r295", "r328" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r295", "r328" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Cash Flow Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryLockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.", "label": "Treasury Lock [Member]", "netLabel": "Treasury Rate Locks", "terseLabel": "Treasury lock", "verboseLabel": "Settled treasury hedges" } } }, "localname": "TreasuryLockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service [Extensible List]", "terseLabel": "Revenue, Product and Service [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "xbrltype": "extensibleListItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r129", "r130" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates in the condensed consolidated financial statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r311", "r318" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease expense" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r110", "r116" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average common shares outstanding - diluted (in shares)", "verboseLabel": "Weighted average common shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r108", "r109" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "verboseLabel": "Weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted average Common Shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r108", "r116" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted average common shares outstanding - basic (in shares)", "verboseLabel": "Weighted average common shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r109" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "negatedTerseLabel": "Non-vested shares" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofbasicanddilutedearningslosspercommonshareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "terseLabel": "Write off of Deferred Debt Issuance Cost" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 16 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2366-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121604594&loc=SL77919101-209958" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919311-209978" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919320-209978" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919327-209978" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337397&loc=d3e23415-158514" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337397&loc=d3e23439-158514" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337411&loc=d3e23528-158515" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r399": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r400": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r401": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r402": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r403": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r404": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3581-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 63 0000899749-20-000097-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000899749-20-000097-xbrl.zip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�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end